TW202221039A - 犬及貓抑瘤素M受體β之抗體及其用途 - Google Patents
犬及貓抑瘤素M受體β之抗體及其用途 Download PDFInfo
- Publication number
- TW202221039A TW202221039A TW110138302A TW110138302A TW202221039A TW 202221039 A TW202221039 A TW 202221039A TW 110138302 A TW110138302 A TW 110138302A TW 110138302 A TW110138302 A TW 110138302A TW 202221039 A TW202221039 A TW 202221039A
- Authority
- TW
- Taiwan
- Prior art keywords
- seq
- antibody
- osmr
- cdr1
- cdr3
- Prior art date
Links
- 241000282465 Canis Species 0.000 title claims abstract description 286
- 241000282324 Felis Species 0.000 title claims abstract description 240
- 102000004664 Oncostatin M Receptor beta Subunit Human genes 0.000 title claims abstract description 12
- 108010003767 Oncostatin M Receptor beta Subunit Proteins 0.000 title claims abstract description 12
- 230000027455 binding Effects 0.000 claims abstract description 173
- 108090000630 Oncostatin M Proteins 0.000 claims abstract description 168
- 102100021596 Interleukin-31 Human genes 0.000 claims abstract description 130
- 101710181613 Interleukin-31 Proteins 0.000 claims abstract description 125
- 230000001404 mediated effect Effects 0.000 claims abstract description 116
- 239000000427 antigen Substances 0.000 claims abstract description 73
- 102000036639 antigens Human genes 0.000 claims abstract description 73
- 108091007433 antigens Proteins 0.000 claims abstract description 73
- 230000011664 signaling Effects 0.000 claims abstract description 49
- 102100031942 Oncostatin-M Human genes 0.000 claims abstract 19
- 238000000034 method Methods 0.000 claims description 96
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 87
- 241000282326 Felis catus Species 0.000 claims description 77
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 52
- 150000007523 nucleic acids Chemical class 0.000 claims description 44
- 241000282472 Canis lupus familiaris Species 0.000 claims description 37
- 201000008937 atopic dermatitis Diseases 0.000 claims description 36
- 208000010668 atopic eczema Diseases 0.000 claims description 34
- 208000035475 disorder Diseases 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 241001465754 Metazoa Species 0.000 claims description 31
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 27
- 101000586302 Homo sapiens Oncostatin-M-specific receptor subunit beta Proteins 0.000 claims description 25
- 201000004624 Dermatitis Diseases 0.000 claims description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 23
- 230000004054 inflammatory process Effects 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 21
- 208000003251 Pruritus Diseases 0.000 claims description 19
- 230000003176 fibrotic effect Effects 0.000 claims description 17
- 230000001823 pruritic effect Effects 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 206010027654 Allergic conditions Diseases 0.000 claims description 15
- 201000008482 osteoarthritis Diseases 0.000 claims description 14
- 208000002193 Pain Diseases 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 12
- 206010065390 Inflammatory pain Diseases 0.000 claims description 12
- 208000006673 asthma Diseases 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 238000011534 incubation Methods 0.000 claims description 10
- 208000027866 inflammatory disease Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 9
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 claims description 9
- 230000005784 autoimmunity Effects 0.000 claims description 9
- 206010050207 Skin fibrosis Diseases 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 201000002793 renal fibrosis Diseases 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 6
- 208000000884 Airway Obstruction Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 206010036030 Polyarthritis Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010039710 Scleroderma Diseases 0.000 claims description 5
- 208000024780 Urticaria Diseases 0.000 claims description 5
- 201000009961 allergic asthma Diseases 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 208000007451 chronic bronchitis Diseases 0.000 claims description 5
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 5
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 5
- 230000000306 recurrent effect Effects 0.000 claims description 5
- 208000023504 respiratory system disease Diseases 0.000 claims description 5
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims description 4
- 230000010085 airway hyperresponsiveness Effects 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 102000003987 Oncostatin M Receptors Human genes 0.000 description 236
- 108010082522 Oncostatin M Receptors Proteins 0.000 description 236
- 125000003729 nucleotide group Chemical group 0.000 description 175
- 239000002773 nucleotide Substances 0.000 description 174
- 102000004140 Oncostatin M Human genes 0.000 description 149
- 210000004027 cell Anatomy 0.000 description 143
- 108090000623 proteins and genes Proteins 0.000 description 89
- 125000003275 alpha amino acid group Chemical group 0.000 description 66
- 241000699666 Mus <mouse, genus> Species 0.000 description 65
- 241000699670 Mus sp. Species 0.000 description 63
- 102000004169 proteins and genes Human genes 0.000 description 57
- 238000006467 substitution reaction Methods 0.000 description 55
- 235000001014 amino acid Nutrition 0.000 description 54
- 108020004414 DNA Proteins 0.000 description 48
- 235000018102 proteins Nutrition 0.000 description 48
- 230000014509 gene expression Effects 0.000 description 42
- 108060003951 Immunoglobulin Proteins 0.000 description 41
- 102000018358 immunoglobulin Human genes 0.000 description 41
- 238000011282 treatment Methods 0.000 description 36
- 239000000523 sample Substances 0.000 description 34
- 150000001413 amino acids Chemical class 0.000 description 33
- 238000002965 ELISA Methods 0.000 description 30
- 241000282414 Homo sapiens Species 0.000 description 30
- 210000003491 skin Anatomy 0.000 description 30
- 238000003556 assay Methods 0.000 description 29
- 210000002706 plastid Anatomy 0.000 description 29
- 239000012634 fragment Substances 0.000 description 28
- 125000000539 amino acid group Chemical group 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 27
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 26
- 230000035772 mutation Effects 0.000 description 25
- 241000824799 Canis lupus dingo Species 0.000 description 24
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 24
- 102000005962 receptors Human genes 0.000 description 24
- 108020003175 receptors Proteins 0.000 description 24
- 108010010147 glycylglutamine Proteins 0.000 description 23
- 108010073969 valyllysine Proteins 0.000 description 23
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 22
- 230000026731 phosphorylation Effects 0.000 description 22
- 238000006366 phosphorylation reaction Methods 0.000 description 22
- 230000004927 fusion Effects 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 241000894007 species Species 0.000 description 21
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 19
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 19
- 239000003112 inhibitor Substances 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 18
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 18
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 18
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 18
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 18
- 108010008355 arginyl-glutamine Proteins 0.000 description 18
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 17
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 17
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 17
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 17
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 17
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 17
- 230000000172 allergic effect Effects 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 16
- 235000004279 alanine Nutrition 0.000 description 16
- 238000000423 cell based assay Methods 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 102000043719 human OSMR Human genes 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 229920001184 polypeptide Polymers 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 239000003981 vehicle Substances 0.000 description 16
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 15
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 15
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 15
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 15
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 15
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 15
- YSKSXVKQLLBVEX-SZMVWBNQSA-N Leu-Gln-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 YSKSXVKQLLBVEX-SZMVWBNQSA-N 0.000 description 14
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 14
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 14
- 239000000872 buffer Substances 0.000 description 14
- 229940072221 immunoglobulins Drugs 0.000 description 14
- 230000003993 interaction Effects 0.000 description 14
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 14
- 229910052717 sulfur Inorganic materials 0.000 description 14
- 210000002437 synoviocyte Anatomy 0.000 description 14
- 108010044292 tryptophyltyrosine Proteins 0.000 description 14
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 13
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 13
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 13
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 13
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 108010034529 leucyl-lysine Proteins 0.000 description 13
- -1 pollen Substances 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- GCTANJIJJROSLH-GVARAGBVSA-N Ala-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C)N GCTANJIJJROSLH-GVARAGBVSA-N 0.000 description 12
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 12
- QNMKWNONJGKJJC-NHCYSSNCSA-N Asp-Leu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O QNMKWNONJGKJJC-NHCYSSNCSA-N 0.000 description 12
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 12
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 12
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 description 12
- ULVMNZOKDBHKKI-ACZMJKKPSA-N Ser-Gln-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ULVMNZOKDBHKKI-ACZMJKKPSA-N 0.000 description 12
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 12
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 238000003018 immunoassay Methods 0.000 description 12
- 230000002393 scratching effect Effects 0.000 description 12
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 11
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 11
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 11
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 11
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 210000004962 mammalian cell Anatomy 0.000 description 11
- AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 10
- QGZSAHIZRQHCEQ-QWRGUYRKSA-N Gly-Asp-Tyr Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QGZSAHIZRQHCEQ-QWRGUYRKSA-N 0.000 description 10
- 102000015696 Interleukins Human genes 0.000 description 10
- 108010063738 Interleukins Proteins 0.000 description 10
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 10
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 229910052731 fluorine Inorganic materials 0.000 description 10
- 108010037850 glycylvaline Proteins 0.000 description 10
- 229910052740 iodine Inorganic materials 0.000 description 10
- 230000009822 protein phosphorylation Effects 0.000 description 10
- 238000006748 scratching Methods 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 229910052727 yttrium Inorganic materials 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 102100021594 Interleukin-31 receptor subunit alpha Human genes 0.000 description 9
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 208000026935 allergic disease Diseases 0.000 description 9
- 239000012491 analyte Substances 0.000 description 9
- 108010068265 aspartyltyrosine Proteins 0.000 description 9
- 230000006399 behavior Effects 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 108010050848 glycylleucine Proteins 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- MFDPBZAFCRKYEY-LAEOZQHASA-N Asp-Val-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MFDPBZAFCRKYEY-LAEOZQHASA-N 0.000 description 8
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 8
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 8
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- 108091060210 Heavy strand Proteins 0.000 description 8
- ZHHLTWUOWXHVQJ-YUMQZZPRSA-N His-Ser-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZHHLTWUOWXHVQJ-YUMQZZPRSA-N 0.000 description 8
- YBKKLDBBPFIXBQ-MBLNEYKQSA-N Ile-Thr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)O)N YBKKLDBBPFIXBQ-MBLNEYKQSA-N 0.000 description 8
- USTCFDAQCLDPBD-XIRDDKMYSA-N Leu-Asn-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N USTCFDAQCLDPBD-XIRDDKMYSA-N 0.000 description 8
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 8
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 8
- KSGKJSFPWSMJHK-JNPHEJMOSA-N Tyr-Tyr-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KSGKJSFPWSMJHK-JNPHEJMOSA-N 0.000 description 8
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 208000017520 skin disease Diseases 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- DEAGTWNKODHUIY-MRFFXTKBSA-N Ala-Tyr-Trp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DEAGTWNKODHUIY-MRFFXTKBSA-N 0.000 description 7
- 108010032595 Antibody Binding Sites Proteins 0.000 description 7
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 7
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 102000008070 Interferon-gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 7
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 7
- QVTDVTONTRSQMF-WDCWCFNPSA-N Lys-Thr-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CCCCN QVTDVTONTRSQMF-WDCWCFNPSA-N 0.000 description 7
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 7
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 108010047857 aspartylglycine Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000005714 functional activity Effects 0.000 description 7
- 102000045345 human IL31 Human genes 0.000 description 7
- 238000007901 in situ hybridization Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108010038745 tryptophylglycine Proteins 0.000 description 7
- 108010003137 tyrosyltyrosine Proteins 0.000 description 7
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 6
- MFAMTAVAFBPXDC-LPEHRKFASA-N Arg-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O MFAMTAVAFBPXDC-LPEHRKFASA-N 0.000 description 6
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 6
- 101710131691 Interleukin-31 receptor subunit alpha Proteins 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 241000880493 Leptailurus serval Species 0.000 description 6
- 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 description 6
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 6
- GHQFLTYXGUETFD-UFYCRDLUSA-N Met-Tyr-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N GHQFLTYXGUETFD-UFYCRDLUSA-N 0.000 description 6
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 6
- XDMMOISUAHXXFD-SRVKXCTJSA-N Phe-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O XDMMOISUAHXXFD-SRVKXCTJSA-N 0.000 description 6
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 6
- WVVOFCVMHAXGLE-LFSVMHDDSA-N Thr-Phe-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O WVVOFCVMHAXGLE-LFSVMHDDSA-N 0.000 description 6
- NUQZCPSZHGIYTA-HKUYNNGSSA-N Tyr-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NUQZCPSZHGIYTA-HKUYNNGSSA-N 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 108010070643 prolylglutamic acid Proteins 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 229910052722 tritium Inorganic materials 0.000 description 6
- 229910052720 vanadium Inorganic materials 0.000 description 6
- STACJSVFHSEZJV-GHCJXIJMSA-N Ala-Asn-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O STACJSVFHSEZJV-GHCJXIJMSA-N 0.000 description 5
- SKQTXVZTCGSRJS-SRVKXCTJSA-N Asn-Tyr-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O SKQTXVZTCGSRJS-SRVKXCTJSA-N 0.000 description 5
- WOPJVEMFXYHZEE-SRVKXCTJSA-N Asp-Phe-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O WOPJVEMFXYHZEE-SRVKXCTJSA-N 0.000 description 5
- OZHXXYOHPLLLMI-CIUDSAMLSA-N Cys-Lys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OZHXXYOHPLLLMI-CIUDSAMLSA-N 0.000 description 5
- VLOLPWWCNKWRNB-LOKLDPHHSA-N Gln-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O VLOLPWWCNKWRNB-LOKLDPHHSA-N 0.000 description 5
- WATXSTJXNBOHKD-LAEOZQHASA-N Glu-Asp-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O WATXSTJXNBOHKD-LAEOZQHASA-N 0.000 description 5
- OCJRHJZKGGSPRW-IUCAKERBSA-N Glu-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O OCJRHJZKGGSPRW-IUCAKERBSA-N 0.000 description 5
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 5
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 description 5
- 101000992170 Homo sapiens Oncostatin-M Proteins 0.000 description 5
- NXRNRBOKDBIVKQ-CXTHYWKRSA-N Ile-Tyr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N NXRNRBOKDBIVKQ-CXTHYWKRSA-N 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 5
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 5
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 5
- RNYLNYTYMXACRI-VFAJRCTISA-N Leu-Thr-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O RNYLNYTYMXACRI-VFAJRCTISA-N 0.000 description 5
- WQDKIVRHTQYJSN-DCAQKATOSA-N Lys-Ser-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WQDKIVRHTQYJSN-DCAQKATOSA-N 0.000 description 5
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 5
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 5
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 5
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 5
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 5
- SBLZVFCEOCWRLS-BPNCWPANSA-N Tyr-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CC=C(C=C1)O)N SBLZVFCEOCWRLS-BPNCWPANSA-N 0.000 description 5
- ZXYPHBKIZLAQTL-QXEWZRGKSA-N Val-Pro-Asp Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N ZXYPHBKIZLAQTL-QXEWZRGKSA-N 0.000 description 5
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 5
- QHSSPPHOHJSTML-HOCLYGCPSA-N Val-Trp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N QHSSPPHOHJSTML-HOCLYGCPSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 102000046686 human LIFR Human genes 0.000 description 5
- 102000043703 human OSM Human genes 0.000 description 5
- 229940047122 interleukins Drugs 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 108010057821 leucylproline Proteins 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000000869 mutational effect Effects 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 108010029020 prolylglycine Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 108010061238 threonyl-glycine Proteins 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 4
- LXMKTIZAGIBQRX-HRCADAONSA-N Arg-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O LXMKTIZAGIBQRX-HRCADAONSA-N 0.000 description 4
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- CRRFJBGUGNNOCS-PEFMBERDSA-N Gln-Asp-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CRRFJBGUGNNOCS-PEFMBERDSA-N 0.000 description 4
- XKBASPWPBXNVLQ-WDSKDSINSA-N Gln-Gly-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XKBASPWPBXNVLQ-WDSKDSINSA-N 0.000 description 4
- LVSYIKGMLRHKME-IUCAKERBSA-N Gln-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N LVSYIKGMLRHKME-IUCAKERBSA-N 0.000 description 4
- UBRQJXFDVZNYJP-AVGNSLFASA-N Gln-Tyr-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O UBRQJXFDVZNYJP-AVGNSLFASA-N 0.000 description 4
- RDPOETHPAQEGDP-ACZMJKKPSA-N Glu-Asp-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RDPOETHPAQEGDP-ACZMJKKPSA-N 0.000 description 4
- WVYJNPCWJYBHJG-YVNDNENWSA-N Glu-Ile-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O WVYJNPCWJYBHJG-YVNDNENWSA-N 0.000 description 4
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 4
- MDOBWSFNSNPENN-PMVVWTBXSA-N His-Thr-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O MDOBWSFNSNPENN-PMVVWTBXSA-N 0.000 description 4
- 101001043817 Homo sapiens Interleukin-31 receptor subunit alpha Proteins 0.000 description 4
- QYZYJFXHXYUZMZ-UGYAYLCHSA-N Ile-Asn-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N QYZYJFXHXYUZMZ-UGYAYLCHSA-N 0.000 description 4
- SAEWJTCJQVZQNZ-IUKAMOBKSA-N Ile-Thr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SAEWJTCJQVZQNZ-IUKAMOBKSA-N 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 4
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 4
- OZVXDDFYCQOPFD-XQQFMLRXSA-N Lys-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N OZVXDDFYCQOPFD-XQQFMLRXSA-N 0.000 description 4
- AWGBEIYZPAXXSX-RWMBFGLXSA-N Met-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N AWGBEIYZPAXXSX-RWMBFGLXSA-N 0.000 description 4
- 101150080012 OSMR gene Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- FSPGBMWPNMRWDB-AVGNSLFASA-N Phe-Cys-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N FSPGBMWPNMRWDB-AVGNSLFASA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 4
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 4
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 4
- RXUOAOOZIWABBW-XGEHTFHBSA-N Ser-Thr-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RXUOAOOZIWABBW-XGEHTFHBSA-N 0.000 description 4
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 4
- XIULAFZYEKSGAJ-IXOXFDKPSA-N Thr-Leu-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 XIULAFZYEKSGAJ-IXOXFDKPSA-N 0.000 description 4
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 4
- JWHOIHCOHMZSAR-QWRGUYRKSA-N Tyr-Asp-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JWHOIHCOHMZSAR-QWRGUYRKSA-N 0.000 description 4
- GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 description 4
- WQOHKVRQDLNDIL-YJRXYDGGSA-N Tyr-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O WQOHKVRQDLNDIL-YJRXYDGGSA-N 0.000 description 4
- MWUYSCVVPVITMW-IGNZVWTISA-N Tyr-Tyr-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 MWUYSCVVPVITMW-IGNZVWTISA-N 0.000 description 4
- VJOWWOGRNXRQMF-UVBJJODRSA-N Val-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 VJOWWOGRNXRQMF-UVBJJODRSA-N 0.000 description 4
- OVLIFGQSBSNGHY-KKHAAJSZSA-N Val-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N)O OVLIFGQSBSNGHY-KKHAAJSZSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 108010084758 arginyl-tyrosyl-aspartic acid Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 229940044627 gamma-interferon Drugs 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 108010089804 glycyl-threonine Proteins 0.000 description 4
- 108010015792 glycyllysine Proteins 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 108010018006 histidylserine Proteins 0.000 description 4
- 102000045410 human IL31RA Human genes 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108010090894 prolylleucine Proteins 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 208000008864 scrapie Diseases 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 229910052721 tungsten Inorganic materials 0.000 description 4
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 3
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 3
- ZDILXFDENZVOTL-BPNCWPANSA-N Ala-Val-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDILXFDENZVOTL-BPNCWPANSA-N 0.000 description 3
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 3
- XVLLUZMFSAYKJV-GUBZILKMSA-N Arg-Asp-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XVLLUZMFSAYKJV-GUBZILKMSA-N 0.000 description 3
- OZNSCVPYWZRQPY-CIUDSAMLSA-N Arg-Asp-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OZNSCVPYWZRQPY-CIUDSAMLSA-N 0.000 description 3
- HAVKMRGWNXMCDR-STQMWFEESA-N Arg-Gly-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HAVKMRGWNXMCDR-STQMWFEESA-N 0.000 description 3
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 3
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 3
- SPWXXPFDTMYTRI-IUKAMOBKSA-N Asp-Ile-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SPWXXPFDTMYTRI-IUKAMOBKSA-N 0.000 description 3
- MVRGBQGZSDJBSM-GMOBBJLQSA-N Asp-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)O)N MVRGBQGZSDJBSM-GMOBBJLQSA-N 0.000 description 3
- ITGFVUYOLWBPQW-KKHAAJSZSA-N Asp-Thr-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O ITGFVUYOLWBPQW-KKHAAJSZSA-N 0.000 description 3
- ALMIMUZAWTUNIO-BZSNNMDCSA-N Asp-Tyr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ALMIMUZAWTUNIO-BZSNNMDCSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- UFNSPPFJOHNXRE-AUTRQRHGSA-N Gln-Gln-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UFNSPPFJOHNXRE-AUTRQRHGSA-N 0.000 description 3
- OKARHJKJTKFQBM-ACZMJKKPSA-N Gln-Ser-Asn Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OKARHJKJTKFQBM-ACZMJKKPSA-N 0.000 description 3
- SYZZMPFLOLSMHL-XHNCKOQMSA-N Gln-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N)C(=O)O SYZZMPFLOLSMHL-XHNCKOQMSA-N 0.000 description 3
- INGJLBQKTRJLFO-UKJIMTQDSA-N Glu-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 description 3
- SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 3
- RVGMVLVBDRQVKB-UWVGGRQHSA-N Gly-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN RVGMVLVBDRQVKB-UWVGGRQHSA-N 0.000 description 3
- ABPRMMYHROQBLY-NKWVEPMBSA-N Gly-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)CN)C(=O)O ABPRMMYHROQBLY-NKWVEPMBSA-N 0.000 description 3
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 3
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- JODPUDMBQBIWCK-GHCJXIJMSA-N Ile-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O JODPUDMBQBIWCK-GHCJXIJMSA-N 0.000 description 3
- FBGXMKUWQFPHFB-JBDRJPRFSA-N Ile-Ser-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N FBGXMKUWQFPHFB-JBDRJPRFSA-N 0.000 description 3
- ZLFNNVATRMCAKN-ZKWXMUAHSA-N Ile-Ser-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZLFNNVATRMCAKN-ZKWXMUAHSA-N 0.000 description 3
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 3
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- LKXANTUNFMVCNF-IHPCNDPISA-N Leu-His-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O LKXANTUNFMVCNF-IHPCNDPISA-N 0.000 description 3
- AKVBOOKXVAMKSS-GUBZILKMSA-N Leu-Ser-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O AKVBOOKXVAMKSS-GUBZILKMSA-N 0.000 description 3
- BOJYMMBYBNOOGG-DCAQKATOSA-N Lys-Pro-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BOJYMMBYBNOOGG-DCAQKATOSA-N 0.000 description 3
- JMNRXRPBHFGXQX-GUBZILKMSA-N Lys-Ser-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JMNRXRPBHFGXQX-GUBZILKMSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- NOFBJKKOPKJDCO-KKXDTOCCSA-N Phe-Ala-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NOFBJKKOPKJDCO-KKXDTOCCSA-N 0.000 description 3
- GLJZDMZJHFXJQG-BZSNNMDCSA-N Phe-Ser-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GLJZDMZJHFXJQG-BZSNNMDCSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- KLSOMAFWRISSNI-OSUNSFLBSA-N Pro-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 KLSOMAFWRISSNI-OSUNSFLBSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- GXXTUIUYTWGPMV-FXQIFTODSA-N Ser-Arg-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O GXXTUIUYTWGPMV-FXQIFTODSA-N 0.000 description 3
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 3
- YXEYTHXDRDAIOJ-CWRNSKLLSA-N Ser-Trp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CO)N)C(=O)O YXEYTHXDRDAIOJ-CWRNSKLLSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 3
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 3
- JVTHIXKSVYEWNI-JRQIVUDYSA-N Thr-Asn-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JVTHIXKSVYEWNI-JRQIVUDYSA-N 0.000 description 3
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 3
- PCMDGXKXVMBIFP-VEVYYDQMSA-N Thr-Met-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(O)=O PCMDGXKXVMBIFP-VEVYYDQMSA-N 0.000 description 3
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 3
- 102000000887 Transcription factor STAT Human genes 0.000 description 3
- 108050007918 Transcription factor STAT Proteins 0.000 description 3
- QARCDOCCDOLJSF-HJPIBITLSA-N Tyr-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QARCDOCCDOLJSF-HJPIBITLSA-N 0.000 description 3
- BCBFMJYTNKDALA-UFYCRDLUSA-N Val-Phe-Phe Chemical compound N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O BCBFMJYTNKDALA-UFYCRDLUSA-N 0.000 description 3
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 3
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 3
- 108010047495 alanylglycine Proteins 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 108010093581 aspartyl-proline Proteins 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010835 comparative analysis Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000011833 dog model Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 3
- 102000046645 human LIF Human genes 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 108010024607 phenylalanylalanine Proteins 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 description 2
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 2
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 2
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 2
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 description 2
- 238000012815 AlphaLISA Methods 0.000 description 2
- GXXWTNKNFFKTJB-NAKRPEOUSA-N Arg-Ile-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O GXXWTNKNFFKTJB-NAKRPEOUSA-N 0.000 description 2
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 description 2
- QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- PFOYSEIHFVKHNF-FXQIFTODSA-N Asn-Ala-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PFOYSEIHFVKHNF-FXQIFTODSA-N 0.000 description 2
- BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 description 2
- HFPXZWPUVFVNLL-GUBZILKMSA-N Asn-Leu-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HFPXZWPUVFVNLL-GUBZILKMSA-N 0.000 description 2
- NCFJQJRLQJEECD-NHCYSSNCSA-N Asn-Leu-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O NCFJQJRLQJEECD-NHCYSSNCSA-N 0.000 description 2
- LGCVSPFCFXWUEY-IHPCNDPISA-N Asn-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N LGCVSPFCFXWUEY-IHPCNDPISA-N 0.000 description 2
- VAWNQIGQPUOPQW-ACZMJKKPSA-N Asp-Glu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VAWNQIGQPUOPQW-ACZMJKKPSA-N 0.000 description 2
- GGBQDSHTXKQSLP-NHCYSSNCSA-N Asp-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N GGBQDSHTXKQSLP-NHCYSSNCSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- BPHKULHWEIUDOB-FXQIFTODSA-N Cys-Gln-Gln Chemical compound SC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O BPHKULHWEIUDOB-FXQIFTODSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 2
- KVXVVDFOZNYYKZ-DCAQKATOSA-N Gln-Gln-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KVXVVDFOZNYYKZ-DCAQKATOSA-N 0.000 description 2
- SBHVGKBYOQKAEA-SDDRHHMPSA-N Gln-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCC(=O)N)N)C(=O)O SBHVGKBYOQKAEA-SDDRHHMPSA-N 0.000 description 2
- ICDIMQAMJGDHSE-GUBZILKMSA-N Gln-His-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O ICDIMQAMJGDHSE-GUBZILKMSA-N 0.000 description 2
- SXFPZRRVWSUYII-KBIXCLLPSA-N Gln-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N SXFPZRRVWSUYII-KBIXCLLPSA-N 0.000 description 2
- IESFZVCAVACGPH-PEFMBERDSA-N Glu-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O IESFZVCAVACGPH-PEFMBERDSA-N 0.000 description 2
- SJJHXJDSNQJMMW-SRVKXCTJSA-N Glu-Lys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SJJHXJDSNQJMMW-SRVKXCTJSA-N 0.000 description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
- 102100022624 Glucoamylase Human genes 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 2
- CUVBTVWFVIIDOC-YEPSODPASA-N Gly-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)CN CUVBTVWFVIIDOC-YEPSODPASA-N 0.000 description 2
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 2
- IZVICCORZOSGPT-JSGCOSHPSA-N Gly-Val-Tyr Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IZVICCORZOSGPT-JSGCOSHPSA-N 0.000 description 2
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 2
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- VQPPIMUZCZCOIL-GUBZILKMSA-N Leu-Gln-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VQPPIMUZCZCOIL-GUBZILKMSA-N 0.000 description 2
- JLYUZRKPDKHUTC-WDSOQIARSA-N Leu-Pro-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JLYUZRKPDKHUTC-WDSOQIARSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 2
- WGILOYIKJVQUPT-DCAQKATOSA-N Lys-Pro-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WGILOYIKJVQUPT-DCAQKATOSA-N 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 101100068676 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gln-1 gene Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 2
- YYKZDTVQHTUKDW-RYUDHWBXSA-N Phe-Gly-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N YYKZDTVQHTUKDW-RYUDHWBXSA-N 0.000 description 2
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- JARJPEMLQAWNBR-GUBZILKMSA-N Pro-Asp-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JARJPEMLQAWNBR-GUBZILKMSA-N 0.000 description 2
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 2
- VTFXTWDFPTWNJY-RHYQMDGZSA-N Pro-Leu-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VTFXTWDFPTWNJY-RHYQMDGZSA-N 0.000 description 2
- RMJZWERKFFNNNS-XGEHTFHBSA-N Pro-Thr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMJZWERKFFNNNS-XGEHTFHBSA-N 0.000 description 2
- VBZXFFYOBDLLFE-HSHDSVGOSA-N Pro-Trp-Thr Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@H](O)C)C(O)=O)C(=O)[C@@H]1CCCN1 VBZXFFYOBDLLFE-HSHDSVGOSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- MIJWOJAXARLEHA-WDSKDSINSA-N Ser-Gly-Glu Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O MIJWOJAXARLEHA-WDSKDSINSA-N 0.000 description 2
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 2
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 2
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 2
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 2
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 2
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 2
- PIQRHJQWEPWFJG-UWJYBYFXSA-N Ser-Tyr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PIQRHJQWEPWFJG-UWJYBYFXSA-N 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- GLQFKOVWXPPFTP-VEVYYDQMSA-N Thr-Arg-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O GLQFKOVWXPPFTP-VEVYYDQMSA-N 0.000 description 2
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 2
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 2
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- YKCXQOBTISTQJD-BZSNNMDCSA-N Tyr-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N YKCXQOBTISTQJD-BZSNNMDCSA-N 0.000 description 2
- GQVZBMROTPEPIF-SRVKXCTJSA-N Tyr-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GQVZBMROTPEPIF-SRVKXCTJSA-N 0.000 description 2
- UMSZZGTXGKHTFJ-SRVKXCTJSA-N Tyr-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UMSZZGTXGKHTFJ-SRVKXCTJSA-N 0.000 description 2
- COYSIHFOCOMGCF-WPRPVWTQSA-N Val-Arg-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-WPRPVWTQSA-N 0.000 description 2
- COYSIHFOCOMGCF-UHFFFAOYSA-N Val-Arg-Gly Natural products CC(C)C(N)C(=O)NC(C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-UHFFFAOYSA-N 0.000 description 2
- ZZGPVSZDZQRJQY-ULQDDVLXSA-N Val-Leu-Phe Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O ZZGPVSZDZQRJQY-ULQDDVLXSA-N 0.000 description 2
- DEGUERSKQBRZMZ-FXQIFTODSA-N Val-Ser-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DEGUERSKQBRZMZ-FXQIFTODSA-N 0.000 description 2
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 2
- DVLWZWNAQUBZBC-ZNSHCXBVSA-N Val-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N)O DVLWZWNAQUBZBC-ZNSHCXBVSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- 108010041407 alanylaspartic acid Proteins 0.000 description 2
- 108010005233 alanylglutamic acid Proteins 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006251 gamma-carboxylation Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 102000002467 interleukin receptors Human genes 0.000 description 2
- 108010093036 interleukin receptors Proteins 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000023185 monocyte chemotactic protein-1 production Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- 101150117081 51 gene Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000203809 Actinomycetales Species 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
- TTXMOJWKNRJWQJ-FXQIFTODSA-N Ala-Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N TTXMOJWKNRJWQJ-FXQIFTODSA-N 0.000 description 1
- GSCLWXDNIMNIJE-ZLUOBGJFSA-N Ala-Asp-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GSCLWXDNIMNIJE-ZLUOBGJFSA-N 0.000 description 1
- KUDREHRZRIVKHS-UWJYBYFXSA-N Ala-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KUDREHRZRIVKHS-UWJYBYFXSA-N 0.000 description 1
- KLALXKYLOMZDQT-ZLUOBGJFSA-N Ala-Ser-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KLALXKYLOMZDQT-ZLUOBGJFSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- 241001504639 Alcedo atthis Species 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241001550224 Apha Species 0.000 description 1
- IJPNNYWHXGADJG-GUBZILKMSA-N Arg-Ala-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O IJPNNYWHXGADJG-GUBZILKMSA-N 0.000 description 1
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 1
- PRLPSDIHSRITSF-UNQGMJICSA-N Arg-Phe-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PRLPSDIHSRITSF-UNQGMJICSA-N 0.000 description 1
- ADPACBMPYWJJCE-FXQIFTODSA-N Arg-Ser-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O ADPACBMPYWJJCE-FXQIFTODSA-N 0.000 description 1
- AUZAXCPWMDBWEE-HJGDQZAQSA-N Arg-Thr-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O AUZAXCPWMDBWEE-HJGDQZAQSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DXVMJJNAOVECBA-WHFBIAKZSA-N Asn-Gly-Asn Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O DXVMJJNAOVECBA-WHFBIAKZSA-N 0.000 description 1
- HYQYLOSCICEYTR-YUMQZZPRSA-N Asn-Gly-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O HYQYLOSCICEYTR-YUMQZZPRSA-N 0.000 description 1
- PTSDPWIHOYMRGR-UGYAYLCHSA-N Asn-Ile-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O PTSDPWIHOYMRGR-UGYAYLCHSA-N 0.000 description 1
- GQRDIVQPSMPQME-ZPFDUUQYSA-N Asn-Ile-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O GQRDIVQPSMPQME-ZPFDUUQYSA-N 0.000 description 1
- XHTUGJCAEYOZOR-UBHSHLNASA-N Asn-Ser-Trp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O XHTUGJCAEYOZOR-UBHSHLNASA-N 0.000 description 1
- RTFXPCYMDYBZNQ-SRVKXCTJSA-N Asn-Tyr-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O RTFXPCYMDYBZNQ-SRVKXCTJSA-N 0.000 description 1
- CGYKCTPUGXFPMG-IHPCNDPISA-N Asn-Tyr-Trp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O CGYKCTPUGXFPMG-IHPCNDPISA-N 0.000 description 1
- LTDGPJKGJDIBQD-LAEOZQHASA-N Asn-Val-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LTDGPJKGJDIBQD-LAEOZQHASA-N 0.000 description 1
- VPPXTHJNTYDNFJ-CIUDSAMLSA-N Asp-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N VPPXTHJNTYDNFJ-CIUDSAMLSA-N 0.000 description 1
- ILJQISGMGXRZQQ-IHRRRGAJSA-N Asp-Arg-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ILJQISGMGXRZQQ-IHRRRGAJSA-N 0.000 description 1
- BFOYULZBKYOKAN-OLHMAJIHSA-N Asp-Asp-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BFOYULZBKYOKAN-OLHMAJIHSA-N 0.000 description 1
- PXLNPFOJZQMXAT-BYULHYEWSA-N Asp-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O PXLNPFOJZQMXAT-BYULHYEWSA-N 0.000 description 1
- YNCHFVRXEQFPBY-BQBZGAKWSA-N Asp-Gly-Arg Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N YNCHFVRXEQFPBY-BQBZGAKWSA-N 0.000 description 1
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 1
- XLILXFRAKOYEJX-GUBZILKMSA-N Asp-Leu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O XLILXFRAKOYEJX-GUBZILKMSA-N 0.000 description 1
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 1
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 1
- AWPWHMVCSISSQK-QWRGUYRKSA-N Asp-Tyr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O AWPWHMVCSISSQK-QWRGUYRKSA-N 0.000 description 1
- OTKUAVXGMREHRX-CFMVVWHZSA-N Asp-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 OTKUAVXGMREHRX-CFMVVWHZSA-N 0.000 description 1
- SQIARYGNVQWOSB-BZSNNMDCSA-N Asp-Tyr-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQIARYGNVQWOSB-BZSNNMDCSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000012739 FreeStyle 293 Expression medium Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- RGXXLQWXBFNXTG-CIUDSAMLSA-N Gln-Arg-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O RGXXLQWXBFNXTG-CIUDSAMLSA-N 0.000 description 1
- PRBLYKYHAJEABA-SRVKXCTJSA-N Gln-Arg-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O PRBLYKYHAJEABA-SRVKXCTJSA-N 0.000 description 1
- XOKGKOQWADCLFQ-GARJFASQSA-N Gln-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XOKGKOQWADCLFQ-GARJFASQSA-N 0.000 description 1
- IXFVOPOHSRKJNG-LAEOZQHASA-N Gln-Asp-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IXFVOPOHSRKJNG-LAEOZQHASA-N 0.000 description 1
- LOJYQMFIIJVETK-WDSKDSINSA-N Gln-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LOJYQMFIIJVETK-WDSKDSINSA-N 0.000 description 1
- RBWKVOSARCFSQQ-FXQIFTODSA-N Gln-Gln-Ser Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O RBWKVOSARCFSQQ-FXQIFTODSA-N 0.000 description 1
- JKGHMESJHRTHIC-SIUGBPQLSA-N Gln-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JKGHMESJHRTHIC-SIUGBPQLSA-N 0.000 description 1
- XZLLTYBONVKGLO-SDDRHHMPSA-N Gln-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XZLLTYBONVKGLO-SDDRHHMPSA-N 0.000 description 1
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 1
- VYOILACOFPPNQH-UMNHJUIQSA-N Gln-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N VYOILACOFPPNQH-UMNHJUIQSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- JVSBYEDSSRZQGV-GUBZILKMSA-N Glu-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O JVSBYEDSSRZQGV-GUBZILKMSA-N 0.000 description 1
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 1
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 description 1
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 1
- UGSVSNXPJJDJKL-SDDRHHMPSA-N Glu-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N UGSVSNXPJJDJKL-SDDRHHMPSA-N 0.000 description 1
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 1
- BPLNJYHNAJVLRT-ACZMJKKPSA-N Glu-Ser-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O BPLNJYHNAJVLRT-ACZMJKKPSA-N 0.000 description 1
- HMJULNMJWOZNFI-XHNCKOQMSA-N Glu-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N)C(=O)O HMJULNMJWOZNFI-XHNCKOQMSA-N 0.000 description 1
- HZISRJBYZAODRV-XQXXSGGOSA-N Glu-Thr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O HZISRJBYZAODRV-XQXXSGGOSA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- JVACNFOPSUPDTK-QWRGUYRKSA-N Gly-Asn-Phe Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JVACNFOPSUPDTK-QWRGUYRKSA-N 0.000 description 1
- FMNHBTKMRFVGRO-FOHZUACHSA-N Gly-Asn-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CN FMNHBTKMRFVGRO-FOHZUACHSA-N 0.000 description 1
- BPQYBFAXRGMGGY-LAEOZQHASA-N Gly-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN BPQYBFAXRGMGGY-LAEOZQHASA-N 0.000 description 1
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 1
- UUWOBINZFGTFMS-UWVGGRQHSA-N Gly-His-Met Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCSC)C(O)=O UUWOBINZFGTFMS-UWVGGRQHSA-N 0.000 description 1
- LHYJCVCQPWRMKZ-WEDXCCLWSA-N Gly-Leu-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LHYJCVCQPWRMKZ-WEDXCCLWSA-N 0.000 description 1
- MDKCBHZLQJZOCJ-STQMWFEESA-N Gly-Met-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)CN MDKCBHZLQJZOCJ-STQMWFEESA-N 0.000 description 1
- WMGHDYWNHNLGBV-ONGXEEELSA-N Gly-Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WMGHDYWNHNLGBV-ONGXEEELSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- UIQGJYUEQDOODF-KWQFWETISA-N Gly-Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 UIQGJYUEQDOODF-KWQFWETISA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- RNAYRCNHRYEBTH-IHRRRGAJSA-N His-Met-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O RNAYRCNHRYEBTH-IHRRRGAJSA-N 0.000 description 1
- GYXDQXPCPASCNR-NHCYSSNCSA-N His-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N GYXDQXPCPASCNR-NHCYSSNCSA-N 0.000 description 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- XLXPYSDGMXTTNQ-DKIMLUQUSA-N Ile-Phe-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(O)=O XLXPYSDGMXTTNQ-DKIMLUQUSA-N 0.000 description 1
- XLXPYSDGMXTTNQ-UHFFFAOYSA-N Ile-Phe-Leu Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 XLXPYSDGMXTTNQ-UHFFFAOYSA-N 0.000 description 1
- CAHCWMVNBZJVAW-NAKRPEOUSA-N Ile-Pro-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O)N CAHCWMVNBZJVAW-NAKRPEOUSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OXKYZSRZKBTVEY-ZPFDUUQYSA-N Leu-Asn-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OXKYZSRZKBTVEY-ZPFDUUQYSA-N 0.000 description 1
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 1
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 1
- ODRREERHVHMIPT-OEAJRASXSA-N Leu-Thr-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ODRREERHVHMIPT-OEAJRASXSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 1
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 1
- DIBZLYZXTSVGLN-CIUDSAMLSA-N Lys-Ser-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O DIBZLYZXTSVGLN-CIUDSAMLSA-N 0.000 description 1
- MEQLGHAMAUPOSJ-DCAQKATOSA-N Lys-Ser-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O MEQLGHAMAUPOSJ-DCAQKATOSA-N 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101150056884 OSM gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- XWBJLKDCHJVKAK-KKUMJFAQSA-N Phe-Arg-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N XWBJLKDCHJVKAK-KKUMJFAQSA-N 0.000 description 1
- GXDPQJUBLBZKDY-IAVJCBSLSA-N Phe-Ile-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GXDPQJUBLBZKDY-IAVJCBSLSA-N 0.000 description 1
- FQUUYTNBMIBOHS-IHRRRGAJSA-N Phe-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FQUUYTNBMIBOHS-IHRRRGAJSA-N 0.000 description 1
- JKJSIYKSGIDHPM-WBAXXEDZSA-N Phe-Phe-Ala Chemical compound C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1ccccc1)C(O)=O JKJSIYKSGIDHPM-WBAXXEDZSA-N 0.000 description 1
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 1
- YMIZSYUAZJSOFL-SRVKXCTJSA-N Phe-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O YMIZSYUAZJSOFL-SRVKXCTJSA-N 0.000 description 1
- UNBFGVQVQGXXCK-KKUMJFAQSA-N Phe-Ser-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O UNBFGVQVQGXXCK-KKUMJFAQSA-N 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- WSRWHZRUOCACLJ-UWVGGRQHSA-N Pro-Gly-His Chemical compound C([C@@H](C(=O)O)NC(=O)CNC(=O)[C@H]1NCCC1)C1=CN=CN1 WSRWHZRUOCACLJ-UWVGGRQHSA-N 0.000 description 1
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 1
- IMNVAOPEMFDAQD-NHCYSSNCSA-N Pro-Val-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IMNVAOPEMFDAQD-NHCYSSNCSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 1
- OOKCGAYXSNJBGQ-ZLUOBGJFSA-N Ser-Asn-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OOKCGAYXSNJBGQ-ZLUOBGJFSA-N 0.000 description 1
- YRBGKVIWMNEVCZ-WDSKDSINSA-N Ser-Glu-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O YRBGKVIWMNEVCZ-WDSKDSINSA-N 0.000 description 1
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 1
- JFWDJFULOLKQFY-QWRGUYRKSA-N Ser-Gly-Phe Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JFWDJFULOLKQFY-QWRGUYRKSA-N 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- CLKKNZQUQMZDGD-SRVKXCTJSA-N Ser-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CN=CN1 CLKKNZQUQMZDGD-SRVKXCTJSA-N 0.000 description 1
- LQESNKGTTNHZPZ-GHCJXIJMSA-N Ser-Ile-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O LQESNKGTTNHZPZ-GHCJXIJMSA-N 0.000 description 1
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 1
- PPNPDKGQRFSCAC-CIUDSAMLSA-N Ser-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPNPDKGQRFSCAC-CIUDSAMLSA-N 0.000 description 1
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 1
- IFLVBVIYADZIQO-DCAQKATOSA-N Ser-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N IFLVBVIYADZIQO-DCAQKATOSA-N 0.000 description 1
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 1
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- 108010017898 Shiga Toxins Proteins 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- PKXHGEXFMIZSER-QTKMDUPCSA-N Thr-Arg-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O PKXHGEXFMIZSER-QTKMDUPCSA-N 0.000 description 1
- NIEWSKWFURSECR-FOHZUACHSA-N Thr-Gly-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O NIEWSKWFURSECR-FOHZUACHSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 1
- BCYUHPXBHCUYBA-CUJWVEQBSA-N Thr-Ser-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O BCYUHPXBHCUYBA-CUJWVEQBSA-N 0.000 description 1
- AHERARIZBPOMNU-KATARQTJSA-N Thr-Ser-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O AHERARIZBPOMNU-KATARQTJSA-N 0.000 description 1
- LXXCHJKHJYRMIY-FQPOAREZSA-N Thr-Tyr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O LXXCHJKHJYRMIY-FQPOAREZSA-N 0.000 description 1
- RPECVQBNONKZAT-WZLNRYEVSA-N Thr-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H]([C@@H](C)O)N RPECVQBNONKZAT-WZLNRYEVSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000005703 Trimethylamine hydrochloride Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- ZCPCXVJOMUPIDD-IHPCNDPISA-N Trp-Asp-Phe Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1 ZCPCXVJOMUPIDD-IHPCNDPISA-N 0.000 description 1
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 1
- AIISTODACBDQLW-WDSOQIARSA-N Trp-Leu-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 AIISTODACBDQLW-WDSOQIARSA-N 0.000 description 1
- RCMHSGRBJCMFLR-BPUTZDHNSA-N Trp-Met-Asn Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(O)=O)=CNC2=C1 RCMHSGRBJCMFLR-BPUTZDHNSA-N 0.000 description 1
- FBGDDUKYOBNZJL-WDSOQIARSA-N Trp-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N FBGDDUKYOBNZJL-WDSOQIARSA-N 0.000 description 1
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- LGEYOIQBBIPHQN-UWJYBYFXSA-N Tyr-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LGEYOIQBBIPHQN-UWJYBYFXSA-N 0.000 description 1
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 description 1
- SZEIFUXUTBBQFQ-STQMWFEESA-N Tyr-Pro-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SZEIFUXUTBBQFQ-STQMWFEESA-N 0.000 description 1
- RWOKVQUCENPXGE-IHRRRGAJSA-N Tyr-Ser-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RWOKVQUCENPXGE-IHRRRGAJSA-N 0.000 description 1
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- HZDQUVQEVVYDDA-ACRUOGEOSA-N Tyr-Tyr-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HZDQUVQEVVYDDA-ACRUOGEOSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- PVPAOIGJYHVWBT-KKHAAJSZSA-N Val-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N)O PVPAOIGJYHVWBT-KKHAAJSZSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 1
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
- UJMCYJKPDFQLHX-XGEHTFHBSA-N Val-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N)O UJMCYJKPDFQLHX-XGEHTFHBSA-N 0.000 description 1
- PGBMPFKFKXYROZ-UFYCRDLUSA-N Val-Tyr-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N PGBMPFKFKXYROZ-UFYCRDLUSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 150000001576 beta-amino acids Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 239000005082 bioluminescent agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 208000010717 cat disease Diseases 0.000 description 1
- 238000013216 cat model Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 108010048032 cyclophilin B Proteins 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 150000002211 flavins Chemical class 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 125000003712 glycosamine group Chemical group 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229950000359 lokivetmab Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000001503 one-tailed test Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- SZYJELPVAFJOGJ-UHFFFAOYSA-N trimethylamine hydrochloride Chemical compound Cl.CN(C)C SZYJELPVAFJOGJ-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本發明提供一種與犬或貓抑瘤素M受體β(OSMR-β)或兩者特異性結合之經分離抗體或其抗原結合部分,其中該抗體在犬及/或貓細胞中拮抗IL-31介導之信號傳導或OSM介導之信號傳導或兩者。
Description
本發明屬於免疫療法領域。更特定言之,其涉及抑瘤素M(OSM)之受體及其調節劑,諸如與犬及/或貓抑瘤素M受體β次單元(OSMR-β)結合之單株抗體。本發明亦涉及使用抗OSMR-β抗體診斷及/或治療與OSM及IL-31相關之犬科動物及貓科動物之疾病。
細胞介素包含一個大的小蛋白質家族,該等小蛋白質在免疫反應之發展及控制中起關鍵作用。某些細胞介素與包括神經及皮膚損傷之病理性疼痛行為的起始及持續相關。最近發現的細胞介素,介白素-31(IL-31)與慢性皮膚炎症之誘導有關(Dillon等人(2004)
Nat. Immunol. 5, 752-760)。人類及鼠類資料已顯示,IL-31之高表現與嚴重的發炎性皮膚病症,包括搔癢症、禿髮、皮膚病變及異位性皮膚炎(AD),以及與其他調節性過敏性疾病諸如哮喘相關(Dillon等人(2004)同上;Neis等人(2006)
J. Allergy Clin. Immunol. 118, 930-937;Rabenhorst等人(2014)
Curr. Allergy Asthma Rep. 14, 423;Cornelissen等人(2012)
Eur. J. Cell Biol. 91, 552-566;Takaoka等人(2006)
Exp. Dermatol. 15, 161-167;Sonkoly等人(2006)
J. Allergy Clin. Immunol. 117, 411-417;Lewis等人(2017)
J. Eur. Acad. Dermatology Venereol. 31, 142-150)。
人類AD之實驗動物模型報告NC/Nga小鼠之搔癢相關性抓撓行為與IL-31 mRNA表現之間的強相關性(Takaoka等人同上)。發現成年AD患者與健康對照個體相比(Raap等人(2008)
J. Allergy Clin. Immunol. 122, 421-423)及小兒患者在AD發作及靜止期(Ezzat等人(2011)
J. Eur. Acad. Dermatology Venereol. 25, 334-339)的IL-31血清含量升高。
此等資料共同表明,IL-31代表開發針對人類此類皮膚發炎性疾病之治療的重要目標。拮抗劑抗IL-31單株抗體(mAb)目前正在開發用於人類健康(Pantazi等人(2017)
Nat. Rev. Drug Discov. 17, 237-238;Nemoto等人(2016)
Br. J. Dermatol. 174, 296-304)。另外,抗IL-31 mAb已在動物健康領域得到開發(Bammert等人之美國專利案第8,790,651B2號;Michels等人(2016)
Vet. Dermatol. 27, 478-e129)。舉例而言,抗hIL-31RA mAb,CIM331與IL-31RA結合,抑制IL-31信號傳導且減少嚴重搔癢症(Nemoto等人(2016)同上)。在獸醫學中,「犬類化」抗IL-31 mAb,洛吉維單抗(Lokivetmab)在臨床試驗中顯示出對犬搔癢症之功效,且目前批准作為狗的AD療法(Michels等人(2016)同上)。
IL-31為IL-6細胞介素超家族之成員,優先由T輔助2型細胞產生(Dillon等人(2004)同上)。成熟的人類IL-31(hIL-31)由141個胺基酸構成(Dillon等人(2004)同上),預測拓樸結構為四個反平行螺旋(Le Saux等人(2010)
J. Biol. Chem. 285, 3470-3477)。IL-31信號傳導路徑被認為係經由gp130樣1型細胞介素受體(IL-31RA,亦稱為GPL)及抑瘤素M受體(OSMR)介導(Dillon等人同上;Le Saux等人(2010)同上;Diveu等人(2004)
Eur. Cytokine Netw. 15, 291-302;Zhang等人(2008)
Cytokine Growth Factor Rev. 19, 347-356)。兩種受體均屬於I型細胞介素受體家族,其共有由兩個纖網蛋白III型樣域形成之共同的細胞介素結合域(CBD)(Diveu等人(2003)
J. Biol. Chem. 278, 49850-49859)。
先前研究提供人類IL-31RA(hIL-31RA)直接與hIL-31結合之免疫沈澱證據。在此等相同研究中,免疫沈澱結果未能偵測到人類OSMR(hOSMR)與hIL-31之直接結合(Le Saux等人(2010)Molecular dissection of human interleukin-31-mediated signal transduction through site-directed mutagenesis.
J. Biol. Chem. 285, 3470-3477;Diveu等人(2004)同上)。然而,當組合hIL-31RA及hOSMR時,結合之增加為突出的,表明hIL-31首先與hIL-31RA結合,此時募集hOSMR形成三元複合物(Le Saux等人(2010)同上;Diveu等人(2004)同上)。在此模型中,三元複合物活化許多下游信號傳導路徑(Dillon等人(2004)同上;Le Saux等人(2010)同上;Diveu等人(2004)同上;Dambacher等人(2007)
Gut 56, 1257-1265;Dreuw等人(2004)
J. Biol. Chem. 279, 36112-36120)。
基於IL-6/IL-6 α受體/gp130複合物之結構(
Boulanger等人(2003)
Science. 300, 2101-2104),IL-6細胞介素超家族被認為經由三個不同的接觸結合位點(位點I、II及III)與其受體相互作用。Le Saux等人使用計算分析及稀疏丙胺酸掃描,僅將位點II及III劃定為hIL-31與其受體之間相互作用的關鍵結合位點(Le Saux等人(2010)同上)。特定言之,Glu44、Glu106及His110鑑別為結合位點II之關鍵殘基,而Lys134經鑑別在結合位點III內。
申請人發起了一項研究,以深入瞭解貓IL-31(fIL-31)與其貓受體fOSMR及fIL-31RA之間的相互作用,且繪製稱為mAb #1或15H05之抗fIL-31 mAb的構形抗原決定基(Medina-Cucurella AV等人;Feline Interleukin-31 Shares Overlapping Epitopes with the Oncostatin M Receptor and IL-31RA. Biochemistry. 2020年6月16日;59(23):2171-2181);WO2019/177697A2(Zoetis Services LLC)。相比於先前用人類同源物進行之研究,其顯示OSMR在不存在IL-31RA之情況下無法與IL-31相互作用,申請人經由多種生物物理方法發現,fOSMR直接結合fIL-31且部分干擾fIL-31RA結合。申請人使用結合精細抗原決定基定位之預測結構模型(Medina-Cucurella (2019)
Methods Mol. Biol. 1764, 101-121)、使用酵母表面呈現(Chao等人(2006)
Nat. Protoc. 1, 755-768)、切口突變誘發(Wrenbeck等人(2016)
Nat. Methods 13, 928-930)及深度定序(Araya及Fowler(2011)
Trends Biotechnol. 29, 435-442)確定fOSMR、fIL31-RA及抗fIL-31 mAb之潛在fIL-31結合位點。所構築之結合位點與先前Le Saux等人同上發現之位點一致,且顯示兩種受體之間的額外重疊位點,申請人稱之為「共享位點」。具體而言,IL31-RA之結合位點含有fIL-31位置E20及K82,而OSMR之結合位點包含「PADNFERK」模體(P103-K110)及位置G39及K100,其與先前對人類同源物之研究一致。然而,申請人之結果亦揭露兩種貓受體之間的新重疊位點,由位置R69、R72、P73、D76、D81及E97構成,先前關於人類未報告過。抑制OSMR及IL-31RA之抗貓IL-31 mAb的構形抗原決定基亦定位至此共享位點。總之,申請人之結果顯示,fIL-31經由部分分享的抗原決定基獨立地結合IL-31RA及OSMR。此等結果表明,諸如貓之伴侶動物的IL-31信號傳導機制可能與人類之IL-31信號傳導機制不同。此又暗示在伴侶動物中拮抗IL-31介導之信號傳導的有效治療策略可能與在高等動物中拮抗IL-31介導之信號傳導的治療策略不同。
期望提供治療性單株抗體,其與犬及/或貓抑瘤素M受體β次單元(OSMR-β)結合且拮抗犬科動物及/或貓科動物之OSM介導及/或IL-31介導之信號傳導。此類抗體將較佳用於診斷及/或治療犬科動物及貓科動物之與OSM及IL-31相關之疾病,包括狗及貓之嚴重發炎性皮膚病症,諸如過敏性皮膚炎及異位性皮膚炎及纖維變性病況,諸如皮膚或腎纖維化。
細胞模型描述OSM藉由影響編碼參與支持結構/代謝、炎症/先天性免疫及組織重塑之蛋白質之基因的表現來調節人類角質細胞功能的作用。(Boniface K等人;Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin
inflammation. J Immunol.2007年4月1日;178(7):4615-22)。此等研究者提供令人信服的證據,證明OSM介導之OSMR活化在使用重組表皮中之初級角質細胞的細胞模型中由角質細胞活化引起之皮膚炎症中的作用。在此等角質細胞培養物中,OSM介導之OSMR活化上調與皮膚之牛皮癬性及異位性疾病一致的基因表現型。此等資料得到發炎性皮膚病症(牛皮癬性或異位性皮膚炎(AD))患者之OSM及OSMR表現增加的支持。藉由用阻斷性單株抗體靶向OSMR-β,IL-31及OSM細胞介素之功能均將被阻斷。藉由阻斷IL-31之功能,預期將達成與洛吉維單抗類似之止癢及消炎特性,但由於對OSM之抑制,可能會達成超出洛吉維單抗之額外消炎及抗纖維變性活性。
本發明提供一種與犬或貓抑瘤素M受體β(OSMR-β)或兩者特異性結合之經分離抗體或其抗原結合部分,其中該抗體拮抗犬及/或貓細胞中IL-31介導之信號傳導或OSM介導之信號傳導或兩者。在一個實施例中,該抗體或其抗原結合部分拮抗犬及/或貓細胞中IL-31介導之信號傳導及OSM介導之信號傳導。在一個實施例中,IL-31介導之信號傳導為pSTAT信號傳導,諸如但不限於pSTAT3信號傳導。在另一個實施例中,OSM介導之信號傳導為pSTAT信號傳導,諸如但不限於pSTAT3信號傳導。
在一個實施例中,本發明之抗體或其抗原結合部分包括選自以下之互補決定區(CDR)序列之組合:
1) 02D09:SEQ ID NO: 1(DYGMH)之可變重鏈(VH)-CDR1、SEQ ID NO: 2(YISSGSRAVFFADTVKG)之VH-CDR、SEQ ID NO: 3(DRYDGRGFAY)之VH-CDR3、SEQ ID NO: 4(RASQSISNNLH)之可變輕鏈(VL)-CDR1、SEQ NO: 5(YASQSIS)之VL-CDR2及SEQ ID NO: 6(QQSNSWPLT)之VL-CDR3;
2) 09E09:SEQ ID NO: 7(SYAMS)之VH-CDR1、SEQ ID NO: 8(YISSGGDYIYYADTVKG)之VH-CDR2、SEQ ID NO: 9(DPITGTFAY)之VH-CDR3、SEQ ID NO: 10 (RASQDINNYLN)之VL-CDR1、SEQ ID NO: 11(YTSTLHS)之VL-CDR2及SEQ ID NO: 12(QQGNTLPWT)之VL-CDR3;
3) 10F07:SEQ ID NO: 13(SYAMS)之VH-CDR1、SEQ ID NO: 14(YISSGGDYFYYADTVKG)之VH-CDR2、SEQ ID NO: 15(DPITGTFAY)之VH-CDR3、SEQ ID NO: 16 (RASQDITNYLN)之VL-CDR1、SEQ ID NO: 17 (YTSTLHS)之VL-CDR2及SEQ ID NO: 18(QQGHMLPWT)之VL-CDR3;
4) 14C04:SEQ ID NO: 19(NYWMN)之VH-CDR1、SEQ ID NO: 20(QIYPGHVNTNYNGNFKD)之VH-CDR2、SEQ ID NO: 21(SADNSGFVLFAY)之VH-CDR3、SEQ ID NO: 22(RASKSVSTSGYSYLH)之VL-CDR1、SEQ ID NO: 23(LASNLES)之VL-CDR2及SEQ ID NO: 24(QHSRELPLT)之VL-CDR3;
5) 19F07:SEQ ID NO: 25(DYYMA)之VH-CDR1、SEQ ID NO: 26(NINYDGSSTYYLDSLKS)之VH-CDR2、SEQ ID NO: 27(GLTWDFDV)之VH-CDR3、SEQ ID NO: 28 (KASQDVDTAVA)之VL-CDR1、SEQ ID NO: 29 (LASTRHT)之VL-CDR2及SEQ ID NO: 30(QQYSRFPLT)之VL-CDR3;或
6) 1、2、3、4或5之CDR變異體。
在親本抗體之CDR變異體的一些實施例中,位於親本抗體02D09、09E09、10F07及19F07中實例部分之表A中所示之突變位置的胺基酸殘基在各自親本抗體之CDR變異體中為保守的。
在其他實施例中,19F07親本抗體之CDR變異體提供於實例部分之表B中。具體而言,表B提供19F07抗體之各CDR的通用描述,且顯示19F07之各CDR的可允許的胺基酸取代。
在一個實施例中,抗體為嵌合的。在另一個實施例中,抗體為犬類化或貓類化的。
在一個實施例中,抗體抑制或中和狗或貓之IL-31介導或OSM介導之搔癢性或過敏性病況。在一個態樣中,IL-31介導或OSM介導之搔癢性病況係選自異位性皮膚炎、濕疹、牛皮癬、硬皮病及搔癢症。在另一態樣中,IL-31介導或OSM介導之過敏性病況係選自過敏性皮膚炎、夏季濕疹、蕁麻疹、氣喘病、發炎性氣道疾病、復發性氣道阻塞、氣道高反應性、慢性阻塞性肺病及由自體免疫導致之發炎性過程。
在一個實施例中,抗體抑制IL-31介導或OSM介導之纖維變性或發炎性病症。在一個態樣中,IL-31介導或OSM介導之纖維變性病症係選自腎纖維化、肺纖維化及皮膚纖維化。在另一態樣中,IL-31介導或OSM介導之發炎性病症係選自由自體免疫導致之發炎性過程、受骨關節炎影響之動物的皮膚或關節之炎症、免疫介導之多發性關節炎、慢性支氣管炎、過敏性哮喘、異位性皮膚炎、過敏性皮膚炎、膿性創傷性皮膚炎、動脈粥樣硬化及心血管疾病。
在另一實施例中,抗體減少IL-31介導或OSM介導之發炎性疼痛。在一個態樣中,IL-31介導或OSM介導之發炎性疼痛為骨關節炎疼痛。
本發明亦提供一種獸用組合物,其包含治療有效量之如上所述之抗體。
本發明亦提供一種治療個體之IL-31介導或OSM介導之病症的方法,其包含向該個體投予根據本發明之抗體。在此方法之一個實施例中,IL-31介導或OSM介導之病症係選自搔癢性病況、過敏性病況、纖維變性病症、發炎性病症或發炎性疼痛。
在治療方法之另一個實施例中,IL-31介導或OSM介導之搔癢性病況係選自由異位性皮膚炎、濕疹、牛皮癬、硬皮病及搔癢症組成之群。在該方法之又一個實施例中,IL-31介導或OSM介導之過敏性病況係選自過敏性皮膚炎、夏季濕疹、蕁麻疹、氣喘病、發炎性氣道疾病、復發性氣道阻塞、氣道高反應性、慢性阻塞性肺病或由自體免疫導致之發炎性過程。
在治療方法之其他實施例中,IL-31介導或OSM介導之纖維變性病症係選自腎纖維化、肺纖維化或皮膚纖維化。在該方法之另一個實施例中,IL-31介導或OSM介導之發炎性病症係選自由自體免疫導致之發炎性過程、受骨關節炎影響之動物的皮膚或關節之炎症、免疫介導之多發性關節炎、慢性支氣管炎、過敏性哮喘、異位性皮膚炎、過敏性皮膚炎、膿性創傷性皮膚炎、動脈粥樣硬化或心血管疾病。
在治療方法之再一個實施例中,IL-31介導或OSM介導之發炎性疼痛為骨關節炎疼痛。
在治療方法之一個實施例中,個體為狗或貓。
本發明進一步提供一種抑制狗或貓之IL-31及/或OSM活性的方法,其包含向狗或貓投予如上所述之抗體。
亦提供一種偵測樣品中之OSMR β的方法。此方法包括在如上所述之抗體存在下培育包含OSMR β之樣品;及偵測與樣品中之OSMR β結合的抗體。在此方法之一個實施例中,抗體包含標記。在一個實施例中,偵測方法進一步包括定量樣品中之OSMR β。
本發明亦提供可用於產生本發明之抗體或其抗原結合部分的宿主細胞及核酸。在一個實施例中,本發明提供一種產生經分離抗體或其抗原結合部分的宿主細胞,該抗體或其抗原結合部分包括以下互補決定區(CDR)序列之組合中之至少一者:
1) 02D09:SEQ ID NO: 1(DYGMH)之可變重鏈(VH)-CDR1、SEQ ID NO: 2(YISSGSRAVFFADTVKG)之VH-CDR2、SEQ ID NO: 3(DRYDGRGFAY)之VH-CDR3、SEQ ID NO: 4(RASQSISNNLH)之可變輕鏈(VL)-CDR1、SEQ NO: 5(YASQSIS)之VL-CDR2及SEQ ID NO: 6 (QQSNSWPLT)之VL-CDR3;
2) 09E09:SEQ ID NO: 7(SYAMS)之VH-CDR1、SEQ ID NO: 8(YISSGGDYIYYADTVKG)之VH-CDR2、SEQ ID NO: 9(DPITGTFAY)之VH-CDR3、SEQ ID NO: 10 (RASQDINNYLN)之VL-CDR1、SEQ ID NO: 11(YTSTLHS)之VL-CDR2及SEQ ID NO: 12(QQGNTLPWT)之VL-CDR3;
3) 10F07:SEQ ID NO: 13(SYAMS)之VH-CDR1、SEQ ID NO: 14(YISSGGDYFYYADTVKG)之VH-CDR2、SEQ ID NO: 15(DPITGTFAY)之VH-CDR3、SEQ ID NO: 16 (RASQDITNYLN)之VL-CDR1、SEQ ID NO: 17(YTSTLHS)之VL-CDR2及SEQ ID NO: 18(QQGHMLPWT)之
VL-CDR3;
4) 14C04:SEQ ID NO: 19(NYWMN)之VH-CDR1、SEQ ID NO: 20(QIYPGHVNTNYNGNFKD)之VH-CDR2、SEQ ID NO: 21(SADNSGFVLFAY)之VH-CDR3、SEQ ID NO: 22(RASKSVSTSGYSYLH)之VL-CDR1、SEQ ID NO: 23 (LASNLES)之VL-CDR2及SEQ ID NO: 24(QHSRELPLT)之VL-CDR3;
5) 19F07:SEQ ID NO: 25(DYYMA)之VH-CDR1、SEQ ID NO: 26(NINYDGSSTYYLDSLKS)之VH-CDR2、SEQ ID NO: 27(GLTWDFDV)之VH-CDR3、SEQ ID NO: 28 (KASQDVDTAVA)之VL-CDR1、SEQ ID NO: 29 (LASTRHT)之VL-CDR2及SEQ ID NO: 30(QQYSRFPLT)之VL-CDR3;或
6) 1、2、3、4或5之CDR變異體。
本發明亦提供一種經分離核酸,其包括編碼以下可變重鏈互補決定區(CDR)序列之組合中之至少一者的核酸序列:
1) 02D09:SEQ ID NO: 1(DYGMH)之可變重鏈(VH)-CDR1、SEQ ID NO: 2(YISSGSRAVFFADTVKG)之VH-CDR2及SEQ ID NO: 3(DRYDGRGFAY)之VH-CDR3;
2) 09E09:SEQ ID NO: 7(SYAMS)之VH-CDR1、SEQ ID NO: 8(YISSGGDYIYYADTVKG)之VH-CDR2及SEQ ID NO: 9(DPITGTFAY)之VH-CDR3;
3) 10F07:SEQ ID NO: 13(SYAMS)之VH-CDR1、SEQ ID NO: 14(YISSGGDYFYYADTVKG)之VH-CDR2及SEQ ID NO: 15(DPITGTFAY)之VH-CDR3;
4) 14C04:SEQ ID NO: 19(NYWMN)之VH-CDR1、SEQ ID NO: 20(QIYPGHVNTNYNGNFKD)之VH-CDR2及SEQ ID NO: 21(SADNSGFVLFAY)之VH-CDR3;
5) 19F07:SEQ ID NO: 25(DYYMA)之VH-CDR1、SEQ ID NO: 26(NINYDGSSTYYLDSLKS)之VH-CDR2及SEQ ID NO: 27(GLTWDFDV)之VH-CDR3;或
6) 1、2、3、4或5之CDR變異體。
在一個實施例中,上述核酸進一步包括編碼以下可變輕鏈CDR序列之組合中之至少一者的核酸序列:
1)02D09:SEQ ID NO: 4(RASQSISNNLH)之可變輕鏈(VL)-CDR1、SEQ NO: 5(YASQSIS)之VL-CDR2及SEQ ID NO: 6(QQSNSWPLT)之VL-CDR3;
2)09E09:SEQ ID NO: 10(RASQDINNYLN)之VL-CDR1、SEQ ID NO: 11(YTSTLHS)之VL-CDR2及SEQ ID NO: 12(QQGNTLPWT)之VL-CDR3;
3)10F07:SEQ ID NO: 16(RASQDITNYLN)之VL-CDR1、SEQ ID NO: 17(YTSTLHS)之VL-CDR2及SEQ ID NO: 18(QQGHMLPWT)之VL-CDR3;
4)14C04:SEQ ID NO: 22(RASKSVSTSGYSYLH)之VL-CDR1、SEQ ID NO: 23(LASNLES)之VL-CDR2及SEQ ID NO: 24(QHSRELPLT)之VL-CDR3;
5)19F07:SEQ ID NO: 28(KASQDVDTAVA)之VL-CDR1、SEQ ID NO: 29(LASTRHT)之VL-CDR2及SEQ ID NO: 30(QQYSRFPLT)之VL-CDR3;或
6)1、2、3、4或5之CDR變異體。
在另一個實施例中,根據本發明之核酸序列編碼以下可變輕鏈CDR序列之組合中之至少一者:
1)02D09:SEQ ID NO: 4(RASQSISNNLH)之可變輕鏈(VL)-CDR1、SEQ NO: 5(YASQSIS)之VL-CDR2及SEQ ID NO: 6(QQSNSWPLT)之VL-CDR3;
2)09E09:SEQ ID NO: 10(RASQDINNYLN)之VL-CDR1、SEQ ID NO: 11(YTSTLHS)之VL-CDR2及SEQ ID NO: 12(QQGNTLPWT)之VL-CDR3;
3)10F07:SEQ ID NO: 16(RASQDITNYLN)之VL-CDR1、SEQ ID NO: 17(YTSTLHS)之VL-CDR2及SEQ ID NO: 18(QQGHMLPWT)之VL-CDR3;
4)14C04:SEQ ID NO: 22(RASKSVSTSGYSYLH)之VL-CDR1、SEQ ID NO: 23(LASNLES)之VL-CDR2及SEQ ID NO: 24(QHSRELPLT)之VL-CDR3;
5)19F07:SEQ ID NO: 28(KASQDVDTAVA)之VL-CDR1、SEQ ID NO: 29(LASTRHT)之VL-CDR2及SEQ ID NO: 30(QQYSRFPLT)之VL-CDR3;或
6)1、2、3、4或5之CDR變異體。
本發明進一步提供一種載體,其包括如上所述之核酸。
此外,本發明提供一種產生抗體之方法。此方法包括在引起抗體產生之條件下培養上述宿主細胞,及自宿主細胞或宿主細胞之培養基分離抗體。
序列之簡要描述
SEQ ID NO: 1為在本文中稱為02D09-VH-CDR1之可變重鏈CDR1;
SEQ ID NO: 2為在本文中稱為02D09-VH-CDR2之可變重鏈CDR2;
SEQ ID NO: 3為在本文中稱為02D09-VH-CDR3之可變重鏈CDR3;
SEQ ID NO: 4為在本文中稱為02D09-VL-CDR1之可變輕鏈CDR1;
SEQ ID NO: 5為在本文中稱為02D09-VL-CDR2之可變輕鏈CDR2;
SEQ ID NO: 6為在本文中稱為02D09-VL-CDR3之可變輕鏈CDR3;
SEQ ID NO: 7為在本文中稱為09E09-VH-CDR1之可變重鏈CDR1;
SEQ ID NO: 8為在本文中稱為09E09-VH-CDR2之可變重鏈CDR2;
SEQ ID NO: 9為在本文中稱為09E09-VH-CDR3之可變重鏈CDR3;
SEQ ID NO: 10為在本文中稱為09E09-VL-CDR1之可變輕鏈CDR1;
SEQ ID NO: 11為在本文中稱為09E09-VL-CDR2之可變輕鏈CDR2;
SEQ ID NO: 12為在本文中稱為09E09-VL-CDR3之可變輕鏈CDR3;
SEQ ID NO: 13為在本文中稱為10F07-VH-CDR1之可變重鏈CDR1;
SEQ ID NO: 14為在本文中稱為10F07-VH-CDR2之可變重鏈CDR2;
SEQ ID NO: 15為在本文中稱為10F07-VH-CDR3之可變重鏈CDR3;
SEQ ID NO: 16為在本文中稱為10F07-VL-CDR1之可變輕鏈CDR1;
SEQ ID NO: 17為在本文中稱為10F07-VL-CDR2之可變輕鏈CDR2;
SEQ ID NO: 18為在本文中稱為10F07-VL-CDR3之可變輕鏈CDR3;
SEQ ID NO: 19為在本文中稱為14C04-VH-CDR1之可變重鏈CDR1;
SEQ ID NO: 20為在本文中稱為14C04-VH-CDR2之可變重鏈CDR2;
SEQ ID NO: 21為在本文中稱為14C04-VH-CDR3之可變重鏈CDR3;
SEQ ID NO: 22為在本文中稱為14C04-VL-CDR1之可變輕鏈CDR1;
SEQ ID NO: 23為在本文中稱為14C04-VL-CDR2之可變輕鏈CDR2;
SEQ ID NO: 24為在本文中稱為14C04-VL-CDR3之可變輕鏈CDR3;
SEQ ID NO: 25為在本文中稱為19F07-VH-CDR1之可變重鏈CDR1;
SEQ ID NO: 26為在本文中稱為19F07-VH-CDR2之可變重鏈CDR2;
SEQ ID NO: 27為在本文中稱為19F07-VH-CDR3之可變重鏈CDR3;
SEQ ID NO: 28為在本文中稱為19F07-VL-CDR1之可變輕鏈CDR1;
SEQ ID NO: 29為在本文中稱為19F07-VL-CDR2之可變輕鏈CDR2;
SEQ ID NO: 30為在本文中稱為19F07-VL-CDR3之可變輕鏈CDR3;
SEQ ID NO: 31為在本文中稱為MU_02D09_VH之可變重鏈序列;
SEQ ID NO: 32為編碼在本文中稱為MU_02D09_VH之可變重鏈序列的核苷酸序列;
SEQ ID NO: 33為在本文中稱為MU_02D09_VL之可變輕鏈序列;
SEQ ID NO: 34為編碼在本文中稱為MU_02D09_VL之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 35為在本文中稱為MU_09E09_VH之可變重鏈序列;
SEQ ID NO: 36為編碼在本文中稱為MU_09E09_VH之可變重鏈序列的核苷酸序列;
SEQ ID NO: 37為在本文中稱為MU_09E09_VL之可變輕鏈序列;
SEQ ID NO: 38為編碼在本文中稱為MU_09E09_VL之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 39為在本文中稱為MU_10F07_VH之可變重鏈序列;
SEQ ID NO: 40為編碼在本文中稱為MU_10F07_VH之可變重鏈序列的核苷酸序列;
SEQ ID NO: 41為在本文中稱為MU_10F07_VL之可變輕鏈序列;
SEQ ID NO: 42為編碼在本文中稱為MU_10F07_VL之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 43為在本文中稱為MU_14C04_VH之可變重鏈序列;
SEQ ID NO: 44為編碼在本文中稱為MU_14C04_VH之可變重鏈序列的核苷酸序列;
SEQ ID NO: 45為在本文中稱為MU_14C04_VL之可變輕鏈序列;
SEQ ID NO: 46為編碼在本文中稱為MU_14C04_VL之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 47為在本文中稱為MU_19F07_VH之可變重鏈序列;
SEQ ID NO: 48為編碼在本文中稱為MU_19F07_VH之可變重鏈序列的核苷酸序列;
SEQ ID NO: 49為在本文中稱為MU_19F07_VL之可變輕鏈序列;
SEQ ID NO: 50為編碼在本文中稱為MU_19F07_VL之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 51為在本文中稱為FEL_02D09_VH1之可變重鏈序列;
SEQ ID NO: 52為編碼在本文中稱為FEL_02D09_VH1之可變重鏈序列的核苷酸序列;
SEQ ID NO: 53為在本文中稱為FEL_02D09_VH2之可變重鏈序列;
SEQ ID NO: 54為編碼在本文中稱為FEL_02D09_VH2之可變重鏈序列的核苷酸序列;
SEQ ID NO: 55為在本文中稱為FEL_02D09_VL1之可變輕鏈序列;
SEQ ID NO: 56為編碼在本文中稱為FEL_02D09_VL1之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 57為在本文中稱為FEL_02D09_VL2之可變輕鏈序列;
SEQ ID NO: 58為編碼在本文中稱為FEL_02D09_VL2之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 59為在本文中稱為CAN_09E09_VH1之可變重鏈序列;
SEQ ID NO: 60為編碼在本文中稱為CAN_09E09_VH1之可變重鏈序列的核苷酸序列;
SEQ ID NO: 61為在本文中稱為CAN_09E09_VH2之可變重鏈序列;
SEQ ID NO: 62為編碼在本文中稱為CAN_09E09_VH2之可變重鏈序列的核苷酸序列;
SEQ ID NO: 63為在本文中稱為CAN_09E09_VL1之可變輕鏈序列;
SEQ ID NO: 64為編碼在本文中稱為CAN_09E09_VL1之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 65為在本文中稱為CAN_09E09_VL2之可變輕鏈序列;
SEQ ID NO: 66為編碼在本文中稱為CAN_09E09_VL2之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 67為在本文中稱為FEL_09E09_VH1之可變重鏈序列;
SEQ ID NO: 68為編碼在本文中稱為FEL_09E09_VH1之可變重鏈序列的核苷酸序列;
SEQ ID NO: 69為在本文中稱為FEL_09E09_VH2之可變重鏈序列;
SEQ ID NO: 70為編碼在本文中稱為FEL_09E09_VH2之可變重鏈序列的核苷酸序列;
SEQ ID NO: 71為在本文中稱為FEL_09E09_VL1之可變輕鏈序列;
SEQ ID NO: 72為編碼在本文中稱為FEL_09E09_VL1之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 73為在本文中稱為FEL_09E09_VL2之可變輕鏈序列;
SEQ ID NO: 74為編碼在本文中稱為FEL_09E09_VL2之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 75為在本文中稱為CAN_10F07_VH1之可變重鏈序列;
SEQ ID NO: 76為編碼在本文中稱為CAN_10F07_VH1之可變重鏈序列的核苷酸序列;
SEQ ID NO: 77為在本文中稱為CAN_10F07_VL1之可變輕鏈序列;
SEQ ID NO: 78為編碼在本文中稱為CAN_10F07_VL1之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 79為在本文中稱為CAN_10F07_VH2之可變重鏈序列;
SEQ ID NO: 80為編碼在本文中稱為CAN_10F07_VH2之可變重鏈序列的核苷酸序列;
SEQ ID NO: 81為在本文中稱為CAN_10F07_VL2之可變輕鏈序列;
SEQ ID NO: 82為編碼在本文中稱為CAN_10F07_VL2之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 83為在本文中稱為FEL_10F07_VH1之可變重鏈序列;
SEQ ID NO: 84為編碼在本文中稱為FEL_10F07_VH1之可變重鏈序列的核苷酸序列;
SEQ ID NO: 85為在本文中稱為FEL_10F07_VL1之可變輕鏈序列;
SEQ ID NO: 86為編碼在本文中稱為FEL_10F07_VL1之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 87為在本文中稱為FEL_10F07_VH2之可變重鏈序列;
SEQ ID NO: 88為編碼在本文中稱為FEL_10F07_VH2之可變重鏈序列的核苷酸序列;
SEQ ID NO: 89為在本文中稱為FEL_10F07_VL2之可變輕鏈序列;
SEQ ID NO: 90為編碼在本文中稱為FEL_10F07_VL2之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 91為在本文中稱為CAN_19F07_VH1之可變重鏈序列;
SEQ ID NO: 92為編碼在本文中稱為CAN_19F07_VH1之可變重鏈序列的核苷酸序列;
SEQ ID NO: 93為在本文中稱為CAN_19F07_VL1之可變輕鏈序列;
SEQ ID NO: 94為編碼在本文中稱為CAN_19F07_VL1之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 95為在本文中稱為CAN_19F07_VH2之可變重鏈序列;
SEQ ID NO: 96為編碼在本文中稱為CAN_19F07_VH2之可變重鏈序列的核苷酸序列;
SEQ ID NO: 97為在本文中稱為CAN_19F07_VL2之可變輕鏈序列;
SEQ ID NO: 98為編碼在本文中稱為CAN_19F07_VL2之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 99為在本文中稱為FEL_19F07_VH1之可變重鏈序列;
SEQ ID NO: 100為編碼在本文中稱為FEL_19F07_VH1之可變重鏈序列的核苷酸序列;
SEQ ID NO: 101為在本文中稱為FEL_19F07_VL1之可變輕鏈序列;
SEQ ID NO: 102為編碼在本文中稱為FEL_19F07_VL1之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 103為在本文中稱為FEL_19F07_VH2之可變重鏈序列;
SEQ ID NO: 104為編碼在本文中稱為FEL_19F07_VH2之可變重鏈序列的核苷酸序列;
SEQ ID NO: 105為在本文中稱為FEL_19F07_VL2之可變輕鏈序列;
SEQ ID NO: 106為編碼在本文中稱為FEL_19F07_VL2之可變輕鏈序列的核苷酸序列;
SEQ ID NO: 107為在本文中命名為犬_OSMR_hIgG1_
Fc之犬OSMR-Fc融合蛋白的胺基酸序列;
SEQ ID NO: 108為編碼在本文中命名為犬_OSMR_
hIgG1_Fc之犬OSMR-Fc融合蛋白的核苷酸序列;
SEQ ID NO: 109為對應於犬OSM之胺基酸序列,其在本文中稱為犬_OSM;
SEQ ID NO: 110為對應於貓OSM-Fc融合蛋白之胺基酸序列,其在本文中稱為貓_OSM_hIgG1_Fc;
SEQ ID NO: 111為對應於貓OSM-Fc融合蛋白之核苷酸序列,其在本文中稱為貓_OSM_hIgG1_Fc;
SEQ ID NO: 112為在本文中命名為
貓_OSMR_hIgG1_Fc之貓OSMR-Fc融合蛋白的胺基酸序列;
SEQ ID NO: 113為編碼在本文中命名為
貓_OSMR_hIgG1_Fc之貓OSMR-Fc融合蛋白的核苷酸序列;
SEQ ID NO: 114為在本文中稱為犬_HC_65_1之犬重鏈恆定區的胺基酸序列;
SEQ ID NO: 115為編碼在本文中稱為犬_HC_65_1之犬重鏈恆定區的核苷酸序列;
SEQ ID NO: 116為在本文中稱為犬_LC_Kappa之犬輕鏈恆定區的胺基酸序列;
SEQ ID NO: 117為編碼在本文中稱為犬_LC_Kappa之犬輕鏈恆定區的核苷酸序列;
SEQ ID NO: 118為在本文中稱為貓_HC_AlleleA_1之貓重鏈恆定區的胺基酸序列;
SEQ ID NO: 119為編碼在本文中稱為貓_HC_AlleleA_1之貓重鏈恆定區的核苷酸序列;
SEQ ID NO: 120為在本文中稱為
貓_LC_Kappa_G_minus之貓輕鏈恆定區的胺基酸序列;
SEQ ID NO: 121為編碼在本文中稱為
貓_LC_Kappa_G_minus之貓輕鏈恆定區之胺基酸序列的核苷酸序列;
SEQ ID NO: 122為在本文中稱為人類_OSMR之人類OSMR蛋白的胺基酸序列;
SEQ ID NO: 123為在本文中稱為犬_IL31之犬IL31蛋白的胺基酸序列;
SEQ ID NO: 124為編碼在本文中稱為犬_IL31之犬IL31蛋白的核苷酸序列;
SEQ ID NO: 125為在本文中稱為貓_IL31之貓IL31蛋白的胺基酸序列;
SEQ ID NO: 126為編碼在本文中稱為貓_IL31之貓IL31蛋白的核苷酸序列;
SEQ ID NO: 127為在本文中稱為CAN_14C04_VH1之可變重鏈序列;
SEQ ID NO: 128為編碼在本文中稱為
CAN_14C04_VH1之可變重鏈序列的核苷酸序列;
SEQ ID NO: 129為在本文中稱為CAN_14C04_VH2之可變重鏈序列;
SEQ ID NO: 130為編碼在本文中稱為
CAN_14C04_VH2之可變重鏈序列的核苷酸序列;
SEQ ID NO: 131為在本文中稱為CAN_14C04_VL1之可變重鏈序列;
SEQ ID NO: 132為編碼在本文中稱為
CAN_14C04_VL2之可變重鏈序列的核苷酸序列;
SEQ ID NO: 133為在本文中稱為CAN_14C04_VL1之可變重鏈序列;
SEQ ID NO: 134為編碼在本文中稱為
CAN_14C04_VL2之可變重鏈序列的核苷酸序列;
SEQ ID NO: 135為在本文中命名為人類_LIFR之人類LIFR蛋白的胺基酸序列;
SEQ ID NO: 136為在本文中命名為人類_LIF之人類LIF蛋白的胺基酸序列;
定義
在詳細描述本發明之前,將定義在本發明之上下文中使用的若干術語。除此等術語以外,其他術語視需要在說明書中之其他地方定義。除非本文中另外明確定義,否則本說明書中所用之技術術語將具有其在此項技術中公認的含義。
如本說明書及申請專利範圍中所用,除非上下文另外明確規定,否則單數形式「一(a/an)」及「該」包括複數個提及物。舉例而言,提及「抗體」包括複數個此類抗體。
如本文所用,術語「包含」欲意謂組合物及方法包括所列舉之元素,但不排除其他元素。
如本文所用,抗原決定基係指由抗體之CDR識別的抗原決定子。換言之,抗原決定基係指任何分子中能夠由抗體識別及結合的部分。除非另外指明,否則如本文所用之術語「抗原決定基」係指抗OSMR β劑對其有反應的OSMR β區域。
「抗原」為能夠與抗體結合之分子或分子之一部分,其另外能夠由抗體識別及結合(相應的抗體結合區可稱為互補位)。一般而言,抗原決定基由分子之化學活性表面分組組成,例如胺基酸或糖側鏈,且具有特定的三維結構特徵以及特定的電荷特徵。
在抗體結合之情況下,術語「特異性」係指抗體與特異性抗原(亦即多肽或抗原決定基)之高活動性及/或高親和力結合。在許多實施例中,特異性抗原為用於使動物宿主免疫之抗原(或抗原之片段或亞部分),而產生抗體之細胞係自該動物宿主分離。抗體與抗原之特異性結合強於相同抗體與其他抗原之結合。與多肽特異性結合之抗體可能能夠以較弱但可偵測之水準(例如,與所關注之多肽顯示之結合的10%或更小)結合其他多肽。此類弱結合或背景結合容易自與主題多肽之特異性抗體結合辨別出來,例如藉由使用適當對照。一般而言,特異性抗體與抗原結合之結合親和力的K
D為10
-7M或更小,例如10
-8M或更小(例如,10
-9M或更小、10
-10或更小、10
-11或更小、10
-12或更小或10
-13或更小等)。
如本文所用,術語「抗體」係指具有兩條輕鏈及兩條重鏈之完整免疫球蛋白。因此,單個經分離抗體或片段可為多株抗體、單株抗體、合成抗體、重組抗體、嵌合抗體、異嵌合抗體、犬類化抗體或貓類化抗體。術語「抗體」較佳係指單株抗體及其片段,及其可與OSMR β蛋白及其片段結合之免疫結合等效物。術語抗體用於指均質分子,或由複數個不同分子實體構成之混合物,諸如血清產品。
「原生抗體」及「原生免疫球蛋白」通常為由兩條相同輕(L)鏈及兩條相同重(H)鏈構成之約150,000道爾頓的異四聚體糖蛋白。各輕鏈藉由一個共價二硫鍵與重鏈連接,而不同免疫球蛋白同型之重鏈之間二硫鍵的數目不同。各重鏈及輕鏈亦具有規則間隔之鏈內二硫橋鍵。各重鏈在一端具有可變域(V
H),其後為多個恆定域。各輕鏈在一端具有可變域(V
L)且在其另一端具有恆定域;輕鏈之恆定域與重鏈之第一恆定域對準,且輕鏈可變域與重鏈之可變域對準。咸信特定胺基酸殘基在輕鏈與重鏈可變域之間形成界面。
術語「抗體片段」係指小於完整的抗體結構,包括但不限於經分離之單一抗體鏈、Fv構築體、Fab構築體、Fc構築體、輕鏈可變或互補決定區(CDR)序列等。
術語「可變」區包含構架及CDR(另外稱為高變區),且係指可變域之某些部分在抗體之間的序列有廣泛的差異,且用於各特定抗體對其特定抗原之結合及特異性之事實。然而,可變性並非均勻分佈於抗體之整個可變域中。其集中於輕鏈及重鏈可變域中稱為高變區之三個區段。可變域之更高度保守的部分稱為構架區(FR)。原生重鏈及輕鏈之可變域各自包含多個FR,其主要採用β褶板組態,由三個高變區連接,形成連接α褶板結構且在一些情況下形成α褶板結構之一部分的環。各鏈中之高變區藉由FR緊密固持在一起,且與另一條鏈之高變區一起促成抗體之抗原結合位點的形成(參見Kabat等人,Sequences of Proteins of Immunological Interest,第5版。Public Health Service, National Institutes of Health, Bethesda, Md. (1991), pages 647-669)。恆定域不直接參與抗體與抗原之結合,但表現出各種效應功能,諸如抗體參與抗體依賴性細胞毒性。
當在本文中使用時,術語「高變區」係指抗體中負責抗原結合之胺基酸殘基。高變區包含來自「互補決定區」或「CDR」之胺基酸殘基(Kabat等人,(1991)同上)及/或來自「高變環」之彼等殘基(Chothia及Lesk J. Mol. Biol. 196:901-917 (1987))。「構架」或「FR」殘基為除如本文所定義之高變區殘基以外的彼等可變域殘基。
番木瓜蛋白酶消化抗體產生兩個相同的抗原結合片段,稱為「Fab」片段,其各自具有單一抗原結合位點;及殘餘「Fc」片段,其名稱反映其容易結晶之能力。胃蛋白酶處理產生F(ab')
2片段,其具有兩個抗原結合位點且仍能夠交聯抗原。
「Fv」為含有完整抗原識別及結合位點之最小抗體片段。此區域由緊密非共價締合之一條重鏈及一個輕鏈可變域的二聚體組成。在此組態中,各可變域之三個高變區相互作用以在V
H-V
L二聚體之表面上界定抗原結合位點。總體而言,六個高變區賦予抗體抗原結合特異性。然而,即使單個可變域(或僅包含對抗原具有特異性之三個高變區的一半Fv)可識別及結合抗原,儘管其親和力低於整個結合位點。
Fab片段亦含有輕鏈之恆定域及重鏈之第一恆定域(CH1)。Fab'片段與Fab片段的不同之處在於在重鏈CH1域之羧基末端添加若干殘基,包括來自抗體鉸鏈區之一或多個半胱胺酸。Fab'-SH為本文中Fab'之名稱,其中恆定域之半胱胺酸殘基帶有游離硫醇基。F(ab')
2抗體片段最初作為成對的Fab'片段產生,在其之間具有鉸鏈半胱胺酸。抗體片段之其他化學偶聯亦為已知的。
來自任何脊椎動物物種之抗體(免疫球蛋白)的「輕鏈」可基於其恆定域之胺基酸序列而歸入兩個明顯不同的類型之一,稱為κ及λ。
視其重鏈恆定域之胺基酸序列而定,免疫球蛋白可歸入不同的類別。目前存在五大類免疫球蛋白:IgA、IgD、IgE、IgG及IgM,其中一些可進一步分為亞類(同型),例如IgG1、IgG2、IgG3、IgG4、IgA及IgA2(如藉由小鼠及人類名稱所定義)。對應於不同類別之免疫球蛋白的重鏈恆定域分別稱為α、δ、ε、γ及μ。不同類別之免疫球蛋白的次單元結構及三維組態在多個物種中為眾所周知的。個別同型之盛行率及與此等恆定域相關之功能活性為物種特異性的且必須以實驗方式加以定義。
如本文所定義之「單株抗體」為由單個細胞純系(特別是單個融合瘤細胞純系)產生之抗體,且因此為單一純均質類型之抗體。所有由同一純系產生之單株抗體為相同的且具有相同的抗原特異性。術語「單株」係關於單個細胞純系、單個細胞及該細胞之後代。
本文的單株抗體具體包括「嵌合」抗體(免疫球蛋白),其中重鏈及/或輕鏈之一部分與來源於特定物種之抗體中的相應序列相同或同源,而鏈的其餘部分與來源於另一物種之抗體中的相應序列相同或同源,以及此類抗體之片段,只要其表現出所需的生物活性即可。通常,嵌合抗體為輕鏈及重鏈基因由屬於不同物種之抗體可變及恆定區基因構築的抗體,通常藉由基因工程改造。舉例而言,來自小鼠單株抗體之基因的可變區段可與犬恆定區段接合。在此實施例中,抗原結合位點來源於小鼠,而F
C部分為犬的。
非犬類(例如鼠類)抗體之「犬類化」形式為經基因工程改造之抗體,其含有來源於非犬類免疫球蛋白之最小序列。犬類化抗體為犬類免疫球蛋白序列(受體抗體),其中受體之高變區殘基經來自非犬類物種(供體抗體)諸如小鼠之具有所需特異性、親和力及能力的高變區殘基置換。在一些情況下,犬類免疫球蛋白序列之構架區(FR)殘基經相應的非犬類殘基置換。此外,犬類化抗體可包括在受體抗體或供體抗體中未發現之殘基。進行此等修飾以進一步改進抗體效能。一般而言,犬類化抗體將包括基本上全部的至少一個且通常兩個可變域,其中全部或基本上全部的高變區對應於非犬類免疫球蛋白序列之高變區,且全部或基本上全部的FR為犬類免疫球蛋白序列之FR。犬類化抗體視情況亦將包含完整或至少一部分的免疫球蛋白恆定區(Fc),通常為犬類免疫球蛋白序列之恆定區。在一個實施例中,將小鼠CDR移植至犬類構架上。
非貓類(例如鼠類)抗體之「貓類化」形式為經基因工程改造之抗體,其含有來源於非貓類免疫球蛋白之最小序列。貓類化抗體為貓類免疫球蛋白序列(受體抗體),其中受體之高變區殘基經來自非貓類物種(供體抗體)諸如小鼠之具有所需特異性、親和力及能力的高變區殘基置換。在一些情況下,貓類免疫球蛋白序列之構架區(FR)殘基經相應的非貓類殘基置換。此外,貓類化抗體可包括在受體抗體或供體抗體中未發現之殘基。進行此等修飾以進一步改進抗體效能。一般而言,貓類化抗體將包括基本上全部的至少一個且通常兩個可變域,其中全部或基本上全部的高變區對應於非貓類免疫球蛋白序列之高變區,且全部或基本上全部的FR為貓類免疫球蛋白序列之FR。貓類化抗體視情況亦將包含完整或至少一部分的免疫球蛋白恆定區(Fc),通常為貓類免疫球蛋白序列之恆定區。
如本文所定義,術語「異嵌合」係指一條抗體鏈(重鏈或輕鏈)經犬類化而另一條為嵌合的抗體。在一個實施例中,犬類化可變重鏈(其中所有CDR為小鼠的且所有FR為犬的)與嵌合可變輕鏈(其中所有CDR為小鼠的且所有FR為小鼠的)配對。在此實施例中,可變重鏈及可變輕鏈均與犬類恆定區融合。
「變異」抗OSMR β抗體在本文中係指胺基酸序列由於親本抗體序列中之一或多個胺基酸殘基的添加、缺失及/或取代而與「親本」抗OSMR β抗體胺基酸序列不同且保留親本抗OSMR β抗體之至少一種所需活性的分子。所需活性可包括特異性結合抗原之能力,降低、抑制或中和動物之OSM活性及/或IL-31活性的能力,及在基於細胞之分析中抑制OSM介導及/或IL-31介導之pSTAT信號傳導(STAT磷酸化)的能力。在一個實施例中,變異體包含親本抗體之一或多個高變(CDR)及/或構架區中的一或多個胺基酸取代。舉例而言,變異體可在親本抗體之一或多個高變(CDR)及/或構架區中包含至少一個,例如約一至約十五個,且較佳約二至約五個或二至約十個取代。在一個實施例中,變異體可在親本抗體之一或多個CDR區中包括至少約以下數目之胺基酸取代:1、2、3、4、5、6、7、8、9、10、11、12、13、14或15。在另一個實施例中,變異體可在親本抗體之一或多個CDR區中包括至多約以下數目之胺基酸取代:1、2、3、4、5、6、7、8、9、10、11、12、13、14或15。關於變異抗體,應理解,在親本抗體之任何給定CDR中之胺基酸取代數目可不同於親本抗體之其他CDR中之取代數目。在一個實施例中,變異體將具有可變重鏈CDR1、可變重鏈CDR2及可變重鏈CDR3胺基酸序列,其可各自獨立地與親本抗體之可變重鏈CDR1、可變重鏈CDR2及可變重鏈CDR3胺基酸序列具有至少5%、至少10%、至少15%、至少20%、至少25%、至少30%、至少35%、至少40%、至少45%、至少50%、至少55%、至少60%、至少65%、至少70%、至少75%、至少80%、至少85%、至少90%、至少95%或100%胺基酸序列一致性。在另一個實施例中,變異體將具有可變輕鏈CDR1、可變輕鏈CDR2及可變輕鏈CDR3胺基酸序列,其可各自獨立地與親本抗體之可變輕鏈CDR1、可變輕鏈CDR2及可變輕鏈CDR3胺基酸序列具有至少5%、至少10%、至少15%、至少20%、至少25%、至少30%、至少35%、至少40%、至少45%、至少50%、至少55%、至少60%、至少65%、至少70%、至少75%、至少80%、至少85%、至少90%、至少95%或100%胺基酸序列一致性。通常,變異體之胺基酸序列將與親本抗體重鏈或輕鏈可變域序列具有至少50%胺基酸序列一致性,更佳至少65%、更佳至少75%、更佳至少80%、更佳至少85%、更佳至少90%且最佳至少95%序列同一性。關於此序列之一致性或同源性在本文中定義為在比對序列且必要時引入空位以實現最大序列一致性百分比之後,候選序列中與親本抗體殘基一致之胺基酸殘基的百分比。抗體序列中之N端、C端或內部延伸、缺失或插入均不應理解為影響序列一致性或同源性。變異體保留結合OSMR β之能力且較佳具有優於親本抗體之活性的所需活性。舉例而言,變異體可具有較強結合親和力,增強的降低、抑制或中和動物之OSM及/或IL31活性之能力及/或增強的在基於細胞之分析中抑制OSM及/或IL-31介導之pSTAT信號傳導之能力。
「變異」核酸在本文中係指在序列上與「親本」核酸不同的分子。多核苷酸序列差異可能由突變變化引起,諸如一或多個核苷酸之缺失、取代或添加。此等變化中之每一者可在給定序列中單獨或組合發生一或多次。
本文中之「親本」抗體為由用於製備變異體之胺基酸序列編碼之抗體。較佳地,親本抗體具有犬類構架區且若存在,具有犬類抗體恆定區。舉例而言,親本抗體可為犬類化或犬類抗體。作為另一個實例,親本抗體可為貓類化或貓類抗體。作為又一個實例,親本抗體為鼠類單株抗體。
術語「經分離」意謂材料(例如抗體或核酸)自其自然環境之組分分離及/或回收。其自然環境之污染組分為會干擾材料之診斷或治療用途的材料,且可包括酶、激素及其他蛋白質或非蛋白質溶質。關於核酸,經分離核酸可包括與染色體中通常與之相關的5'至3'序列分離的核酸。在較佳實施例中,材料將純化至材料之大於95重量%且最佳大於99重量%。經分離材料包括重組細胞內之原位材料,因為該材料之自然環境中之至少一種組分將不存在。然而,通常,經分離材料將藉由至少一個純化步驟來製備。
當在本文中使用時,「標記」一詞係指直接或間接與抗體或核酸結合之可偵測化合物或組合物。標記本身可為單獨可偵測的(例如放射性同位素標記或螢光標記),或在酶標記之情況下,可催化受質化合物或組合物發生可偵測的化學變化。
術語「核酸」、「多核苷酸」、「核酸分子」等可在本文中互換使用,且係指DNA及RNA中之一系列核苷酸鹼基(亦稱為「核苷酸」)。核酸可含有去氧核糖核苷酸、核糖核苷酸及/或其類似物。術語「核酸」包括例如單股及雙股分子。核酸可為例如基因或基因片段、外顯子、內含子、DNA分子(例如cDNA)、RNA分子(例如mRNA)、重組核酸、質體及其他載體、引子及探針。包括5'至3'(有義)及3'至5'(反義)多核苷酸。
「個體」或「患者」係指需要治療且可能受本發明分子影響的動物。可根據本發明治療之動物包括脊椎動物,其中哺乳動物諸如犬科動物、貓科動物及馬科動物為尤其較佳的實例。
「治療有效量」(或「有效量」)係指當向個體或患者投予時足以實現有益或所需結果之活性成分(例如根據本發明之藥劑)的量。有效量可以一或多次投藥、施用或劑量形式投予。根據本發明之組合物之治療有效量可容易地由一般熟習此項技術者確定。在本發明之上下文中,「治療有效量」為在與治療搔癢性病況或過敏性病況相關之一或多個參數中產生客觀量測到之改變(包括症狀之臨床改善)的量。當然,治療有效量將視以下而變:所治療之特定個體及病況、個體之體重及年齡、疾病狀況之嚴重程度、所選擇之特定化合物、欲遵循之給藥方案、投藥時序、投藥方式等,其皆可容易地由一般熟習此項技術者確定。
如本文所用,術語「治療性」涵蓋疾病或病症之全方位治療。本發明之「治療性」藥劑可以預防性或防治性方式起作用,包括併入經設計以靶向可鑑別為處於風險下(藥物遺傳學)之動物之程序的彼等藥劑;或以改善或治癒性質的方式起作用;或可用以減緩所治療之疾病或病症之至少一種症狀的進展速率或程度。
「治療(Treatment)」、「治療(treating)」等係指治療性治療及預防性或防治性措施。需要治療之動物包括已患有病症之動物以及要預防病症之動物。術語「治療」疾病或病症包括預防或防止疾病或病症(亦即,致使臨床症狀不出現);抑制疾病或病症(亦即,遏制或抑制臨床症狀之發展);及/或緩解疾病或病症(亦即,致使臨床症狀消退)。如將瞭解,未必總是有可能區分「預防」及「抑制」疾病或病症,因為一或多個最終誘導事件可為未知的或潛伏的。因此,術語「預防」應理解為構成涵蓋「防治」及「抑制」之一種「治療」。因此,術語「治療」包括「預防」。
術語「過敏性病況」在本文中定義為由免疫系統與身體外來物質之間的相互作用引起的病症或疾病。此外來物質稱為「過敏原」。常見過敏原包括空氣過敏原,諸如花粉、粉塵、黴菌、塵蟎蛋白、昆蟲叮咬注射之唾液等。過敏性病況之實例包括但不限於以下:過敏性皮膚炎、夏季濕疹、蕁麻疹、氣喘病、發炎性氣道疾病、復發性氣道阻塞、氣道高反應性、慢性阻塞性肺病及由自體免疫導致之發炎性過程,諸如腸躁症候群(IBS)。
術語「搔癢性病況」在本文中定義為以強烈的癢覺為特徵的疾病或病症,其產生摩擦或抓撓皮膚之衝動以獲得緩解。搔癢性病況之實例包括但不限於以下:異位性皮膚炎、濕疹、牛皮癬、硬皮病及搔癢症。
術語「纖維變性病症」在本文中定義為以纖維化為特徵的疾病或病症,其為胞外基質組分在器官或組織中之積聚,改變其結構且導致正常功能的破壞。纖維化可發生在幾乎任何器官或組織中且與多種疾病相關。纖維變性病症類型之實例包括但不限於腎纖維化、肺纖維化及皮膚纖維化。
術語「發炎性病症」包括大量以炎症為特徵的病症及病況。實例包括但不限於由自體免疫導致之發炎性過程、受骨關節炎影響之動物的皮膚或關節之炎症、免疫介導之多發性關節炎、慢性支氣管炎、過敏性哮喘、異位性皮膚炎、過敏性皮膚炎、膿性創傷性皮膚炎、動脈粥樣硬化及心血管疾病。
如本文所用,術語「發炎性疼痛」為響應於組織損傷及炎症(例如手術後疼痛、創傷、關節炎)而發生的自發性疼痛過敏。在一個非限制性實例中,發炎性疼痛為與骨關節炎相關之疼痛。
如本文所用,術語「細胞」、「細胞株」及「細胞培養物」可互換使用。所有此等術語亦包括其子代,其為任何及所有後續世代。應理解,歸因於有意或無意突變,部分子代可能不相同。在表現異源核酸序列之上下文中,「宿主細胞」係指原核或真核細胞(例如細菌細胞、酵母細胞、哺乳動物細胞及昆蟲細胞),無論其位於活體外或活體內。舉例而言,宿主細胞可位於轉殖基因動物中。宿主細胞可用作載體之受體且可包括能夠複製載體及/或表現由載體編碼之異源核酸的任何可轉型生物體。
「組合物」欲意謂活性劑與另一種可為惰性(例如標記)或活性(諸如佐劑)之化合物或組合物的組合。
如本文所定義,適用於本發明之醫藥學上可接受之載劑為熟習此項技術者所熟知。此類載劑包括但不限於水、鹽水、緩衝鹽水、磷酸鹽緩衝液、醇/水溶液、乳液或懸浮液。其他習知採用之稀釋劑、佐劑及賦形劑可根據習知技術添加。此類載劑可包括乙醇、多元醇及其適合混合物、植物油及可注射有機酯。亦可採用緩衝液及pH調節劑。緩衝液包括但不限於由有機酸或鹼製備之鹽。代表性緩衝液包括但不限於有機酸鹽,諸如檸檬酸鹽、抗壞血酸鹽、葡糖酸鹽、組胺酸-HCl鹽、碳酸鹽、酒石酸鹽、琥珀酸鹽、乙酸鹽或鄰苯二甲酸鹽、Tris、三甲胺鹽酸鹽或磷酸鹽緩衝液。非經腸載劑可包括氯化鈉溶液、林格氏右旋糖、右旋糖、海藻糖、蔗糖及氯化鈉、乳酸林格氏溶液或不揮發性油。靜脈內載劑可包括流體及營養補充劑、電解質補充劑,諸如基於林格氏右旋糖等之補充劑。防腐劑及其他添加劑,諸如例如抗微生物劑、抗氧化劑、螯合劑(例如EDTA)、惰性氣體等亦可提供於醫藥載劑中。本發明不受載劑選擇之限制。由上述組分製備具有適當pH等張性、穩定性及其他習知特徵之此等醫藥學上可接受之組合物在此項技術之技能內。參見例如文本,諸如Remington:The Science and Practice of Pharmacy,第20版,Lippincott Williams & Wilkins, publ., 2000;及The Handbook of Pharmaceutical Excipients,第4版,R. C. Rowe等人編,APhA Publications, 2003。
術語「保守胺基酸取代」指示對給定胺基酸殘基之任何胺基酸取代,其中取代殘基與給定殘基在化學上非常相似,不會導致多肽功能(例如酶活性)之實質性降低。保守胺基酸取代為此項技術中眾所周知的,且其實例描述於例如美國專利第6,790,639號、第6,774,107號、第6,194,167號或第5,350,576號中。在一較佳實施例中,保守胺基酸取代將為發生在以下六組之一中的任一者:
● 1. 小的脂族、基本上非極性殘基:Ala、Gly、Pro、Ser及Thr;
● 2. 大的脂族、非極性殘基:Ile、Leu及Val;Met;
● 3. 極性、帶負電荷殘基及其醯胺:Asp及Glu;
● 4. 極性、帶負電荷殘基之醯胺:Asn及Gln;His;
● 5. 極性、帶正電荷殘基:Arg及Lys;His;及
● 6. 大的芳族殘基:Trp及Tyr;Phe。
在一較佳實施例中,保守胺基酸取代將為以下中之任一者,其列為原生殘基(保守取代)對:Ala(Ser);Arg(Lys);Asn(Gln;His);Asp(Glu);Gln(Asn);Glu(Asp);Gly(Pro);His(Asn;Gln);Ile(Leu;Val);Leu(Ile;Val);Lys(Arg;Gln;Glu);Met(Leu;Ile);Phe(Met;Leu;Tyr);Ser(Thr);Thr(Ser);Trp(Tyr);Tyr(Trp;Phe);及Val(Ile;Leu)。
正如多肽可含有保守胺基酸取代一般,本文的多核苷酸可含有保守密碼子取代。若密碼子取代在表現時產生如上所述之保守胺基酸取代,則將密碼子取代視為保守的。不產生胺基酸取代之簡併密碼子取代亦可用於根據本發明之多核苷酸。因此,例如編碼可用於本發明之一實施例中之所選多肽的多核苷酸可藉由簡併密碼子取代進行突變,以接近欲用其轉型之表現宿主細胞所展現的密碼子使用頻率,或以其他方式改良其表現。
應理解,本發明不限於本文所述之特定方法、方案及試劑等且因此可變化。本文所用之術語僅出於描述特定實施例之目的,且並不意欲限制本發明之範疇,本發明範疇僅由申請專利範圍界定。
除非另外定義,否則結合本文所述之抗體使用之科學與技術術語應具有一般熟習此項技術者通常所理解之含義。此外,除非上下文另外需要,否則單數術語應包括複數且複數術語應包括單數。一般而言,本文所述之與細胞及組織培養、分子生物學以及蛋白質及寡核苷酸或多核苷酸化學及雜交結合使用的命名法及其技術為此項技術中眾所周知且常用者。
標準技術用於重組DNA、寡核苷酸合成以及組織培養及轉染(例如電穿孔、脂質體轉染)。酶促反應及純化技術係根據製造商說明書或如此項技術中通常實現或如本文中所述進行。前述技術及程序一般根據此項技術中眾所周知的習知方法且如整個本說明書中引用及論述之各種一般及更具體的參考文獻所述來進行,參見例如Sambrook等人MOLECULAR CLONING: LAB. MANUAL(第3版,Cold Spring Harbor Lab. Press, Cold Spring Harbor, N.Y., 2001)及Ausubel等人Current Protocols in Molecular Biology (New York: Greene Publishing Association/Wiley Interscience), 1993。本文所述之與分析化學、合成有機化學及藥物與醫藥化學結合使用的命名法以及其實驗室程序及技術為此項技術中眾所周知且常用者。標準技術用於化學合成、化學分析、醫藥製備、調配及遞送以及患者治療。
除在操作實例中或在另外指示之情況下,表達本文所用之成分或反應條件之量的所有數字應理解為在所有情況下由術語「約」修飾。
所有確定的專利及其他出版物均以引用的方式明確併入本文中,其目的在於描述及揭示例如此類出版物中所述之可結合本發明使用之方法。此等出版物僅提供在本申請案之申請日之前的揭示內容。
本發明提供重組單株抗體及肽以及其在臨床及科學程序(包括診斷程序)中之用途。隨著分子生物學及重組技術方法之出現,有可能藉由重組手段產生抗體及抗體樣分子,且從而產生編碼抗體之多肽結構中發現之特異性胺基酸序列的基因序列。此類抗體可藉由選殖編碼該等抗體之多肽鏈的基因序列或藉由直接合成該等多肽鏈,組裝合成的鏈以形成對特異性抗原決定基及抗原決定子具有親和力之活性四聚體(H
2L
2)結構來產生。此允許隨時產生具有來自不同物種及來源之中和抗體之序列特徵的抗體。
不管抗體來源,或其如何以重組方式構築,或其如何合成、活體外或活體內、使用轉殖基因動物、實驗室或商業規模之大型細胞培養、使用轉殖基因植物或藉由在製程之任何階段均不採用活生物體進行直接化學合成,所有抗體均具有類似的整體3維結構。此結構通常以H
2L
2形式給出且係指抗體通常包含兩條輕(L)胺基酸鏈及2條重(H)胺基酸鏈之事實。兩條鏈具有能夠與結構上互補之抗原目標相互作用的區域。與目標相互作用之區域稱為「可變」或「V」區且特徵在於具有不同抗原特異性之抗體的胺基酸序列不同。H或L鏈之可變區含有能夠與抗原目標特異性結合之胺基酸序列。
如本文所用,術語「抗原結合區」係指抗體分子中含有與抗原相互作用且賦予抗體對抗原之特異性及親和力的胺基酸殘基的部分。抗體結合區包括維持抗原結合殘基之適當構形所必需的「構架」胺基酸殘基。
在提供抗原結合區之H或L鏈的可變區內,有稱為「高變」之較小序列,因為其在具有不同特異性之抗體之間具有極端變異性。此類高變區亦稱為「互補決定區」或「CDR」區。此等CDR區引起抗體對特定抗原決定子結構之基本特異性。
CDR代表可變區內之非連續胺基酸段,但無論物種如何,已發現此等關鍵胺基酸序列在可變重鏈及輕鏈區內之位置在可變鏈之胺基酸序列內具有類似位置。所有抗體之可變重鏈及輕鏈各自具有三個CDR區,各區與其他區不連續。
在所有哺乳動物物種中,抗體肽含有恆定(亦即高度保守)及可變區,且在後者內,存在CDR及所謂的「構架區」,其由在重鏈或輕鏈之可變區內但在CDR外之胺基酸序列構成。
關於抗體之CDR區所識別之抗原決定子,此亦稱為「抗原決定基」。換言之,抗原決定基係指任何分子中能夠由抗體識別及結合之部分(相應的抗體結合區可稱為互補位)。
「抗原」為能夠與抗體結合之分子或分子之一部分,其另外能夠誘導動物產生能夠與彼抗原之抗原決定基結合的抗體。抗原可具有一個或多於一個抗原決定基。上文提及之特異性反應意欲指示抗原將以高度選擇性方式與其相應的抗體反應且不與可由其他抗原誘發之多種其他抗體反應。
術語「抗體」意欲包括完整的免疫球蛋白分子以及其部分、片段、肽及衍生物,諸如例如Fab、Fab'、F(ab')
2、Fv、Fse、CDR區、互補位或抗體中能夠結合抗原或抗原決定基之任何部分或肽序列。若抗體能夠與分子特異性反應,從而使分子與抗體結合,則稱抗體「能夠結合」分子。
抗體亦包括嵌合抗體、異嵌合抗體、犬類化抗體或貓類化抗體以及其片段、部分、區域、肽或衍生物,藉由任何已知技術提供,諸如但不限於酶促裂解、肽合成或重組技術。本發明之此類抗體能夠特異性結合犬OSMR β或貓OSMR β中之至少一者。抗體片段或部分可能缺乏完整抗體之Fc片段,更快速地自循環中清除,且可能具有比完整抗體更少的非特異性組織結合。抗體片段之實例可使用此項技術中熟知之方法由完整抗體產生,例如藉由用諸如番木瓜蛋白酶(以產生Fab片段)或胃蛋白酶(以產生F(ab').
2片段)之酶蛋白水解裂解。參見例如Wahl等人,24 J. Nucl. Med. 316-25 (1983)。抗體之部分可藉由上述方法中之任一者來製備,或可藉由表現重組分子之一部分來製備。舉例而言,重組抗體之CDR區可經分離且次選殖至適當表現載體中。參見例如美國專利第6,680,053號。
純系02D09、09E09、10F07、14C04及19F07核苷酸及胺基酸序列
在一些實施例中,本發明提供新穎單株抗體,其與犬OSMR β或貓OSMR β中之至少一者特異性結合。在一個實施例中,本發明之單株抗體與犬OSMR β或貓OSMR β結合且防止或抑制包含IL-31受體A(IL-31Ra)及抑瘤素M特異性受體(OsmR或OSMR β)之IL-31共受體複合物的活化。本發明之單株抗體在本文中標識為「02D09」、「09E09」、「10F07」、「14C04」及「19F07」,其係指分配給其融合瘤純系之編號。在本文中,「02D09」、「09E09」、「10F07」、「14C04」及「19F07」亦指單株抗體之部分、互補位或CDR,其與標識為02D09、09E09、10F07、14C04及19F07之OSMR β抗原決定基特異性結合,因為其能夠分別結合02D09、09E09、10F07、14C04及19F07抗體。本文所述之02D09、09E09、10F07、14C04及19F07之數種重組、嵌合、異嵌合、犬類化及/或貓類化形式可用相同的名稱指代。
在一個實施例中,本發明之抗體或其抗原結合部分包括選自以下之互補決定區(CDR)序列之組合:
1) 02D09:SEQ ID NO: 1(DYGMH)之可變重鏈(VH)-CDR1、SEQ ID NO: 2(YISSGSRAVFFADTVKG)之VH-CDR2、SEQ ID NO: 3(DRYDGRGFAY)之VH-CDR3、SEQ ID NO: 4(RASQSISNNLH)之可變輕鏈(VL)-CDR1、SEQ NO: 5(YASQSIS)之VL-CDR2及SEQ ID NO: 6
(QQSNSWPLT)之VL-CDR3;
2) 09E09:SEQ ID NO: 7(SYAMS)之VH-CDR1、SEQ ID NO: 8(YISSGGDYIYYADTVKG)之VH-CDR2、SEQ ID NO: 9(DPITGTFAY)之VH-CDR3、SEQ ID NO: 10 (RASQDINNYLN)之VL-CDR1、SEQ ID NO: 11(YTSTLHS)之VL-CDR2及SEQ ID NO: 12(QQGNTLPWT)之VL-CDR3;
3) 10F07:SEQ ID NO: 13(SYAMS)之VH-CDR1、SEQ ID NO: 14(YISSGGDYFYYADTVKG)之VH-CDR2、SEQ ID NO: 15(DPITGTFAY)之VH-CDR3、SEQ ID NO: 16 (RASQDITNYLN)之VL-CDR1、SEQ ID NO: 17(YTSTLHS)之VL-CDR2及SEQ ID NO: 18(QQGHMLPWT)之VL-CDR3;
4) 14C04:SEQ ID NO: 19(NYWMN)之VH-CDR1、SEQ ID NO: 20(QIYPGHVNTNYNGNFKD)之VH-CDR2、SEQ ID NO: 21(SADNSGFVLFAY)之VH-CDR3、SEQ ID NO: 22(RASKSVSTSGYSYLH)之VL-CDR1、SEQ ID NO: 23 (LASNLES)之VL-CDR2及SEQ ID NO: 24(QHSRELPLT)之VL-CDR3;
5) 19F07:SEQ ID NO: 25(DYYMA)之VH-CDR1、SEQ ID NO: 26(NINYDGSSTYYLDSLKS)之VH-CDR2、SEQ ID NO: 27(GLTWDFDV)之VH-CDR3、SEQ ID NO: 28 (KASQDVDTAVA)之VL-CDR1、SEQ ID NO: 29 (LASTRHT)之VL-CDR2及SEQ ID NO: 30(QQYSRFPLT)之VL-CDR3;或
6) 1、2、3、4或5之CDR變異體。
在親本抗體之CDR變異體的一些實施例中,位於親本抗體02D09、09E09、10F07及19F07中實例部分之表A中所示之突變位置的胺基酸殘基在各自親本抗體之CDR變異體中為保守的。
在其他實施例中,19F07親本抗體之CDR變異體提供於實例部分之表B中。具體而言,表B提供19F07抗體之各CDR的通用描述,且顯示19F07之各CDR的可允許的胺基酸取代。
在其他實施例中,本發明提供產生上述抗體之宿主細胞。
本發明在其範疇內亦包括編碼本發明之抗OSMR β抗體之輕鏈及重鏈之可變區的核苷酸序列。在本發明之範疇內亦包括編碼02D09、09E09、10F07、14C04及19F07抗體或其抗原結合部分之胺基酸序列的任何核苷酸序列。
本發明亦提供一種經分離核酸,其包括編碼以下可變重鏈互補決定區(CDR)序列之組合中之至少一者的核酸序列:
1) 02D09:SEQ ID NO: 1(DYGMH)之可變重鏈(VH)-CDR1、SEQ ID NO: 2(YISSGSRAVFFADTVKG)之VH-CDR2及SEQ ID NO: 3(DRYDGRGFAY)之VH-CDR3;
2) 09E09:SEQ ID NO: 7(SYAMS)之VH-CDR1、SEQ ID NO: 8(YISSGGDYIYYADTVKG)之VH-CDR2及SEQ ID NO: 9(DPITGTFAY)之VH-CDR3;
3) 10F07:SEQ ID NO: 13(SYAMS)之VH-CDR1、SEQ ID NO: 14(YISSGGDYFYYADTVKG)之VH-CDR2及SEQ ID NO: 15(DPITGTFAY)之VH-CDR3;
4) 14C04:SEQ ID NO: 19(NYWMN)之VH-CDR1、SEQ ID NO: 20(QIYPGHVNTNYNGNFKD)之VH-CDR2及SEQ ID NO: 21(SADNSGFVLFAY)之VH-CDR3;
5) 19F07:SEQ ID NO: 25(DYYMA)之VH-CDR1、SEQ ID NO: 26(NINYDGSSTYYLDSLKS)之VH-CDR2及SEQ ID NO: 27(GLTWDFDV)之VH-CDR3;或
6) 1、2、3、4或5之CDR變異體。
在一個實施例中,上述核酸進一步包括編碼以下可變輕鏈CDR序列之組合中之至少一者的核酸序列:
1)02D09:SEQ ID NO: 4(RASQSISNNLH)之可變輕鏈(VL)-CDR1、SEQ NO: 5(YASQSIS)之VL-CDR2及SEQ ID NO: 6(QQSNSWPLT)之VL-CDR3;
2)09E09:SEQ ID NO: 10(RASQDINNYLN)之VL-CDR1、SEQ ID NO: 11(YTSTLHS)之VL-CDR2及SEQ ID NO: 12(QQGNTLPWT)之VL-CDR3;
3)10F07:SEQ ID NO: 16(RASQDITNYLN)之VL-CDR1、SEQ ID NO: 17(YTSTLHS)之VL-CDR2及SEQ ID NO: 18(QQGHMLPWT)之VL-CDR3;
4)14C04:SEQ ID NO: 22(RASKSVSTSGYSYLH)之VL-CDR1、SEQ ID NO: 23(LASNLES)之VL-CDR2及SEQ ID NO: 24(QHSRELPLT)之VL-CDR3;
5)19F07:SEQ ID NO: 28(KASQDVDTAVA)之VL-CDR1、SEQ ID NO: 29(LASTRHT)之VL-CDR2及SEQ ID NO: 30(QQYSRFPLT)之VL-CDR3;或
6)1、2、3、4或5之CDR變異體。
在另一個實施例中,根據本發明之核酸序列編碼以下可變輕鏈CDR序列之組合中之至少一者:
1)02D09:SEQ ID NO: 4(RASQSISNNLH)之可變輕鏈(VL)-CDR1、SEQ NO: 5(YASQSIS)之VL-CDR2及SEQ ID NO: 6(QQSNSWPLT)之VL-CDR3;
2)09E09:SEQ ID NO: 10(RASQDINNYLN)之VL-CDR1、SEQ ID NO: 11(YTSTLHS)之VL-CDR2及SEQ ID NO: 12(QQGNTLPWT)之VL-CDR3;
3)10F07:SEQ ID NO: 16(RASQDITNYLN)之VL-CDR1、SEQ ID NO: 17(YTSTLHS)之VL-CDR2及SEQ ID NO: 18(QQGHMLPWT)之VL-CDR3;
4)14C04:SEQ ID NO: 22(RASKSVSTSGYSYLH)之VL-CDR1、SEQ ID NO: 23(LASNLES)之VL-CDR2及SEQ ID NO: 24(QHSRELPLT)之VL-CDR3;
5)19F07:SEQ ID NO: 28(KASQDVDTAVA)之VL-CDR1、SEQ ID NO: 29(LASTRHT)之VL-CDR2及SEQ ID NO: 30(QQYSRFPLT)之VL-CDR3;或
6)1、2、3、4或5之CDR變異體。
本發明進一步提供一種載體,其包括如上所述之核酸。單個表現載體可攜帶編碼可變輕鏈CDR序列之核酸序列以及編碼可變重鏈CDR序列之核酸序列。或者,編碼可變輕鏈CDR之核酸序列可由一個載體攜帶,而編碼可變重鏈CDR之核酸序列可由另一個載體攜帶。
因為遺傳密碼係簡併的,所以可使用超過一個密碼子編碼特定胺基酸。使用遺傳密碼,可確定一或多個不同的核苷酸序列,其中之每一者均能夠編碼胺基酸。特定寡核苷酸事實上構成實際XXX編碼序列之概率可藉由考慮異常鹼基配對關係及在表現抗OSMR β抗體或其部分之真核或原核細胞中實際上使用特定密碼子(編碼特定胺基酸)之頻率來估計。此類「密碼子使用規則」由Lathe等人,183 J. Molec. Biol. 1-12 (1985)揭示。使用Lathe之「密碼子使用規則」,可確定含有能夠編碼抗OSMR β序列之理論上「最可能的」核苷酸序列的單個核苷酸序列或一組核苷酸序列。
亦預期用於本發明之抗體編碼區亦可藉由使用標準分子生物學技術改變現有抗體基因來提供,產生本文所述之抗體及抗原結合部分的變異體(促效劑)。此類變異體包括但不限於抗OSMR β抗體或其抗原結合部分之胺基酸序列中的缺失、添加及取代。
舉例而言,一類取代為保守胺基酸取代。此類取代為抗OSMR β抗體序列中之給定胺基酸經具有類似特徵之另一種胺基酸取代的彼等取代。通常視為保守取代的為脂族胺基酸Ala、Val、Leu及Ile之間的相互置換;羥基殘基Ser及Thr之交換;酸性殘基Asp及Glu之交換;醯胺殘基Asn及Gln之間的取代;鹼性殘基Lys及Arg之交換;芳族殘基Phe、Tyr等之間的置換。關於哪些胺基酸變化可能在表型上為沉默的指導見於Bowie等人,247 Science 1306-10 (1990)。
變異體或促效劑抗OSMR β抗體或其抗原結合部分可為全功能的或可能在一或多種活性中缺乏功能。全功能變異體通常僅含有保守變異或非關鍵殘基或非關鍵區之變異。功能變異體亦可含有類似胺基酸之取代,導致功能無變化或變化不顯著。或者,此類取代可能在一定程度上對功能產生正面或負面影響。非功能變異體通常含有一或多個非保守胺基酸取代、缺失、插入、倒位或截短,或在關鍵殘基或關鍵區域之取代、插入、倒位或缺失。
功能必需的胺基酸可藉由此項技術中已知的方法來鑑別,諸如定點突變誘發或丙胺酸掃描突變誘發。Cunningham等人,244 Science 1081-85 (1989)。後一程序在分子中之每個殘基處引入單丙胺酸突變。隨後測試所得突變分子之生物活性,諸如抗原決定基結合或活體外ADCC活性。配體-受體結合之關鍵位點亦可藉由結構分析來確定,諸如晶體學、核磁共振或光親和性標記。Smith等人,224 J. Mol. Biol. 899-904 (1992);de Vos等人,255 Science 306-12 (1992)。
此外,多肽通常含有除二十種「天然存在」之胺基酸以外的胺基酸。此外,許多胺基酸,包括末端胺基酸,可藉由天然過程,諸如加工及其他轉譯後修飾,或藉由此項技術中眾所周知化學修飾技術來修飾。已知的修飾包括但不限於乙醯化、醯化、ADP核糖基化、醯胺化、黃素之共價連接、血紅素部分之共價連接、核苷酸或核苷酸衍生物之共價連接、脂質或脂質衍生物之共價連接、磷脂醯肌醇之共價連接、交聯、環化、二硫鍵形成、去甲基化、共價交聯之形成、胱胺酸之形成、焦麩胺酸之形成、甲醯化、γ羧化、糖基化、GPI錨形成、羥基化、碘化、甲基化、肉豆蔻醯化、氧化、蛋白質水解加工、磷酸化、異戊烯化、外消旋化、硒醯化、硫酸化、轉移RNA介導之胺基酸添加至蛋白質,諸如精胺醯化及泛素化。
此類修飾為熟習此項技術者所熟知的,且已非常詳細地描述於科學文獻中。數種特別常見的修飾,例如糖基化、脂質附接、硫酸化、麩胺酸殘基之γ-羧化、羥基化及ADP核糖基化描述於大部分基礎文本中,諸如Proteins--Structure and Molecular Properties(第2版,T. E. Creighton, W.H. Freeman & Co., NY, 1993)。可獲得關於此主題之許多詳細的綜述,諸如Wold, Posttranslational Covalent Modification of proteins, 1-12(Johnson編,Academic Press, NY, 1983);Seifter等人182 Meth. Enzymol. 626-46 (1990);及Rattan等人663 Ann. NY Acad. Sci. 48-62 (1992)。
因此,本發明之抗體及其抗原結合部分亦涵蓋其中經取代之胺基酸殘基並非由遺傳密碼編碼之胺基酸殘基的衍生物或類似物。
同樣,剛才描述之胺基酸序列中之添加及取代以及變異及修飾可同樣適用於OSM β抗原及/或其抗原決定基之胺基酸序列,且因此涵蓋於本發明中。如上所述,編碼根據本發明之單株抗體的基因在識別OSMR β方面特別有效。
抗體衍生物
本發明之範疇內包括抗體衍生物。抗體之「衍生物」含有通常並非蛋白質之一部分的額外化學部分。蛋白質之共價修飾包括於本發明之範疇內。此類修飾可藉由使抗體之目標胺基酸殘基與能夠與所選側鏈或末端殘基反應之有機衍生劑反應而引入分子中。舉例而言,用此項技術中眾所周知的雙官能劑進行衍生化可用於將抗體或片段交聯至水不溶性支持基質或其他大分子載體。
衍生物亦包括放射性標記之單株抗體,該等抗體經標記。舉例而言,具有放射性碘(
125I、
131I)、碳(
14C)、硫(
35S)、銦(
111In)、氚(
3H)等;單株抗體與生物素或抗生物素蛋白、與酶(諸如辣根過氧化物酶、鹼性磷酸酶、β-D-半乳糖苷酶、葡萄糖氧化酶、葡萄糖澱粉酶、羧酸酐酶、乙醯膽鹼酯酶、溶菌酶、蘋果酸去氫酶或葡萄糖6-磷酸去氫酶)之結合物;以及單株抗體與生物發光劑(諸如螢光素酶)、化學發光劑(諸如吖啶酯)或螢光劑(諸如藻膽蛋白)之結合物。
本發明之另一種衍生雙功能抗體為雙特異性抗體,藉由將識別兩個不同抗原基團之兩個單獨抗體的部分組合而產生。此可藉由交聯或重組技術來實現。另外,可向抗體或其一部分添加部分以增加活體內半衰期(例如,藉由延長自血流中清除之時間)。此類技術包括例如添加PEG部分(亦稱為聚乙二醇化化)且為此項技術中眾所周知的。參見美國專利申請公開案第20030031671號。
抗體之重組表現
在一些實施例中,將編碼主題單株抗體之核酸直接引入宿主細胞中,且在足以誘導所編碼抗體表現之條件下培育細胞。在主題核酸已引入細胞中之後,細胞通常在37℃下,有時在選擇下培育約1-24小時之時段,以使抗體表現。在一個實施例中,抗體分泌於細胞生長之培養基的上清液中。
傳統上,單株抗體已在鼠類融合瘤細胞株中作為原生分子產生。除該技術以外,本發明亦提供單株抗體之重組DNA表現。此允許在所選宿主物種中產生犬類化及貓類化抗體,以及一系列抗體衍生物及融合蛋白。
編碼本發明之至少一種抗OSMR β抗體或其抗原結合部分之核酸序列可根據習知技術與載體DNA重組,包括用於連接之平端式或交錯端式末端、限制酶消化以提供適當末端、視需要填充黏性末端、鹼性磷酸酶處理以避免不合需要的接合及用適當連接酶連接。此類操作技術例如由Maniatis等人,MOLECULAR CLONING, LAB. MANUAL, (Cold Spring Harbor Lab. Press, NY, 1982 and 1989)及Ausubel等人1993同上揭示,可用於構築編碼單株抗體分子或其抗原結合區之核酸序列。
若諸如DNA之核酸分子含有含轉錄及轉譯調節資訊之核苷酸序列且此類序列「可操作地連接」至編碼多肽之核苷酸序列,則該核酸分子稱為「能夠表現」該多肽。可操作的連接為調節性DNA序列及試圖表現之DNA序列以一定的方式連接,以允許基因表現為可回收量之抗OSMR β多肽或抗體部分的連接。基因表現所需之調節區之精確性質可能因不同生物體而不同,如類似技術中所熟知。參見例如Sambrook等人,2001同上;Ausubel等人,1993同上。
本發明因此涵蓋在原核或真核細胞中表現抗OSMR β抗體或其抗原結合部分。適合之宿主包括細菌或真核宿主,包括活體內或原位的細菌、酵母、昆蟲、真菌、鳥類及哺乳動物細胞,或哺乳動物、昆蟲、鳥類或酵母來源之宿主細胞。哺乳動物細胞或組織可來源於人類、靈長類、倉鼠、兔、嚙齒動物、牛、豬、綿羊、馬、山羊、狗或貓,但可使用任何其他哺乳動物細胞。
在一個實施例中,所引入之核苷酸序列將併入能夠在受體宿主中自主複製之質體或病毒載體中。為此目的可採用多種載體中之任一者。參見例如Ausubel等人,1993同上。選擇特定質體或病毒載體之重要因素包括:含有載體之受體細胞可經識別且自不含有載體之彼等受體細胞中選擇出的容易性;特定宿主中所需要的載體複本數目;及是否期望能夠在不同物種之宿主細胞之間「穿梭」載體。
此項技術中已知的例示性原核載體包括質體,諸如能夠在大腸桿菌中複製之質體(諸如例如pBR322、ColE1、pSC101、pACYC 184、.pi.VX)。此類質體例如由Maniatis等人,1989同上;Ausubel等人,1993同上揭示。芽孢桿菌質體包括pC194、pC221、pT127等。此類質體由Gryczan在THE MOLEC. BIO. OF THE BACILLI 307-329 (Academic Press, NY, 1982)中揭示。適合的鏈黴菌質體包括pIJ101(Kendall等人,169 J. Bacteriol. 4177-83 (1987))及鏈黴菌噬菌體,諸如.phi.C31(Chater等人,SIXTH INT'L SYMPOSIUM ON ACTINOMYCETALES BIO. 45-54 (Akademiai Kaido, Budapest, Hungary 1986))。假單胞菌質體綜述於John等人,8 Rev. Infect. Dis. 693-704(1986);Izaki, 33 Jpn. J. Bacteriol. 729-42 (1978);及Ausubel等人,1993同上中。
或者,可用於表現編碼抗OSMR β抗體或其抗原結合部分之cDNA的基因表現元件包括但不限於(a)病毒轉錄啟動子及其強化子元件,諸如SV40早期啟動子(Okayama等人,3 Mol. Cell. Biol. 280 (1983))、勞斯肉瘤病毒LTR(Gorman等人,79 Proc. Natl. Acad. Sci., USA 6777 (1982))及莫洛尼鼠類白血病病毒LTR(Grosschedl等人,41 Cell 885 (1985));(b)剪接區及多腺苷酸化位點,諸如來源於SV40晚期區之彼等者(Okayarea等人,1983)及(c)諸如SV40中之多腺苷酸化位點(Okayama等人,1983)。
免疫球蛋白cDNA基因可如Weidle等人,51 Gene 21 (1987)所描述,使用SV40早期啟動子及其強化子、小鼠免疫球蛋白H鏈啟動子強化子、SV40晚期區mRNA剪接、兔S-球蛋白插入序列、免疫球蛋白及兔S-球蛋白多腺苷酸化位點及SV40多腺苷酸化元件作為表現元件來表現。
對於由部分cDNA、部分基因體DNA構成之免疫球蛋白基因(Whittle等人,1 Protein Engin. 499 (1987)),轉錄啟動子可為人類細胞巨大病毒,啟動子強化子可為細胞巨大病毒及小鼠/人類免疫球蛋白,且mRNA剪接及多腺苷酸化區可為原生染色體免疫球蛋白序列。
在一個實施例中,為了在嚙齒動物細胞中表現cDNA基因,轉錄啟動子為病毒LTR序列,轉錄啟動子強化子為小鼠免疫球蛋白重鏈強化子及病毒LTR強化子中之任一者或兩者,剪接區含有大於31 bp之內含子,且多腺苷酸化及轉錄終止區來源於與所合成之免疫球蛋白鏈相對應的原生染色體序列。在其他實施例中,編碼其他蛋白質之cDNA序列與上文列舉之表現元件組合以實現蛋白質在哺乳動物細胞中之表現。
各融合基因可組裝於表現載體中或插入表現載體中。能夠表現嵌合免疫球蛋白鏈基因產物之受體細胞隨後用編碼抗OSMR β免疫球蛋白鏈之基因或嵌合H或嵌合L鏈編碼基因單獨轉染,或用嵌合H及嵌合L鏈基因共轉染。經轉染之受體細胞在允許表現併入基因之條件下培養,且自培養物回收所表現之免疫球蛋白鏈或完整抗體或片段。
在一個實施例中,編碼抗OSMR β免疫球蛋白H及L鏈或嵌合H及L鏈之融合基因或其部分組裝於單獨的表現載體中,隨後用於共轉染受體細胞。或者,編碼嵌合H及L鏈之融合基因可組裝於同一表現載體上。
對於表現載體之轉染及嵌合抗體之產生,受體細胞株可為骨髓瘤細胞。骨髓瘤細胞可合成、組裝及分泌由經傳染之免疫球蛋白基因編碼之免疫球蛋白且具有免疫球蛋白之糖基化機制。骨髓瘤細胞可在培養物中或在小鼠腹腔中生長,其中分泌之免疫球蛋白可自腹水液中獲得。其他適合之受體細胞包括淋巴細胞,諸如人類或非人類來源之B淋巴球、人類或非人類來源之融合瘤細胞或種間異種融合瘤細胞。
攜帶本發明之嵌合、犬類化或貓類化抗體構築體或抗OSMR β免疫球蛋白基因構築體之表現載體可藉由多種適合的手段中之任一者引入適當宿主細胞中,包括諸如轉型、轉染、結合、原生質體融合、磷酸鈣沈澱及應用諸如二乙胺基乙基(DEAE)葡聚糖之聚陽離子之生物化學手段,及諸如電穿孔、直接顯微注射及微彈轟擊之機械手段。Johnston等人,240 Science 1538 (1988)。
對於免疫球蛋白H及L鏈之產生,酵母可提供優於細菌之明顯優勢。酵母會進行包括糖基化之轉譯後肽修飾。目前存在許多重組DNA策略,其利用強啟動子序列及高複本數質體,可用於在酵母中產生所需蛋白質。酵母識別經選殖哺乳動物基因產物之前導序列且分泌攜帶前導序列之肽(亦即前肽)。Hitzman等人,11th Int'l Conference on Yeast, Genetics & Molec. Biol. (Montpelier, France, 1982)。
酵母基因表現系統可對抗OSMR β抗體序列、抗體及組裝的鼠類及嵌合、異嵌合、犬類化或貓類化抗體、其片段及區域之產生、分泌及穩定性水準進行常規評估。可利用一系列酵母基因表現系統中之任一者,該等系統併入來自編碼糖酵解酶之活躍表現基因之啟動子及終止元件,當酵母在富含葡萄糖之培養基中生長時大量產生糖酵解酶。已知的糖酵解基因亦可提供非常有效的轉錄控制信號。舉例而言,可利用磷酸甘油酸激酶(PGK)基因之啟動子及終止子信號。可採取多種方法來評估用於在酵母中表現經選殖之免疫球蛋白cDNA的最佳表現質體。參見第II卷DNA Cloning, 45-66,(Glover編,)IRL Press, Oxford, UK 1985)。
細菌菌株亦可用作宿主以產生本發明所述之抗體分子或肽。含有複製子及控制序列之質體載體來源於與宿主細胞相容之物種,與此等細菌宿主結合使用。載體攜帶複製位點以及能夠在經轉型細胞中提供表型選擇之特定基因。可採取許多方法來評估在細菌中產生由經選殖免疫球蛋白cDNA編碼之鼠類、嵌合、異嵌合、犬類化或貓類化抗體、片段及區域或抗體鏈的表現質體(參見Glover,1985同上;Ausubel,1993同上;Sambrook,2001同上;Colligan等人編,Current Protocols in Immunology, John Wiley & Sons, NY, NY (1994-2001);Colligan等人編,Current Protocols in Protein Science, John Wiley & Sons, NY, NY (1997-2001)。
宿主哺乳動物細胞可活體外或活體內生長。哺乳動物細胞為免疫球蛋白的蛋白質分子提供轉譯後修飾,包括前導肽移除、H及L鏈之摺疊及組裝、抗體分子之糖基化及功能性抗體蛋白之分泌。
除上述淋巴來源之細胞以外,可用作產生抗體蛋白之宿主的哺乳動物細胞亦包括纖維母細胞來源之細胞,諸如Vero(ATCC CRL 81)或CHO-K1(ATCC CRL 61)細胞。
許多載體系統可用於在哺乳動物細胞中表現經選殖之抗OSMR β H及L鏈基因(參見Glover,1985同上)。可遵循不同方法以獲得完整H
2L
2抗體。可在相同細胞中共表現H及L鏈,以實現H及L鏈之胞內締合及鍵聯成完整四聚體H
2L
2抗體及/或抗OSMR β片段(例如其抗原結合部分)。共表現可藉由在同一宿主中使用相同或不同質體來進行。H及L鏈及/或抗OSMR β片段之基因可置於同一質體中,隨後將其轉染至細胞中,從而直接選擇表現兩條鏈的細胞。或者,可首先用編碼一條鏈(例如L鏈)之質體轉染細胞,隨後用含有第二可選標記之H鏈質體轉染所得細胞株。經由任一途徑產生抗OSMR β胺基酸序列及/或H
2L
2分子之細胞株可用編碼肽、H、L或H加L鏈之額外複本連同額外可選標記之質體轉染,以產生具有增強特性之細胞株,諸如更高的組裝H
2L
2抗體分子之產量或增強的經轉染細胞株之穩定性。
為了長期、高產率產生重組抗體,可使用穩定表現。舉例而言,可對穩定表現抗體分子之細胞株進行工程改造。可用免疫球蛋白表現卡匣及可選標記轉型宿主細胞,而非使用含有病毒複製起點之表現載體。在引入外來DNA後,可使經工程改造之細胞在富集培養基中生長1-2天,且隨後切換成選擇性培養基。重組質體中之可選標記賦予選擇抗性,且允許細胞將質體穩定整合至染色體中且生長形成變異區(foci),其繼而可選殖及擴增至細胞株中。此類經工程改造之細胞株在篩選及評估直接或間接與抗體分子相互作用之化合物/組分時可能特別有用。
一旦產生本發明抗體,則其可藉由此項技術中已知的用於純化免疫球蛋白分子之任何方法來純化,例如藉由層析法(例如離子交換,親和力,特別是對蛋白A後之特定抗原的親和力,及篩分管柱層析法)、離心、差異溶解性或藉由用於純化蛋白質之任何其他標準技術。在許多實施例中,抗體自細胞分泌至培養基中且自培養基中收穫。
醫藥應用
本發明之抗OSMR β抗體或其抗原結合部分可用於例如治療諸如狗及貓之伴侶動物的各種病況。此等病況包括搔癢性病況、過敏性病況、發炎性病況、纖維變性病況及與炎症相關之疼痛。本文揭示此等類型病況之具體但非限制性實例。應理解,在一些情況下,可認為特定病症屬於不止一個類別。舉例而言,某些過敏性病況亦可視為發炎性病況。更特定言之,本發明進一步提供一種醫藥組合物,其包含醫藥學上可接受之載劑或稀釋劑及作為活性成分的根據本發明之抗體或肽。抗體可為根據本發明之嵌合、異嵌合、犬類化或貓類化抗體。亦設想完整的免疫球蛋白或其結合片段,諸如Fab。本發明之抗體及其醫藥組合物可用於非經腸投予,例如皮下、肌肉內或靜脈內。
本發明之抗OSMR β抗體及/或其抗原結合部分可作為單獨的治療劑或與其他治療劑組合投予。其可單獨投予,但一般與基於所選投藥途徑及標準醫藥實踐選擇的醫藥載劑一起投予。
本文所揭示之抗體的投予可藉由任何適合手段進行,包括非經腸注射(諸如腹膜內、皮下或肌肉內注射)、經口或藉由向氣道表面局部投予抗體(通常攜帶於醫藥調配物中)。向氣道表面之局部投予可藉由鼻內投予(例如藉由使用滴管、拭子或吸入器)來進行。向氣道表面局部投予抗體亦可藉由吸入投予來進行,諸如藉由將含有抗體之醫藥調配物的可吸入粒子(包括固體及液體粒子)製造為氣溶膠懸浮液,且隨後使個體吸入可吸入粒子。用於投予醫藥調配物之可吸入粒子的方法及設備為眾所周知的,且可採用任何習知技術。經口投予可例如以可攝入之液體或固體調配物的形式。
在一些所需實施例中,抗體係藉由非經腸注射來投予。對於非經腸投予,抗OSMR β抗體或其抗原結合部分可結合醫藥學上可接受之非經腸媒劑調配為溶液、懸浮液、乳液或凍乾粉。舉例而言,媒劑可為抗體或其混合物溶解於可接受之載劑(諸如水性載劑)中之溶液,此類媒劑為水、生理鹽水、林格氏溶液、右旋糖溶液、海藻糖或蔗糖溶液或5%血清白蛋白、0.4%生理鹽水、0.3%甘胺酸等。亦可使用脂質體及非水性媒劑,諸如不揮發性油。此等溶液為無菌的且一般不含顆粒物質。此等組合物可藉由習知、眾所周知的滅菌技術來滅菌。組合物可含有接近生理條件所需的醫藥學上可接受之輔助物質,諸如pH調節劑及緩衝劑、毒性調節劑等,例如乙酸鈉、氯化鈉、氯化鉀、氯化鈣、乳酸鈉等。此等調配物中之抗體濃度可廣泛變化,例如自小於約0.5重量%、通常為或至少約1重量%至高達15重量%或20重量%,且將主要基於流體體積、黏度等,根據所選特定投藥模式進行選擇。媒劑或凍乾粉可含有維持等張性之添加劑(例如氯化鈉、甘露醇)及維持化學穩定性之添加劑(例如緩衝液及防腐劑)。調配物藉由常用技術來滅菌。
用於製備可非經腸投予組合物的實際方法將為熟習此項技術者已知或顯而易見的,且更詳細地描述於例如REMINGTON'S PHARMA. SCI.(第15版,Mack Pub. Co., Easton, Pa., 1980)中。
本發明之抗體可凍乾儲存且在使用之前在適合之載劑中復原。此技術已顯示對習知免疫球蛋白有效。可採用任何適合的凍乾及復原技術。熟習此項技術者應瞭解,凍乾及復原可導致不同程度的抗體活性損失且可能必須調整使用水準以進行補償。
可投予含有本發明抗體或其混合物之組合物以預防現有疾病之復發及/或治療性治療現有疾病。適合之醫藥載劑描述於最新版本的REMINGTON'S
PHARMACEUTICAL SCIENCES中,其為此技術領域中之標準參考文本。
在治療性應用中,向已患有疾病之個體投予足以治癒或至少部分遏制或減輕疾病及其併發症之量的組合物。足以實現此目的之量定義為「治療有效劑量」或「治療有效量」。對此用途有效之量將取決於疾病之嚴重程度及個體自身免疫系統之一般狀態,但一般範圍介於每kg體重約0.1 mg抗體至每kg體重約10 mg抗體,較佳每kg體重約0.3 mg抗體至每kg體重約5 mg抗體。鑒於藉由本發明之犬樣及貓樣抗體使外來物質減至最少及降低「外來物質」排斥反應之概率,可投予大量過量的此等抗體。
當然,投予劑量將視已知因素而變化,諸如特定藥劑之藥效學特徵及其投藥模式及途徑;受體之年齡、健康狀況及體重;症狀之性質及程度;同時治療之種類;治療之頻率及期望的效果。
作為非限制性實例,對狗或貓之IL-31相關或OSM相關病變的治療可以上述劑量範圍內之本發明之抗OSMR β抗體的每兩週或每月劑量形式來提供。
根據本發明,用於犬科動物或貓科動物治療用途之例示性抗體為具有強效活體內抗OSMR β活性之高活動性(此等亦可為高親合力)抗體及其片段、區域及衍生物。
可進行組合物之單次或多次投予,劑量及模式由治療獸醫選擇。在任何情況下,醫藥調配物應提供足以有效治療個體之量的本發明抗體。
診斷應用
本發明亦提供上述抗OSMR β抗體及其抗原結合部分,用於在已知或疑似患有OSM及/或IL-31介導之病況的伴侶動物中偵測OSMR β的診斷方法,該病況諸如搔癢性病況、過敏性病況、發炎性病況、纖維變性病狀或與炎症相關之疼痛。
本發明之抗OSMR β抗體及/或其抗原結合部分可用於偵測或定量樣品中之OSMR β或抗OSMR β抗體的免疫分析。OSMR β之免疫分析通常包含在能夠選擇性地與OSMR β結合之本發明之可偵測標記之高親和力(或活動性)抗OSMR β抗體存在下培育臨床或生物樣品,且偵測樣品中結合之經標記抗體。各種臨床分析程序為此項技術中眾所周知的。參見例如IMMUNOASSAYS FOR THE 80'S (Voller等人編,Univ. Park, 1981)。此類樣品包括組織生物檢體、血液、血清及糞便樣品或自動物個體收集之液體,且進行如下所述之ELISA分析。
在一些實施例中,在不使用固體支撐物之情況下偵測抗原與抗體之結合。舉例而言,抗原與抗體之結合可以液體形式偵測。
在其他實施例中,抗OSMR β抗體可例如固定至硝化纖維素或能夠固定細胞、細胞粒子或可溶性蛋白質之另一種固體支撐物。支撐物可隨後用適合之緩衝液洗滌,隨後用可偵測標記之OSMR β特異性抗體處理。固相支撐物可隨後用緩衝液第二次洗滌以移除未結合之經標記抗體。可隨後藉由已知方法步驟偵測固體支撐物上結合之標記的量。
「固相支撐物」或「載體」係指能夠結合肽、抗原或抗體之任何支撐物。眾所周知的支撐物或載體包括玻璃、聚苯乙烯、聚丙烯、聚乙烯、聚偏二氟乙烯(PVDF)、葡聚糖、耐綸、澱粉酶、天然及改質纖維素、聚丙烯醯胺、瓊脂糖及磁鐵。出於本發明之目的,載體之性質可在一定程度上可溶或不溶。只要偶聯分子能夠與OSMR β或抗OSMR β抗體結合,支撐材料幾乎可具有任何可能的結構組態。因此,支撐物組態可為球形的,如珠粒,或圓柱形,如試管之內表面或桿之外表面。或者,表面可為平的,諸如薄片、培養皿、測試條等。舉例而言,支撐物可包括聚苯乙烯珠粒。熟習此項技術者將知道許多其他適合結合抗體、肽或抗原之載體,或可藉由常規實驗來確定。
眾所周知的方法步驟可確定給定批次之抗OSMR β抗體的結合活性。熟習此項技術者可藉由常規實驗確定操作及最佳分析條件。
可偵測地標記OSMR β特異性抗體可藉由連接至用於酶免疫分析法(EIA)或酶聯免疫吸附分析(ELISA)之酶來實現。連接的酶與暴露的受質反應以產生化學部分,其可例如藉由分光光度法、螢光法或藉由視覺手段來偵測。可用於可偵測地標記本發明之OSMR β特異性抗體的酶包括但不限於蘋果酸去氫酶、葡萄球菌核酸酶、δ-5-類固醇異構酶、酵母醇去氫酶、α-甘油磷酸去氫酶、丙醣磷酸異構酶、辣根過氧化酶、鹼性磷酸酶、天冬醯胺酶、葡萄糖氧化酶、β-半乳糖苷酶、核糖核酸酶、脲酶、過氧化氫酶、葡萄糖-6-磷酸去氫酶、葡萄糖澱粉酶及乙醯膽鹼酯酶。
藉由放射性標記OSMR β特異性抗體,可經由使用放射免疫分析(RIA)偵測OSMR β。參見Work等人,LAB. TECHNIQUES & BIOCHEM. 1N MOLEC. Bio. (No. Holland Pub. Co., NY, 1978)。放射性同位素可藉由諸如使用γ計數器或閃爍計數器之方式或藉由自動放射照像術偵測。對本發明之目的特別有用的同位素包括:
3H、
125I、
131I、
35S、
14C及
125I。
亦可用螢光化合物來標記OSMR β特異性抗體。當螢光標記之抗體暴露於適當波長之光時,則可由於螢光偵測到該抗體之存在。最常用的螢光標記化合物為異硫氰酸螢光素、若丹明、藻紅素、藻藍蛋白、別藻藍蛋白、鄰苯二甲醛及螢光胺。
OSMR β特異性抗體亦可使用螢光發射金屬(諸如
125Eu或其他鑭系元素)進行可偵測標記。此等金屬可使用諸如二伸乙三胺五乙酸(DTPA)或乙二胺四乙酸(EDTA)之金屬螯合基團連接至OSMR β特異性抗體。
OSMR β特異性抗體亦可藉由與化學發光化合物偶聯來進行可偵測標記。隨後藉由偵測在化學反應過程中產生之發光的存在來確定經化學發光標記之抗體的存在。有用的化學發光標記化合物之實例為魯米諾(luminol)、異魯米諾(isoluminol)、熱敏吖啶酯、咪唑、吖啶鹽及草酸酯。
同樣,生物發光化合物可用於標記本發明之OSMR β特異性抗體、部分、片段、多肽或衍生物。生物發光為生物系統中發現之化學發光類型,其中催化蛋白提高化學發光反應之效率。生物發光蛋白之存在係藉由偵測發光之存在來確定。用於標記目的之重要生物發光化合物為螢光素、螢光素酶及水母發光蛋白。
OSMR β特異性抗體、部分、片段、多肽或衍生物之偵測可藉由閃爍計數器(例如若可偵測標記為放射性γ發射體)或藉由螢光計(例如若標記為螢光材料)來實現。在酶標記之情況下,偵測可藉由採用酶受質之比色法來實現。偵測亦可藉由與類似地製備之標準品相比,目測比較受質之酶促反應程度來實現。
出於本發明之目的,藉由上述分析偵測之OSMR β可存在於生物樣品中。可使用任何含有OSMR β之樣品。舉例而言,樣品為生物體液,諸如例如血液、血清、淋巴、尿液、糞便、炎性滲出物、腦脊髓液、羊膜液、組織提取物或勻漿等。然而,本發明不限於僅使用此等樣品之分析,一般熟習此項技術者根據本說明書可確定允許使用其他樣品之適合條件。
原位偵測可藉由自動物個體移出組織學樣本且向此類樣本提供本發明之經標記抗體之組合來實現。抗體(或其部分)可藉由將經標記抗體(或部分)施加或覆蓋至生物樣品來提供。經由使用此類程序,可不僅確定OSMR β之存在且亦確定OSMR β在所檢查組織中之分佈。使用本發明,一般技術者將易於感知到,可修改多種組織學方法(諸如染色程序)中之任一者以便達成此類原位偵測。
本發明之抗體、片段或衍生物可適用於亦稱為「雙位點」或「夾心」分析之免疫測定分析中。在典型的免疫測定分析中,一定量的未標記抗體(或抗體片段)結合至不可溶於待測試流體中之固體支撐物,且添加一定量的可偵測標記之可溶性抗體以允許偵測及/或定量在固相抗體、抗原及經標記抗體之間形成的三元複合物。
抗體可用於定量或定性地偵測樣品中之OSMR β或偵測表現OSMR β之細胞的存在。此可藉由採用螢光標記之抗體(參見下文)的免疫螢光技術,結合螢光顯微法、流動式細胞測量術或螢光偵測來實現。出於診斷目的,抗體可經標記或未經標記。未經標記之抗體可與其他可與該抗體反應之經標記之抗體(第二抗體)組合使用,諸如對犬或貓免疫球蛋白恆定區具有特異性之抗體。或者,抗體可直接經標記。可採用多種標記,諸如放射性核種、螢光劑、酶、酶受質、酶輔因子、酶抑制劑、配體(尤其半抗原)等。許多類型之免疫分析,諸如先前所論述之彼等免疫分析為可用的且為熟習此項技術者所熟知的。
在一個實施例中,用於偵測OSMR β之診斷方法為側流免疫分析測試。此亦稱為免疫層析分析、快速免疫遷移(RIM™)或條帶測試。側流免疫分析本質上為經調適以沿單軸操作以符合測試條形式之免疫分析。該技術之許多變化形式已開發為商業產品,但其皆根據相同基本原理操作。典型的測試條由以下組分組成:(1)樣品墊——上面施加測試樣品之吸收墊;(2)結合物或試劑墊——此含有與著色粒子(通常為膠體金粒子或乳膠微球體)結合之對目標分析物具有特異性的抗體;(3)反應膜——通常為疏水性硝化纖維素或乙酸纖維素膜,抗目標分析物抗體固定於跨膜之一條線上作為捕捉區或測試線(亦可能存在對照區,含有對結合物抗體具有特異性的抗體);及(4)芯或廢料儲集器——另一吸收墊,經設計以藉由毛細作用將樣品吸過反應膜且收集。條帶之組件通常固定至惰性襯底材料,且可以簡單試紙形式或在具有樣品口及顯示捕捉及對照區之反應窗的塑膠殼體內呈現。
微生物測試中使用之側流免疫分析有兩種主要類型:雙抗體夾心分析及競爭性分析。在雙抗體夾心形式中,樣品自樣品墊遷移通過結合物墊,在此處存在之任何目標分析物將與結合物結合。樣品接著繼續跨膜遷移直至其到達捕捉區,在此處目標/結合物複合物將與固定的抗體結合,在膜上產生一條可見線。樣品接著沿著條帶進一步遷移直至其到達對照區,在此處過量的結合物將結合且在膜上產生第二條可見線。此對照線指示樣品如所預期已遷移跨過該膜。膜上有兩條清晰的線為陽性結果。對照區中有單線為陰性結果。競爭性分析不同於雙抗體夾心形式,因為結合物墊含有已與目標分析物或其類似物結合之抗體。若樣品中存在目標分析物,則其將因此不與結合物結合且將保持未標記。隨著樣品沿著膜遷移且到達捕捉區,過量未標記之分析物將與固定的抗體結合且阻斷結合物捕捉,因此不會產生可見線。未結合之結合物接著將與對照區中之抗體結合,產生可見對照線。膜上有單一對照線為陽性結果。捕捉及對照區中有兩條可見線為陰性結果。然而,若不存在過量的未標記之目標分析物,則在捕捉區中可能產生一條微弱的線,指示不確定的結果。側流技術存在許多變化。膜上之捕捉區可含有固定的抗原或酶類-取決於目標分析物-而非抗體。亦可應用多個捕捉區來創建多重測試。舉例而言,已開發出能夠在同一樣品中分別偵測EHEC志賀毒素ST1及ST2之商業測試條。
重要的是,本發明之抗體可有助於診斷狗或貓之搔癢性病況、過敏性病況、發炎性病症、纖維變性病症、與炎症相關之疼痛或其組合。更特定言之,本發明之抗體可鑑別伴侶動物中OSMR β之過度表現。因此,本發明之抗體可提供一種重要的免疫組織化學工具。
本發明之抗體可用於抗體陣列上,非常適合於量測基因表現譜。
套組
本發明之範疇內亦包括用於實踐主題方法之套組。該等套組至少包括一或多種本發明之抗體、編碼其之核酸或含有其之細胞。在一個實施例中,本發明抗體可通常以凍乾形式提供於容器中。可與標記或毒素結合或未結合之抗體通常與緩衝液(諸如Tris、磷酸鹽、碳酸鹽等)、穩定劑、殺生物劑、惰性蛋白質(例如血清白蛋白)等一起包括於套組中。一般而言,此等材料將以活性抗體之量計小於5重量%存在,且通常再以抗體濃度計至少約0.001重量%之總量存在。通常,將需要包括惰性增量劑或賦形劑以稀釋活性成分,其中賦形劑可以總組合物之約1重量%至99重量%存在。在分析中採用能夠與初級抗體結合之第二抗體的情況下,此將通常存在於獨立小瓶中。第二抗體通常與標記結合且以與上述抗體調配物類似之方式調配。套組一般亦將包括一組使用說明。
在一個實施例中,根據本發明之套組為可用於偵測樣品中之犬或貓OSMR β蛋白的測試條套組(側流免疫分析套組)。此類測試條將通常包括樣品墊,上面施加測試樣品;結合物或試劑墊,其含有對犬或貓OSMR β具有特異性之抗體,其中該抗體與著色粒子(通常為膠體金粒子)結合;反應膜,抗OSMR β抗體固定於跨膜之一條線上作為捕捉區或測試線(亦可能存在對照區,含有對結合物抗體具有特異性的抗體);及另一吸收墊,其經設計以藉由毛細作用將樣品吸過反應膜且收集。測試條套組一般亦將包括使用說明。
用於評定犬或貓OSMR β抑制劑候選物之功能活性的基於細胞之分析
本發明亦提供一種用於評定犬或貓OSMR β抑制劑候選物之功能活性的基於細胞之分析。此方法包括:提供內源性表現犬或貓OSM之受體且對犬或貓OSM有反應的細胞;在包含OSMR β抑制劑候選物或媒劑對照之組合物存在下培育犬或貓OSM;用培育的犬或貓OSM處理細胞;量測藉由犬或貓OSM處理誘導之蛋白質的直接磷酸化;且相對於媒劑對照,確定包含犬或貓OSMR β抑制劑候選物之組合物是否抑制犬或貓OSM誘導之直接蛋白質磷酸化。
在一個實施例中,量測步驟包含量測STAT蛋白之直接磷酸化。在一個特定實施例中,STAT蛋白為STAT3。
在基於細胞之分析的另一個實施例中,細胞為單核球及/或巨噬細胞。舉例而言,在一個實施例中,細胞為犬DH82細胞。DH82細胞為來自患有惡性組織細胞增多症之狗的巨噬細胞-單核球細胞株。
在一個實施例中,由犬或貓OSM處理誘導之直接蛋白質磷酸化導致信號增加。在另一個實施例中,由犬或貓OSMR β抑制劑候選物誘導之直接蛋白質磷酸化的抑制使得信號降低。
在一個實施例中,犬或貓OSMR β抑制劑候選物為重組犬或貓抗OSMR β抗體。在一個特定實施例中,重組犬或貓抗OSMR β抗體包含於融合瘤培養上清液中。在其他實施例中,犬或貓OSMR β抑制劑候選物為小分子醫藥化合物。
在一個實施例中,在用犬或貓OSM處理細胞之前,將犬或貓OSM與犬或貓OSMR β抑制劑候選物共培育。在另一個實施例中,在犬或貓OSM處理之前,將細胞與γ干擾素一起預培育一段足以增加OSM β受體表現之時間。在一個實施例中,細胞與犬γ干擾素一起預培育。在一些實施例中,在與犬γ干擾素一起預培育之後,隨後在犬或貓OSM處理之前使細胞血清饑餓。
在一些實施例中,選擇相對於媒劑對照抑制大於50%之直接蛋白質磷酸化的犬或貓OSMR β抑制劑候選物用於進一步純化及/或表徵。在一個實施例中,該方法可進一步包括經由基於細胞之分析鑑別犬或貓OSMR β抑制劑候選物之IC
50值,例如對於相對於媒劑對照抑制大於50%之直接蛋白質磷酸化的任何候選物。
在一個實施例中,在分析中觀察到的犬或貓OSM誘導之直接蛋白質磷酸化的抑制與犬或貓中IL-31介導或OSM介導之病況的抑制相關。此類病症包括但不限於本文所述之IL-31介導或OSM介導之搔癢性、過敏性、發炎性及纖維變性病症,以及OSM介導之發炎性疼痛,諸如骨關節炎疼痛。
在一個特定實施例中,本發明提供一種用於評定犬或貓IL-31抑制劑候選物之功能活性的基於細胞之分析,其包括:提供內源性表現犬或貓OSM之受體且對犬或貓OSM有反應之犬DH82細胞;在包含OSMR β抑制劑候選物或媒劑對照之組合物存在下培育犬或貓OSM;用培育的犬或貓OSM處理DH82細胞;量測由犬或貓OSM處理誘導之DH82細胞中的生物活性;且相對於媒劑對照,確定包含犬或貓OSMR β抑制劑候選物之組合物是否抑制犬或貓OSM誘導之生物活性。此基於細胞之分析在下文中稱為DH82分析。
在DH82分析之一個實施例中,生物活性為由犬或貓OSM處理誘導之蛋白質之直接磷酸化。在DH82分析之一個實施例中,蛋白質為STAT蛋白,諸如STAT3。在DH82分析之另一個實施例中,由犬或貓OSM處理誘導之直接蛋白質磷酸化導致信號增加。在DH82分析之另一個實施例中,由犬或貓OSMR β抑制劑候選物誘導之直接蛋白質磷酸化的抑制使得信號降低。
在DH82分析之另一個實施例中,犬或貓OSMR β抑制劑候選物為重組犬或貓抗OSMR β抗體。此類重組犬或貓抗OSMR β抗體可包含於例如融合瘤培養上清液中。在DH82分析之其他實施例中,犬或貓OSMR β抑制劑候選物為小分子醫藥化合物。
在DH82分析之另一個實施例中,在用犬或貓OSM處理DH82細胞之前,將犬或貓OSM與犬或貓OSMR β抑制劑候選物共培育。在DH82分析之另一個實施例中,在犬或貓OSM處理之前,將DH82細胞與γ干擾素(諸如但不限於犬γ干擾素)一起預培育一段足以增加OSMR β受體表現之時間。在一個實施例中,DH82細胞隨後在犬或貓OSM處理之前血清饑餓。
在DH82分析之一個特定實施例中,選擇相對於媒劑對照抑制大於50%之直接蛋白質磷酸化的犬或貓OSMR β抑制劑候選物用於進一步純化及/或表徵。在一個實施例中,舉例而言,該方法可包括經由基於DH82細胞之分析鑑別犬或貓OSMR β抑制劑候選物之IC50值。
在DH82分析之一個實施例中,在分析中觀察到的犬或貓OSM誘導之直接蛋白質磷酸化的抑制與犬或貓中IL-31介導或OSM介導之病況的抑制相關。此類病症包括但不限於本文所述之IL-31介導或OSM介導之搔癢性、過敏性、發炎性及纖維變性病症,以及OSM介導之發炎性疼痛,諸如骨關節炎疼痛。
現將藉由以下非限制性實例進一步描述本發明。
實例
實例1. 用於此研究之重組蛋白的產生
重組蛋白係出於產生抗體及評估候選抗體之親和力及效力之目的產生。藉由與人類同源物之同源性,鑑別犬及貓OSMR之細胞介素結合域、Ig樣域及纖網蛋白III域。合成DNA構築體經設計以用於將犬OSMR蛋白(SEQ ID NO: 107,犬_OSMR_hIgG1_Fc)(其對應核苷酸序列為(SEQ ID NO: 108;犬_OSMR_hIgG1_Fc))及貓OSMR蛋白(SEQ ID NO: 112;貓_OSMR_hIgG1_Fc)(其對應核苷酸序列為(SEQ ID NO: 113;貓_OSMR_hIgG1_Fc))最佳表現為人類IgG1 Fc融合物。亦設計合成DNA構築體以用於最佳表現貓OSM基因(SEQ ID NO: 110;貓_OSM_hIgG1_Fc),其對應核苷酸序列為(SEQ ID NO: 111;
貓_OSM_hIgG1_Fc)。犬OSM係購自Kingfisher Biotech, Inc. (Saint Paul, MN)且蛋白質序列為(SEQ ID NO: 109;
犬_OSM)。所有合成卡匣使用標準分子生物學方法選殖至pcDNA3.1中,且在兩種哺乳動物懸浮細胞系統Freestyle 293F(人類胚胎腎)細胞或EXPICHO-S(中國倉鼠卵巢)細胞中之一者中表現。
懸浮細胞在Freestyle 293表現培養基(Gibco)中維持在0.15與大約2.5×10e6個細胞/毫升之間。在轉染當天,細胞稀釋至1.0×10e6個細胞/毫升,且按照條件C用FectoPro方案中所述之質體DNA及FectoPRO(Polyplus Transfection)試劑之混合物進行轉染。大約24小時後,不同於FectoPro方案,向各培養物中添加由稀釋於Freestyle 293培養基中之20% w/v胰蛋白腖組成的進料。在培育7天後,收穫培養物且進行澄清。對於懸浮EXPICHO-S,細胞在EXPICHO表現培養基(Gibco)中維持在0.14與8.0×10e6個細胞/毫升之間。細胞在第-1天及轉染當天按照ExpiCHO方案使用者手冊進行稀釋。使用來源於ExpiFectamine CHO轉染套組(Gibco)之試劑,按照最大效價條件,如方案中所述轉染經稀釋之細胞。在培育12-14天後,收穫培養物且進行澄清。
為了純化帶六組胺酸標籤之蛋白質,將條件培養基調整為500 mM氯化鈉、5 mM咪唑及pH 7.4,且裝載於IMAC樹脂(Ni Sepharose Excel (GE Healthcare)或HisPur Cobalt (Thermo Scientific))上,該樹脂已用緩衝液A(5 mM咪唑、20 mM磷酸鈉、500 mM氯化鈉,pH 7.4)預平衡。裝載後,IMAC樹脂用緩衝液A充分洗滌,且隨後在相同緩衝液中經由濃度自5增加至500 mM之咪唑進行溶離。藉由SDS-PAGE評估溶離份。進行彙集且自咪唑透析至最終緩衝液中。使用蛋白A層析純化Fc融合蛋白及抗體。將條件培養基裝載於已用PBS預平衡之MabSelect Sure LX (GE Healthcare)或AmMag蛋白A磁珠(Genscript)上。在樣品裝載後,樹脂用PBS洗滌且隨後用20 mM乙酸鈉pH 5.5洗滌。在使用磁珠之情況下,向平衡及洗滌緩衝液中添加0.05% tween-20。無論使用何種方法,樣品均用20 mM乙酸pH 3.5自管柱溶離。溶離後,進行彙集且藉由添加1 M乙酸鈉中和至4%。視可用體積及預期用途而定,有時將樣品交換至最終緩衝液(例如PBS、其他)中。藉由280 nm下之吸光度或藉由BCA蛋白質分析量測最終蛋白質濃度。
先前(Bammert等人之美國專利案第8,790,651號)已描述犬IL-31蛋白(SEQ ID NO: 123;犬_IL31)之合成及表徵,其對應核苷酸序列為(SEQ ID NO: 124;犬_IL31)。先前(Bammert等人之美國專利申請案第20190284272號)已描述貓IL-31蛋白(SEQ ID NO: 125;貓_IL31)之合成及表徵,其對應核苷酸序列為(SEQ ID NO: 126;貓_IL31)。
實例2. 識別犬及/或貓OSMR之小鼠單株抗體的鑑別
分別由(SEQ ID NO: 107;
犬_OSMR_hIgG1_Fc)(其對應核苷酸序列為(SEQ ID NO: 108;犬_OSMR_hIgG1_Fc))及(SEQ ID NO: 112;
貓_OSMR_hIgG1_Fc)(其對應核苷酸序列為(SEQ ID NO: 113;貓_OSMR_hIgG1_Fc))代表之重組犬及貓OSMR蛋白之混合物用於使雌性AJ及CD1小鼠免疫以產生單株抗體。小鼠使用28天快速免疫方案(RIMMS)進行免疫,該方案包括經兩週時段投予一系列低劑量免疫接種。使用酶聯免疫吸附分析(ELISA)測定經免疫小鼠之血清抗體效價。將犬或貓OSMR(50 ng/孔)固定於聚苯乙烯微量盤上且用作捕捉抗原。進行單獨的ELISA以確定對不相關人類IgG Fc融合蛋白之抗體反應。在分析之前,各盤使用酪蛋白阻斷,且來自經免疫小鼠之血清在含0.05% tween-20(PBST)之磷酸鹽緩衝鹽水中稀釋。用抗小鼠HRP標記之二級抗體偵測抗OSMR(或抗人類IgG Fc)抗體之存在。在添加顯色受質(SureBlue Reserve TMB 1-Component Microwell Peroxidase Substrate, KPL, Inc., Gaithersburg, MD)後且在室溫(RT)下培育10分鐘後,藉由添加100 µL 0.1 N HCl停止反應。在450 nm之光密度(OD)下測定各孔之吸光度。
在第20天採集測試用血,且評定抗血清樣品以確定是否已達到融合就緒效價,如在1:31K血清稀釋下OD>0.1高於背景所定義。此外,利用人類IgG吸收分析來評估抗OSMR特異性。在施加於ELISA盤之前,將血清樣品外加彙集/純化之人類IgG。識別融合蛋白之「不相關」人類IgG Fc組分之抗體自系統中吸收;OSMR特異性抗體在ELISA盤上結合OSMR。吸收後之抗OSMR信號指示目標特異性反應。在吸收抗人類IgG後,選擇對犬及貓OSMR具有高特異性效價之單隻反應性CD-1小鼠。此小鼠接受融合前加強,且供體脾細胞在第28天用於融合。
藉由ELISA篩選融合瘤上清液中與犬及/或貓OSMR蛋白結合但不與不相關人類IgG Fc結合的抗體。進一步次選殖選擇性結合犬及/或貓OSMR之候選小鼠抗OSMR融合瘤,得到產生均質抗體之融合瘤且對可變重鏈及輕鏈進行定序。選擇產生具有此等所需特性之抗體的細胞進行可變重鏈(VH)及可變輕鏈(VL)IgG鏈之RNA轉錄物的序列分析。
實例3. 使用表面電漿子共振測定抗OSMR抗體對OSMR之親和力的方法
候選mAb結合犬、貓及人類(SEQ ID NO: 122;人類_OSMR)(R&D Systems, Minneapolis, MN)OSMR之親和力係在Biacore系統(Biacore Life Sciences (GE Healthcare), Uppsala, Sweden)上使用表面電漿子共振(SPR)來測定。為了避免在將抗體固定於表面時可能出現的與差異性表面製備相關的親和力差異,將各物種之OSMR直接結合至個別表面。藉由使用N-羥基丁二醯亞胺(NHS)/1-乙基-3-(3-二甲胺基丙基)碳化二亞胺(EDC)化學試劑對5 μg/mL OSMR進行胺偶聯來獲得固定化。晶片用乙醇胺淬滅,且評估所有候選mAb與固定的OSMR結合之親和力。所有曲線均擬合1:1模型。小於1×10
-11M(1E-11 M)之親和力常數(KD)低於儀器偵測定量之下限。親和力量測之結果描述於本文中。
實例4. 藉由抑制犬及貓IL-31在犬及貓巨噬細胞中誘導之pSTAT3信號傳導來評定確定抗OSMR抗體之效力的方法
為了鑑別具有抑制活性之候選物,在基於犬或貓細胞之分析中評定抗體影響IL-31介導之STAT3磷酸化的能力。在犬DH-82(ATCC
®CRL-10389
™)或貓Fcwf-4巨噬細胞樣細胞(ATCC CRL-2787)中測定STAT3磷酸化。DH82及Fcwf-4細胞分別用10 ng/mL犬干擾素γ(R&D Systems, Minneapolis, MN)預致敏24小時或用125 ng/mL貓干擾素γ(R&D Systems, Minneapolis, MN)預致敏96小時,以增加受體表現。在IL-31及mAb處理之前,兩種細胞類型經血清饑餓2小時。使用兩種獨立的方法,評估所有候選mAb抑制1 μg/mL犬或42 ng/mL貓IL-31誘導之STAT3磷酸化的能力。亦進行分析以證明犬及貓細胞介素之交叉反應性及抗體抑制兩種物種中之信號傳導能力的交叉功能。為了確保複合物的形成,在細胞刺激之前完成mAb及IL-31細胞介素之一小時共培育。進行IL-31細胞刺激五分鐘。使用AlphaLISA SureFire ULTRA™技術(Perkin Elmer, Waltham, MA)來量測STAT3磷酸化。在抗體濃度及純度未知的情況下,融合瘤上清液在與1 μg/ml犬或42 ng/ml貓IL-31共培育一小時後,對其抑制STAT3磷酸化之能力進行定性量測。個別單株抗體之效力由其在此等分析中抑制IL-31介導之STAT3磷酸化的能力定義,視為進一步推進選擇抗體之關鍵選擇準則。術語效力係指由此等分析計算之IC
50值且為由IL-31誘導之信號傳導降低至其最大值之一半的抗體濃度。本文所述之增加的效力與較低的IC
50值相關。
實例5. 藉由抑制犬及貓OSM在犬及貓巨噬細胞中誘導之pSTAT3信號傳導來評定確定抗OSMR抗體之效力的方法
為了鑑別具有抑制活性之候選物,在基於犬或貓細胞之分析中評定抗體影響OSM介導之STAT3磷酸化的能力。在犬DH-82(ATCC CRL-10389™)或貓Fcwf-4巨噬細胞樣細胞(ATCC CRL-2787)中測定STAT3磷酸化。為了評定此等分析之動力學範圍,在兩種細胞類型中評定使用犬及貓OSM之劑量反應曲線。細胞經血清饑餓2小時,隨後用1 μg/mL至0.0001 μg/mL犬或貓OSM之九點半對數曲線處理10分鐘以誘導STAT3磷酸化。用溶解緩衝液淬滅反應,且使用AlphaLISA SureFire ULTRA™技術(Perkin Elmer, Waltham, MA)來量測STAT3磷酸化。EC
50值確定為誘導50%最大信號之OSM蛋白濃度。圖1A及1B分別顯示犬及貓OSM在犬DH-82及貓Fcwf-4細胞中之劑量反應曲線及EC
50值。
為了藉由分析候選抗體抑制OSM介導之STAT3磷酸化之能力來確定候選抗體之效力,進行犬及貓分析。在OSM及mAb處理之前,細胞經血清饑餓2小時。使用兩種獨立的方法,評估所有候選mAb抑制0.02 μg/mL犬OSM誘導之STAT3磷酸化的能力。進行分析,使得抗OSMR mAb與血清饑餓細胞培育30分鐘(對於DH-82)或培育20分鐘(對於Fcwf-4細胞)。此時移除上清液,且添加含有0.02 μg/mL犬OSM之培養基對細胞進行刺激十分鐘。用溶解緩衝液淬滅反應且量測STAT3磷酸化。在抗體濃度及純度未知的情況下,融合瘤上清液在如上所述對細胞進行30分鐘或20分鐘培育後,接著用0.02 μg/mL犬OSM刺激,對其抑制STAT3磷酸化之能力進行定性量測。個別單株抗體之效力由其在此等分析中抑制OSM介導之STAT3磷酸化的能力定義,視為進一步推進選擇抗體之關鍵選擇準則。術語效力係指由此等分析計算之IC
50值且為由OSM誘導之信號傳導降低至其最大值之一半的抗體濃度。本文所述之增加的效力與較低的IC
50值相關。
實例6. 選擇能夠中和犬及貓細胞中IL-31及OSM介導之STAT磷酸化的抗OSMR單株抗體
基於圖2中概述之準則選擇小鼠抗OSMR抗體。用與人類IgG1 Fc融合之犬及貓OSMR蛋白之組合對小鼠進行免疫,該等蛋白含有三個細胞介素結合域及單個纖網蛋白III域,以促進表現及純化。藉由ELISA對由融合瘤產生之抗體與犬及貓OSMR之結合進行篩選,且針對不相關人類IgG進行反篩選。選擇產生與犬及/或貓OSMR結合但不與人類IgG結合之抗體的融合瘤進行進一步分析。由此等初始命中產生經耗竭之融合瘤上清液且純化抗體用於進一步分析。來自此等非純系融合瘤之抗體最初使用Biacore分析與犬及貓OSMR之結合,以確認ELISA篩選之結果。進一步測試此等融合瘤候選物抑制犬DH82及貓Fcwf-4細胞中IL-31及OSM介導之STAT磷酸化的能力。選擇與犬及/或貓OSMR結合且在基於IL-31及OSM細胞之分析中之一者中具有一些抑制活性的融合瘤候選物進行次選殖。融合瘤候選物之次選殖係藉由細胞之限制稀釋來進行,且確認單純系性。藉由ELISA確認此等產生單株抗體之細胞的上清液與犬及/或貓OSMR蛋白結合,且將產生此等抗體之細胞用於分離RNA以進行可變重鏈及可變輕鏈IgG鏈之序列分析。亦測試自此等培養物純化之單株抗體與人類OSMR之結合。本文所述之候選抗體中無一者與人類OSMR結合。
此融合瘤活動最初產生五種具有獨特可變重鏈及可變輕鏈組合之單株抗體。此等小鼠抗OSMR抗體為02D09,具有可變重鏈序列(SEQ ID NO: 31;MU_02D09_VH)(其對應核苷酸序列為(SEQ ID NO: 32;MU_02D09_VH))及可變輕鏈序列(SEQ ID NO: 33;MU_02D09_VL)(其對應核苷酸序列為(SEQ ID NO: 34;MU_02D09_VL));09E09,具有可變重鏈序列(SEQ ID NO: 35;MU_09E09_VH)(其對應核苷酸序列為(SEQ ID NO: 36;MU_09E09_VH))及可變輕鏈序列(SEQ ID NO: 37;MU_09E09_VL)(其對應核苷酸序列為(SEQ ID NO: 38;MU_09E09_VL));10F07,具有可變重鏈序列(SEQ ID NO: 39;MU_10F07_VH)(其對應核苷酸序列為(SEQ ID NO: 40;MU_10F07_VH))及可變輕鏈序列(SEQ ID NO: 41;MU_10F07_VL)(其對應核苷酸序列為(SEQ ID NO: 42;MU_10F07_VL));14C04,具有可變重鏈序列(SEQ ID NO: 43;MU_14C04_VH)(其對應核苷酸序列為(SEQ ID NO: 44;MU_14C04_VH))及可變輕鏈序列(SEQ ID NO: 45;MU_14C04_VL)(其對應核苷酸序列為(SEQ ID NO: 46;MU_14C04_VL));及19F07,具有可變重鏈序列(SEQ ID NO: 47;MU_19F07_VH)(其對應核苷酸序列為(SEQ ID NO: 48;MU_19F07_VH))及可變輕鏈序列(SEQ ID NO: 49;MU_19F07_VL)(其對應核苷酸序列為(SEQ ID NO: 50;MU_19F07_VL))。圖3顯示此等可變重鏈及輕鏈之clustalW比對,其中黑框中突出顯示CDR。
表1. 使用Biacore之小鼠抗OSMR抗體對人類、犬及貓OSMR蛋白的親和力(KD)。
表2. 用抗犬及/或抗貓OSMR抗體抑制犬DH82及貓Fcwf-4細胞中IL-31及OSM介導之pSTAT3信號傳導。
實例7. 嵌合抗體之產生
抗體可變域負責抗原結合。預期將完整可變域移植至各別恆定區對抗體結合OSMR免疫原之能力具有極小影響或無影響。為了同時確認重鏈及輕鏈可變區之正確序列經鑑別且產生均質材料,表現載體經設計以在哺乳動物表現系統中產生重組嵌合抗體。本文所述之嵌合抗體由來自宿主物種抗體之可變序列(CDR及構架)移植至犬或貓IgG分子各自的重鏈及輕鏈恆定區組成(例如,小鼠可變:犬恆定稱為小鼠:犬嵌合體)。針對所選抗體之可變重鏈(VH)及可變輕鏈(VL)序列構築合成DNA序列。
對於小鼠:犬嵌合體,將各小鼠可變區選殖至哺乳動物表現質體中,該質體含有犬IgG重鏈(SEQ ID NO: 114;犬_HC_65_1)(其對應核苷酸序列為(SEQ ID NO: 115;犬_HC_65_1))或輕鏈(SEQ ID NO: 116;
犬_LC_Kappa)(其對應核苷酸序列為(SEQ ID NO: 117;
犬_LC_Kappa))恆定區。對於小鼠:貓嵌合體,將每個各自的可變區選殖至哺乳動物表現質體中,該質體含有貓IgG重鏈(SEQ ID NO: 118;貓_HC_AlleleA_1)(其對應核苷酸序列為(SEQ ID NO: 119;貓_HC_AlleleA_1))或輕鏈(SEQ ID NO: 120;貓_LC_Kappa_G_minus)(其對應核苷酸序列為(SEQ ID NO: 121;貓_LC_Kappa_G_minus))恆定區。此等抗體為小鼠:犬02D09嵌合體,具有可變重鏈序列(SEQ ID NO: 31;MU_02D09_VH)(其對應核苷酸序列為(SEQ ID NO: 32;MU_02D09_VH))及可變輕鏈序列(SEQ ID NO: 33;MU_02D09_VL)(其對應核苷酸序列為(SEQ ID NO: 34;MU_02D09_VL));小鼠:犬09E09嵌合體,具有可變重鏈序列(SEQ ID NO: 35;MU_09E09_VH)(其對應核苷酸序列為(SEQ ID NO: 36;MU_09E09_VH))及可變輕鏈序列(SEQ ID NO: 37;MU_09E09_VL)(其對應核苷酸序列為(SEQ ID NO: 38;MU_09E09_VL));小鼠:犬10F07嵌合體,具有可變重鏈序列(SEQ ID NO: 39;MU_10F07_VH)(其對應核苷酸序列為(SEQ ID NO: 40;MU_10F07_VH))及可變輕鏈序列(SEQ ID NO: 41;MU_10F07_VL)(其對應核苷酸序列為(SEQ ID NO: 42;MU_10F07_VL));小鼠:犬14C04嵌合體,具有可變重鏈序列(SEQ ID NO: 43;MU_14C04_VH)(其對應核苷酸序列為(SEQ ID NO: 44;MU_14C04_VH))及可變輕鏈序列(SEQ ID NO: 45;MU_10F07_VL)(其對應核苷酸序列為(SEQ ID NO: 46;MU_10F07_VL));小鼠:犬19F07嵌合體,具有可變重鏈序列(SEQ ID NO: 47;MU_19F07_VH)(其對應核苷酸序列為(SEQ ID NO: 48;MU_19F07_VH))及可變輕鏈序列(SEQ ID NO: 49;MU_19F07_VL)(其對應核苷酸序列為(SEQ ID NO: 50;MU_19F07_VL));小鼠:貓02D09嵌合體,具有可變重鏈序列(SEQ ID NO: 31;MU_02D09_VH) (其對應核苷酸序列為(SEQ ID NO: 32;MU_02D09_VH))及可變輕鏈序列(SEQ ID NO: 33;MU_02D09_VL)(其對應核苷酸序列為(SEQ ID NO: 34;MU_02D09_VL));小鼠:貓09E09嵌合體,具有可變重鏈序列(SEQ ID NO: 35;MU_09E09_VH)(其對應核苷酸序列為(SEQ ID NO: 36;MU_09E09_VH))及可變輕鏈序列(SEQ ID NO: 37;MU_09E09_VL)(其對應核苷酸序列為(SEQ ID NO: 38;MU_09E09_VL));小鼠:貓10F07嵌合體,具有可變重鏈序列(SEQ ID NO: 39;MU_10F07_VH)(其對應核苷酸序列為(SEQ ID NO: 40;MU_10F07_VH))及可變輕鏈序列(SEQ ID NO: 41;MU_10F07_VL)(其對應核苷酸序列為(SEQ ID NO: 42;MU_10F07_VL));小鼠:貓14C04嵌合體,具有可變重鏈序列(SEQ ID NO: 43;MU_14C04_VH)(其對應核苷酸序列為(SEQ ID NO: 44;MU_14C04_VH))及可變輕鏈序列(SEQ ID NO: 45;MU_14C04_VL)(其對應核苷酸序列為(SEQ ID NO: 46;MU_14C04_VL));及小鼠:貓19F07嵌合體,具有可變重鏈序列(SEQ ID NO: 47;MU_19F07_VH) (其對應核苷酸序列為(SEQ ID NO: 48;MU_19F07_VH))及可變輕鏈序列(SEQ ID NO: 49;MU_19F07_VL)(其對應核苷酸序列為(SEQ ID NO: 50;MU_19F07_VL))。此等序列含有特有的限制性核酸內切酶位點、Kozak共同序列及N端分泌前導序列,以促進嵌合重組抗體在哺乳動物細胞株中之表現及分泌。在CMV啟動子控制下,將編碼各重鏈及輕鏈之質體共轉染至宿主細胞中且如本文所述進行純化。
表3. 使用Biacore之小鼠:犬抗OSMR嵌合抗體對人類、犬及貓OSMR蛋白的親和力(KD)。
表4. 用抗犬及/或抗貓小鼠:犬抗OSMR嵌合抗體抑制犬DH82及貓Fcwf-4細胞中IL-31及OSM介導之pSTAT3信號傳導。
實例8. 種化抗OSMR抗體之設計及表現
抗藥物抗體(ADA)之產生可能與包括單株抗體之任何生物治療蛋白之功效損失相關。對文獻之綜合評估表明,單株抗體之種化可降低mAb之免疫原性傾向,儘管可找到免疫原性完全人類mAb及非免疫原性嵌合mAb之實例。吾等在本文中描述兩種種化方法;犬類化意謂將小鼠CDR移植至犬屬物種(例如家犬或狗)之框架上,且貓類化意謂將小鼠CDR移植至貓屬物種(例如家貓或貓)之框架上。為了幫助減輕與本文提供之抗OSMR單株抗體之ADA形成相關的風險,採用犬類化及貓類化策略。犬類化及貓類化策略係基於鑑別最適合用於CDR移植之犬或貓生殖系抗體序列。在對可變重鏈及輕鏈之所有可用生殖系序列進行廣泛分析後,基於其與小鼠抗OSMR mAb之同源性選擇生殖系候選物,且使用來自此等小鼠祖先mAb之CDR置換原生犬或貓CDR。目標為使用犬或貓抗體框架保留高親和力及基於細胞之活性,以使活體內免疫原性之可能性降至最低。
表現犬類化及貓類化mAb,且對其與犬及貓OSMR之親和力及其在基於細胞之分析中的效力進行表徵。在犬類化或貓類化抗體喪失其結合犬或貓OSMR之能力的情況下,進行系統性剖析以鑑別:1)造成功能喪失之鏈,2)造成功能喪失之構架及3)造成功能喪失之胺基酸。本文所述之種化抗體由與犬或貓IgG分子各自的重鏈及輕鏈恆定區一起表現的可變序列(CDR及構架)組成。針對所選抗體之可變重鏈(VH)及可變輕鏈(VL)序列構築合成DNA序列。此等序列含有特有的限制性核酸內切酶位點、Kozak共同序列及N端分泌前導序列,以促進重組抗體在哺乳動物細胞株中之表現及分泌。對於犬類化抗體,將各犬類化可變區選殖至哺乳動物表現質體中,該質體含有犬IgG重鏈(SEQ ID NO: 114;犬_HC_65_1)(其對應核苷酸序列為(SEQ ID NO: 115;犬_HC_65_1))或輕鏈(SEQ ID NO: 116;犬_LC_Kappa)(其對應核苷酸序列為(SEQ ID NO: 117;犬_LC_Kappa))恆定區。對於貓類化抗體,將每個各自的可變區選殖至哺乳動物表現質體中,該質體含有貓IgG重鏈(SEQ ID NO: 118;貓_HC_AlleleA_1)(其對應核苷酸序列為(SEQ ID NO: 119;貓_HC_AlleleA_1))或輕鏈(SEQ ID NO: 120;貓_LC_Kappa_G_minus)(其對應核苷酸序列為(SEQ ID NO: 121;貓_LC_Kappa_G_minus))恆定區。在CMV啟動子控制下,將編碼各重鏈及輕鏈之質體共轉染至宿主細胞中,如本文所述進行表現及純化。
貓02D09 1.1為可變重鏈序列(SEQ ID NO: 51;FEL_02D09_VH1)(其對應核苷酸序列為(SEQ ID NO: 52;FEL_02D09_VH1))及可變輕鏈序列(SEQ ID NO: 55;FEL_02D09_VL1)(其對應核苷酸序列為(SEQ ID NO: 56;FEL_02D09_VL1));貓02D09 2.1為可變重鏈序列(SEQ ID NO: 53;FEL_02D09_VH2)(其對應核苷酸序列為(SEQ ID NO: 54;FEL_02D09_VH2))及可變輕鏈序列(SEQ ID NO: 55;FEL_02D09_VL1)(其對應核苷酸序列為(SEQ ID NO: 56;FEL_02D09_VL1));貓02D09 1.2為可變重鏈序列(SEQ ID NO: 51;FEL_02D09_VH1)(其對應核苷酸序列為(SEQ ID NO: 52;FEL_02D09_VH1))及可變輕鏈序列(SEQ ID NO: 57;FEL_02D09_VL2)(其對應核苷酸序列為(SEQ ID NO: 58;FEL_02D09_VL2));貓02D09 2.2為可變重鏈序列(SEQ ID NO: 53;FEL_02D09_VH2)(其對應核苷酸序列為(SEQ ID NO: 54;FEL_02D09_VH2))及可變輕鏈序列(SEQ ID NO: 57;FEL_02D09_VL2)(其對應核苷酸序列為(SEQ ID NO: 58;FEL_02D09_VL2))。
犬09E09 1.1為可變重鏈序列(SEQ ID NO: 59;CAN_09E09_VH1)(其對應核苷酸序列為(SEQ ID NO: 60;CAN_09E09_VH1))及可變輕鏈序列(SEQ ID NO: 63;CAN_09E09_VL1)(其對應核苷酸序列為(SEQ ID NO: 64;CAN_09E09_VL1));犬09E09 2.1為可變重鏈序列(SEQ ID NO: 61;CAN_09E09_VH2)(其對應核苷酸序列為(SEQ ID NO: 62;CAN_09E09_VH2))及可變輕鏈序列(SEQ ID NO: 63;CAN_09E09_VL1)(其對應核苷酸序列為(SEQ ID NO: 64;CAN_09E09_VL1));犬09E09 1.2為可變重鏈序列(SEQ ID NO: 59;CAN_09E09_VH1)(其對應核苷酸序列為(SEQ ID NO: 60;CAN_09E09_VH1))及可變輕鏈序列(SEQ ID NO: 65;CAN_09E09_VL2)(其對應核苷酸序列為(SEQ ID NO: 66;CAN_09E09_VL2));犬09E09 2.2為可變重鏈序列(SEQ ID NO: 61;CAN_09E09_VH2)(其對應核苷酸序列為(SEQ ID NO: 62;CAN_09E09_VH2))及可變輕鏈序列(SEQ ID NO: 65;CAN_09E09_VL2)(其對應核苷酸序列為(SEQ ID NO: 66;CAN_09E09_VL2))。貓09E09 1.1為可變重鏈序列(SEQ ID NO: 67;FEL_09E09_VH1)(其對應核苷酸序列為(SEQ ID NO: 68;FEL_09E09_VH1))及可變輕鏈序列(SEQ ID NO: 71;FEL_09E09_VL1)(其對應核苷酸序列為(SEQ ID NO: 72;FEL_09E09_VL1);貓09E09 2.1為可變重鏈序列(SEQ ID NO: 69;FEL_09E09_VH2)(其對應核苷酸序列為(SEQ ID NO: 70;FEL_09E09_VH2))及可變輕鏈序列(SEQ ID NO: 71;FEL_09E09_VL1)(其對應核苷酸序列為(SEQ ID NO: 72;FEL_09E09_VL1));貓09E09 1.2為可變重鏈序列(SEQ ID NO: 67;FEL_09E09_VH1)(其對應核苷酸序列為(SEQ ID NO: 68;FEL_09E09_VH1))及可變輕鏈序列(SEQ ID NO: 73;FEL_09E09_VL2)(其對應核苷酸序列為(SEQ ID NO: 74;FEL_09E09_VL2));貓09E09 2.2為可變重鏈序列(SEQ ID NO: 69;FEL_09E09_VH2)(其對應核苷酸序列為(SEQ ID NO: 70;FEL_09E09_VH2))及可變輕鏈序列(SEQ ID NO: 73;FEL_09E09_VL2)(其對應核苷酸序列為(SEQ ID NO: 74;FEL_09E09_VL2))。
犬10F07 1.1為可變重鏈序列(SEQ ID NO: 75;CAN_10F07_VH1)(其對應核苷酸序列為(SEQ ID NO: 76;CAN_10F07_VH1))及可變輕鏈序列(SEQ ID NO: 77;CAN_10F07_VL1)(其對應核苷酸序列為(SEQ ID NO: 78;CAN_10F07_VL1));犬10F07 2.1為可變重鏈序列(SEQ ID NO: 79;CAN_10F07_VH2)(其對應核苷酸序列為(SEQ ID NO: 80;CAN_10F07_VH2))及可變輕鏈序列(SEQ ID NO: 77;CAN_10F07_VL1)(其對應核苷酸序列為(SEQ ID NO: 78;CAN_10F07_VL1));犬10F07 1.2為可變重鏈序列(SEQ ID NO: 75;CAN_10F07_VH1)(其對應核苷酸序列為(SEQ ID NO: 76;CAN_10F07_VH1))及可變輕鏈序列(SEQ ID NO: 81;CAN_10F07_VL2)(其對應核苷酸序列為(SEQ ID NO: 82;CAN_10F07_VL2));犬10F07 2.2為可變重鏈序列(SEQ ID NO: 79;CAN_10F07_VH2)(其對應核苷酸序列為(SEQ ID NO: 80;CAN_10F07_VH2))及可變輕鏈序列(SEQ ID NO: 81;CAN_10F07_VL2)(其對應核苷酸序列為(SEQ ID NO: 82;CAN_10F07_VL2))。貓10F07 1.1為可變重鏈序列(SEQ ID NO: 83;FEL_10F07_VH1)(其對應核苷酸序列為(SEQ ID NO: 84;FEL_10F07_VH1))及可變輕鏈序列(SEQ ID NO: 85;FEL_10F07_VL1)(其對應核苷酸序列為(SEQ ID NO: 86;FEL_10F07_VL1));貓10F07 2.1為可變重鏈序列(SEQ ID NO: 87;FEL_10F07_VH2)(其對應核苷酸序列為(SEQ ID NO: 88;FEL_10F07_VH2))及可變輕鏈序列(SEQ ID NO: 85;FEL_10F07_VL1)(其對應核苷酸序列為(SEQ ID NO: 86;FEL_10F07_VL1));貓10F07 1.2為可變重鏈序列(SEQ ID NO: 83;FEL_10F07_VH1)(其對應核苷酸序列為(SEQ ID NO: 84;FEL_10F07_VH1))及可變輕鏈序列(SEQ ID NO: 89;FEL_10F07_VL2)(其對應核苷酸序列為(SEQ ID NO: 90;FEL_10F07_VL2));貓10F07 2.2為可變重鏈序列(SEQ ID NO: 87;FEL_10F07_VH2)(其對應核苷酸序列為(SEQ ID NO: 88;FEL_10F07_VH2))及可變輕鏈序列(SEQ ID NO: 89;FEL_10F07_VL2)(其對應核苷酸序列為(SEQ ID NO: 90;FEL_10F07_VL2))。
犬19F07 1.1為可變重鏈序列(SEQ ID NO: 91;CAN_19F07_VH1)(其對應核苷酸序列為(SEQ ID NO: 92;CAN_19F07_VH1))及可變輕鏈序列(SEQ ID NO: 93;CAN_19F07_VL1)(其對應核苷酸序列為(SEQ ID NO: 94;CAN_19F07_VL1));犬19F07 2.1為可變重鏈序列(SEQ ID NO: 95;CAN_19F07_VH2)(其對應核苷酸序列為(SEQ ID NO: 96;CAN_19F07_VH2))及可變輕鏈序列(SEQ ID NO: 93;CAN_19F07_VL1)(其對應核苷酸序列為(SEQ ID NO: 94;CAN_19F07_VL1));犬19F07 1.2為可變重鏈序列(SEQ ID NO: 91;CAN_19F07_VH1)(其對應核苷酸序列為(SEQ ID NO: 92;CAN_19F07_VH1))及可變輕鏈序列(SEQ ID NO: 97;CAN_19F07_VL2)(其對應核苷酸序列為(SEQ ID NO: 98;CAN_19F07_VL2));犬19F07 2.2為可變重鏈序列(SEQ ID NO: 95;CAN_19F07_VH2)(其對應核苷酸序列為(SEQ ID NO: 96;CAN_19F07_VH2))及可變輕鏈序列(SEQ ID NO: 97;CAN_19F07_VL2)(其對應核苷酸序列為(SEQ ID NO: 98;CAN_19F07_VL2))。貓19F07 1.1為可變重鏈序列(SEQ ID NO: 99;FEL_19F07_VH1)(其對應核苷酸序列為(SEQ ID NO: 100;FEL_19F07_VH1))及可變輕鏈序列(SEQ ID NO: 101;FEL_19F07_VL1)(其對應核苷酸序列為(SEQ ID NO: 102;FEL_19F07_VL1));貓19F07 2.1為可變重鏈序列(SEQ ID NO: 103;FEL_19F07_VH2)(其對應核苷酸序列為(SEQ ID NO: 104;FEL_19F07_VH2))及可變輕鏈序列(SEQ ID NO: 101;FEL_19F07_VL1)(其對應核苷酸序列為(SEQ ID NO: 102;FEL_19F07_VL1));貓19F07 1.2為可變重鏈序列(SEQ ID NO: 99;FEL_19F07_VH1)(其對應核苷酸序列為(SEQ ID NO: 100;FEL_19F07_VH1))及可變輕鏈序列(SEQ ID NO: 105;FEL_19F07_VL2)(其對應核苷酸序列為(SEQ ID NO: 106;FEL_19F07_VL2));貓19F07 2.2為可變重鏈序列(SEQ ID NO: 103;FEL_19F07_VH2)(其對應核苷酸序列為(SEQ ID NO: 104;FEL_19F07_VH2))及可變輕鏈序列(SEQ ID NO: 105;FEL_19F07_VL2)(其對應核苷酸序列為(SEQ ID NO: 106;FEL_19F07_VL2))。
犬14C04 1.1為可變重鏈序列(SEQ ID NO: 127;CAN_14C04_VH1)(其對應核苷酸序列為(SEQ ID NO: 128;CAN_14C04_VH1))及可變輕鏈序列(SEQ ID NO: 131;CAN_14C04_VL1)(其對應核苷酸序列為(SEQ ID NO: 132;CAN_14C04_VL1));犬14C04 2.1為可變重鏈序列(SEQ ID NO: 129;CAN_14C04_VH2)(其對應核苷酸序列為(SEQ ID NO: 130;CAN_14C04_VH2))及可變輕鏈序列(SEQ ID NO: 131;CAN_14C04_VL1)(其對應核苷酸序列為(SEQ ID NO: 132;CAN_14C04_VL1));犬14C04 1.2為可變重鏈序列(SEQ ID NO: 127;CAN_14C04_VH1)(其對應核苷酸序列為(SEQ ID NO: 128;CAN_14C04_VH1))及可變輕鏈序列(SEQ ID NO: 133;CAN_14C04_VL2)(其對應核苷酸序列為(SEQ ID NO: 134;CAN_14C04_VL2));犬14C04 2.2為可變重鏈序列(SEQ ID NO: 129;CAN_14C04_VH2)(其對應核苷酸序列為(SEQ ID NO: 130;CAN_14C04_VH2))及可變輕鏈序列(SEQ ID NO: 133;CAN_14C04_VL2)(其對應核苷酸序列為(SEQ ID NO: 134;CAN_14C04_VL2))。
實例9. 候選抗OSMR抗體之同源模型化及CDR之間結構差異的比較
基於已知蛋白質結構生成同源模型可用於理解抗體之三維結構。經由疊加重疊此等蛋白質模型允許直接比較抗體類似且在三維空間中彼此不同之區域。此等方法克服將蛋白質作為線性胺基酸序列串進行比較的侷限性,其沒有考慮各胺基酸相對於其周圍環境之物理化學特性的集體表現。本文所述之5種小鼠抗OSMR抗體之抗體模型係使用Molecular Operating Environment(MOE™)軟體(Chemical Computing Group, Montreal, Canada)生成的,該軟體能夠創建類似於其他可用軟體的此類模型。參見例如Almagro等人;Antibody Modeling Assessment;
Proteins: Struct. Func. Bioinf. 79(
2011) 3050-3066之記錄。
為了比較5個小鼠抗OSMR抗體模型之結構,由各抗體CDR之間的成對比較確定均方根偏差(RMSD)值,該等CDR被認為對於抗原結合最關鍵。RMSD值為此項技術中的已知指標,用於藉由比較其充當蛋白質主鏈骨架之α碳原子的座標來確定三維空間中結構的相似性。當計算RMSD時,MOE軟體使用各α碳與其他結構上分別對準之α碳的比較,以產生均方根偏差,其代表所選相關區域之結構的總體差異。吾等在本文中僅描述各抗體之間的CDR區而非整個可變域的比較。當計算三種抗體結構之間的RMSD值時,考慮結構重疊及引入空位以最佳化比對之區域進行序列比對。在某些情況下,由於沒有考慮到環長度之變化,此導致高估RMSD相似性(RMSD值較低)。在考慮5個小鼠抗OSMR抗體候選物之CDRH3及CDRL1時,情況就是如此,其中CDR長度不同(圖3)。大於或等於2埃之RMSD表示三維空間中之顯著分離。
圖4顯示六個矩陣,其中RMSD來自本文所述之5種小鼠抗OSMR抗體之各CDR的成對比較。來自此等結構模型之CDRH1的比較表明,此等抗體在此環中彼此具有一般結構相似性,其中RMSD值中無一者超過2埃。具有可變重鏈序列(SEQ ID NO: 43;MU_14C04_VH)(其對應核苷酸序列為(SEQ ID NO: 44;MU_14C04_VH))及可變輕鏈序列(SEQ ID NO: 45;MU_14C04_VL)(其對應核苷酸序列為(SEQ ID NO: 46;MU_14C04_VL))之小鼠抗體14C04具有最獨特的CDRH1結構(與其他抗體相比,RMSD最大),且值得注意的是,此抗體為唯一僅對犬OSMR具有特異性的抗體。鼠類抗OSMR抗體14C04與其他抗體之間的RMSD差異在比較CDRH2時更為明顯,每次比較的RMSD值均超過2。
比較5種小鼠抗OSMR抗體之CDRH3結構的RMSD結果突出抗體與其目標OSMR之結構功能關係的另一個重要考慮因素。小鼠抗OSMR抗體14C04在此CDR中與其他抗體之結構高度不同,在4次比較中之3次中RMSD值超過2埃,且如先前所提及,14C04為犬OSMR特異性的(親和力資料參見表1)。在小鼠抗OSMR 02D09中,另一種與其他4種具有高度結構區別的抗體具有可變重鏈序列(SEQ ID NO: 31;MU_02D09_VH)(其對應核苷酸序列為(SEQ ID NO: 32;MU_02D09_VH))及可變輕鏈序列(SEQ ID NO: 33;MU_02D09_VL)(其對應核苷酸序列為(SEQ ID NO: 34;MU_02D09_VL))。小鼠抗OSMR 02D09為受關注的,因為此抗體顯示與貓OSMR結合之特異性(參見表1及表3,表3支持嵌合02D09抗體對貓OSMR之親和力更高(與犬OSMR相比),以及較慢解離速率支持其對貓OSMR蛋白之優先特異性)。為了重申先前提出的觀點,抗體02D09及14C04亦具有較長CDRH3且此等額外胺基酸在直接結構比較中未被考慮,然而,當與其他3種與犬及貓OSMR兩者[強調添加]結合之抗體相比時,其確實對此兩個CDRH3環之獨特結構產生高度影響。
繼續比較輕鏈CDR結構,圖4 CDRL1矩陣顯示5種抗OSMR抗體之RMSD比較不超過2埃的差異。同樣,犬OSMR抗體14C04具有較高RMSD值,表明在不考慮此CDR中之4個額外胺基酸的情況下有結構區分的趨勢。此CDR環中之額外4個胺基酸代表與其他4種抗體相比之顯著結構差異,且進一步支持此抗體之結合互補位的獨特結構組成。抗體02D09及14C04在CDRL2環中之結構差異最大,它們之間的比較存在最顯著的(RMSD大於2埃)。
值得指出的是,來自抗體09E09及10F07之CDRL2的胺基酸序列為相同的,但它們之間的RMSD比較不為零(值為0.31)。RMSD值為0.31代表結構彼此高度相似。差異起因於抗體09E09及10F07不具有相同可變輕鏈,且因此彼此不相同之事實。在蛋白質鏈之其他區域中引入的結構變化可能為造成遠端出現差異的原因,且反映在RMSD值的細微差異中。
輕鏈CDRL3之比較再次揭露,抗體02D09與09E09之間存在顯著結構差異,且當與對犬及貓OSMR具有雙重特異性之抗體相比時,此兩種物種特異性抗OSMR mAb顯示出更大的結構變化趨勢。儘管不希望束縛於一個特定假設,但吾等提出證據支持此等抗OSMR抗體之CDR環之結構與其特異性結合且阻斷犬及/或貓OSMR之功能之間的聯繫,因而此結合抑制由IL-31或OSM蛋白誘導之pSTAT3信號傳導的能力。
實例10. 犬及貓OSM:OSMR受體之同源模型化
OSMR受體之特徵在於細胞介素與其結合之情形產生細胞信號傳導反應。此等細胞介素(包括OSM)為gp130家族細胞介素之成員,其在不同的細胞及組織分佈之情形下引發多效性反應,包括細胞分化、增殖、造血、免疫反應及發炎反應(Richards CD.; The Enigmatic
Cytokine Oncostatin M and Roles in Disease;
ISRN Inflammation. 2013:512103(
2013))。OSMR蛋白與LIFR具有相似的結構架構,LIFR在人類中與gp130形成異二聚體受體複合物,以響應LIF及OSM傳導信號。此類功能特徵之重疊允許在物種內及物種間比較此等受體結構。目前尚未獲得OSMR之蛋白質結構,但可使用與LIF受體(LIFR)複合之白血病抑制因子(LIF)的晶體結構(PDB ID: 2Q7N,4埃)(Huyton T等人;An unusual cytokine: Ig-domain
interaction revealed in the crystal structure of leukemia inhibitory factor (LIF) in complex with the LIF receptor. Proc Natl Acad Sci U S A。2007年7月31日;104(31): 12737-42)。儘管不希望束縛於一個假設,但吾等在本文中提出結構同源性資料,使用此LIF:LIFR共晶體結構作為模板來指導對IL-31、OSM及OSMR之間相互作用的理解。此等結構資料與參與人類OSM與人類OSMR相互作用之胺基酸殘基的功能圖譜報告相結合,可推斷出犬及貓OSMR之同源區,且支持對抑制性抗OSMR抗體所結合之抗原決定基的理解。
圖5A顯示在人類LIFR(SEQ ID NO: 135;
人類_LIFR)之模板結構2Q7N上使用(SEQ ID NO: 107;
犬_OSMR_hIgG1_Fc)(其對應核苷酸序列為(SEQ ID NO: 108;犬_OSMR_hIgG1_Fc))之胺基酸28-329(犬OSMR之胞外域)生成的代表性同源模型。在人類LIFR(SEQ ID NO: 135;人類_LIFR)之模板結構2Q7N上使用(SEQ ID NO: 112;貓_OSMR_hIgG1_Fc)(其對應核苷酸序列為(SEQ ID NO: 113;貓_OSMR_hIgG1_Fc))之胺基酸28-329(貓OSMR之胞外域)生成類似的同源模型。圖5顯示在人類LIF(SEQ ID NO: 136;人類_LIF)之模板結構2Q7N上使用犬OSM(SEQ ID NO: 109;犬_OSM)生成的同源模型。在人類LIF(SEQ ID NO: 136;人類_LIF)之模板結構2Q7N上使用貓OSM(SEQ ID NO: 110;貓_OSM_hIgG1_Fc)(其對應核苷酸序列為(SEQ ID NO: 111;貓_OSM_hIgG1_Fc))之胺基酸23-234生成類似的同源模型。
圖5A顯示犬OSM同源模型靠近犬OSMR蛋白之結合界面,基於LIF:LIFR共晶體模板。圖5B顯示突出顯示圓圈內所含區域之放大圖像。在此放大圖示中,標註之胺基酸係自先前研究中鑑別的,該研究定義參與人類OSM:OSMR相互作用之相關胺基酸(Adrian-Segarra JM等人;The AB loop of Oncostatin M (OSM) determines
species-specific signaling in humans and mice. J Biol Chem. 2018年12月28日;293(52):20181-20199)。值得注意的是,儘管此出版物使用人類蛋白質來評定參與OSM與OSMR結合之重要胺基酸殘基的功能,但此犬OSM:OSMR同源模型上標註之同源胺基酸確實位於此結合界面中,且因此提供自人類蛋白質結構之推斷支持犬及貓受體系統之支持證據。
實例11. 基於與已知OSM結合域之同源性及物種間之胺基酸序列變化確定犬及貓OSMR上之抗OSMR結合區
圖6顯示邏輯上界定5種小鼠抗OSMR抗體在犬及/或貓OSMR上之結合區的圖。亦即,由於界定OSMR上之OSM(及可能IL-31)結合位點的胺基酸殘基數目少,結合人類OSMR蛋白之序列分異度及犬與貓OSMR之間的有限分異度,僅存在少數位置此等抗體可特異性結合且引發本文所述之功能活性。在圖6中,人類OSMR之胞外域用填充的黑色橢圓及代表細胞介素結合域之影線方塊及代表纖網蛋白III域之空心圓表示。如本文所述之定位研究界定負責人類OSM與OSMR結合之特定區域(關鍵的個別胺基酸接觸)。此處亦描繪用於使小鼠免疫以產生抗OSMR抗體之同源犬及貓OSMR蛋白區域。本文所述之選擇用於與犬及/或貓OSMR結合之抗體中無一者與人類OSMR結合,表明結合發生在犬及/或貓OSMR上與人類有差異的區域。亦即,犬及貓OSMR之此等區域中的胺基酸與人類不同。知道此等抗體與犬及/或貓OSMR結合且抑制由犬及/或貓OSM(及/或IL-31)誘導之pSTAT3介導之信號傳導,意味著其在OSM及/或IL-31與OSMR結合以活化受體之離散區域中結合,且此區域在犬及貓OSMR中之胺基酸序列與人類OSMR不同。
本文所述之小鼠抗OSMR抗體有3種類型,1)優先與貓OSMR結合之抗體,2)與犬OSMR特異性結合之抗體,及3)與犬及貓OSMR結合之3種抗體。基於此等3種結合表型,與犬OSMR特異性結合之抗體必須在OSMR靠近OSM(及IL-31)之結合位點的區域中結合,該區域之胺基酸序列相對於犬對於貓OSMR為特有的。與犬OSMR相比,優先與貓OSMR結合之抗體將與貓OSMR特有的靠近OSM(及IL-31)結合位點之區域結合。結合犬及貓OSMR、抑制OSM(及/或)IL-31介導之信號傳導的抗體將與OSMR上胺基酸序列在犬與貓OSMR之間保守的區域結合。基於本文所述之模型化及已確定之此等抗體的功能資料,此等資料定義本文所述之抗OSMR抗體的抗原決定基。
實例12. 抗OSMR抗體在OSMR受體模型上之對接
本文描述針對經選擇與犬及/或貓OSMR結合之5種候選小鼠抗OSMR抗體生成的同源模型。亦描述此等抗體之間在CDR結構及針對中和犬及/或貓細胞中犬及/或貓IL-31及/或OSM pSTAT3信號傳導的差異結合及效力方面的結構:功能關係的變化。另外,描述OSM:OSMR結合界面之同源模型,其定義OSM細胞介素及受體上對受體活化重要的區域。使用此等模型及參與此等相互作用之特定胺基酸殘基的知識可轉化為犬及貓OSM及OSMR蛋白中之同源區域。
蛋白質與另一蛋白質(或蛋白複合物)之對接係使用如MOE之軟體或目前可用的相關軟體來進行。使用來自使用者之輸入來界定蛋白質上之區域(例如特定胺基酸殘基)以指導軟體,將抗體同源模型(或抗體之解析結構)對接至受體上。此等區域係由定義殘基之實驗資料的知識來界定,該等殘基對細胞介素與其所結合的受體之間的接觸很重要。此等資料可來源於同源蛋白質結構及/或具有類似功能特徵及類似架構(且不一定為類似胺基酸序列)之蛋白質結構。在MOE軟體中,利用人類OSM:OSMR相互作用之知識以及哪些小鼠抗犬及/或貓CDR對於物種特異性很重要的知識,將抗OSMR抗體對接至OSMR結構上。將抗體模型置於OSM:OSMR相互作用之相關區域亦得到以下事實的支持:a)本文所述之小鼠抗OSMR抗體確實與犬及/或貓OSMR結合及b)此等抗體阻斷IL-31及/或OSM在犬及/或貓細胞中誘導pSTAT3信號傳導之能力。此等事實界定OSMR蛋白上此等抗體可邏輯上與之結合的離散區域,且限制該區域以界定CDR之對接應發生在何處。
實例13. 使用原位雜交(ISH)分析患有過敏性皮膚炎之貓科動物之皮膚組織生物檢體中的OSMR基因表現
對來自患有過敏性皮膚病之貓科動物的二十個皮膚生物檢體進行福馬林固定及石蠟包埋(FFPE),隨後切片進行ISH分析。對來自無過敏性疾病徵象之正常貓科動物皮膚的十九個生物檢體進行FFPE且切片進行比較分析。使用Leica Bond-RX系統執行Advanced Cell
Diagnostics, RNAscope 2.5 LS Reagent Kit-Red (ACD, 322750-USM)之自動化單顯色ISH方案。在探針雜交之前,使用ACD專有蛋白酶試劑對組織樣品進行加熱及酶促抗原決定基修復。對各樣品進行陽性對照染色,以使用針對親環蛋白B(PPIB)基因之探針(Advanced Cell
Diagnostics, Inc., Newark, CA)確定RNA完整性。定製探針經設計以偵測貓OSMR基因之表現(Advanced Cell Diagnostics, Inc., Newark, CA)。在Leica Aperio
ImageScope 12.3.2.8013上對各載片進行觀測及定量。各影像均有註釋,且用嵌入ImageScope軟體之宏觀算法Leica RNA ISH v2分析RNA表現。資料自ImageScope軟體提取且以RNA信號與分析組織面積之比率報告。使用學生單尾檢驗來確定信號顯著性。
圖7顯示使用ISH對正常及過敏性貓科動物皮膚生物檢體之OSMR mRNA成像後的定量結果。使用RNAScope之mRNA ISH對偵測目標轉錄物(在此情況下為貓OSMR mRNA)具有高度特異性。在患有過敏性疾病之貓科動物的皮膚中,存在明顯、顯著的OSMR mRNA過度表現。此等結果表明,貓科動物之過敏性皮膚病的臨床相關診斷與OSMR基因之過度表現之間存在相關性,代表OSMR與疾病病理生理學之間的聯繫。此等結果支持OSMR參與貓科動物皮膚病症之假設,且用能夠阻斷細胞介素介導之經由受體之信號傳導的抗體靶向OSMR可用於治療此類病症,包括但不限於過敏性及異位性皮膚炎。
實例14. 使用免疫組織化學(IHC)分析患有過敏性皮膚炎之貓科動物之皮膚組織生物檢體中的OSMR蛋白
對來自患有過敏性皮膚病之貓科動物的五個皮膚生物檢體進行福馬林固定及石蠟包埋(FFPE),隨後切片進行IHC分析。對來自無過敏性疾病徵象之正常貓科動物皮膚的五個生物檢體進行FFPE且切片進行比較分析。使用Leica Bond-RX系統(Leica Biosystems, Buffalo Grove, IL)進行自動化單顯色IHC精煉紅方案。在抗體染色之前,藉由在EDTA緩衝液中熱誘導之抗原決定基修復來暴露樣品抗原決定基。使用多株兔抗OSMR抗體(LSBio LS-B11477, Seattle, WA)進行貓OSMR蛋白之表現,且用Leica Bond精煉紅AP連接之聚合物及堅牢紅色素原(Leica Biosystems, Buffalo Grove, IL)進行偵測。藉由檢查各影像之紅色染色進行定性分析,表明OSMR蛋白之表現。
圖8顯示比較正常貓科動物皮膚切片與患有過敏性疾病之貓科動物皮膚切片的代表性影像。皮膚之彩色載片影像含有淺棕色表皮區域;點狀深紫色斑點,其為細胞核之Dapi染色;及紅色,其為在鹼性磷酸酶(AP)標記之二級抗體顯色後OSMR蛋白之比色染色。圖8顯示在將彩色影像轉換為灰度格式後,對照皮膚組織影像及過敏性皮膚組織影像中貓OSMR蛋白的染色。在對照(非過敏性)皮膚樣品中,OSMR蛋白在表皮下空間中有少量表現,而表皮層附近的細胞分佈正常。過敏性皮膚樣品之影像清楚地顯示OSMR蛋白在整個表皮下空間之表現升高,細胞大量浸潤,表皮與表皮下空間之間的區別很小。在此等影像中,OSMR蛋白在細胞核之黑色界定染色之外的空間中視覺化為灰色至黑色的陰影。值得注意的是,儘管此等影像中之細胞邊界沒有註釋,但在可能遠離細胞之間質區域出現染色,表明可能有分泌的可溶性形式的OSMR受體存在。儘管不希望束縛於一個假設,但可設想,此類分泌的受體可藉由充當OSMR與之相互作用之蛋白質的拮抗劑或載體蛋白質而具有調節作用。若此等可溶性形式具有與受體之細胞相關形式相同的胺基酸序列及結構,則如本文所述之抗OSMR抗體亦將與可溶性形式結合。對五張對照貓科動物皮膚切片及五張過敏性皮膚切片之目視檢查表明,OSMR染色之模式與此處描述之兩個代表性影像相似。結果支持本文所述之定量結果,顯示當與無過敏性疾病之貓科動物皮膚樣品相比時,患有過敏性疾病之貓科動物皮膚中OSMR之過度表現。此等結果提供OSMR蛋白在患有皮膚病症之貓科動物皮膚中之作用的證據,該等病症包括但不限於過敏性及異位性皮膚炎。
實例15. IL-31誘導之狗及貓之搔癢模型確定抗OSMR抗體之活體內功效。
儘管不希望束縛於一個特定假設,但吾等提出證據表明所選抗體與犬及/或貓OSMR之結合能夠阻斷(或中和)由IL-31及/或OSM誘導之pSTAT3信號傳導的生物活性,且在OSMR受體層面上之此類IL-31及/或OSM抑制作為針對本文所述之犬科動物及貓科動物之異位性、過敏性、發炎性及其他病症的治療可為有益的。抗體有效中和其目標之能力可使用適當模型活體內評定在宿主物種中之功效。描述此類測定活體內功效之模型。
為了確定狗之活體內功效,向實驗室的狗皮下(SC)投予抗犬OSMR抗體。對所有狗進行基線反應,且基於其搔癢評分指數(PSI)將狗隨機分組並圈養。隨後在第7天向狗投予抗犬OSMR抗體,且在第8天、第14天及第22天進行IL-31攻擊。在比較未處理動物之PSI評分時,將經抗體處理之動物在第8天及第14天之平均PSI相對於第1天的減少視為功效終點。在IL-31攻擊之前的每天,評定與狗之搔癢行為相關之PSI日間變化係藉由為每隻狗確定30分鐘的PSI基線來控制變化。此類活體內模型資料可提供以下證據:1)抗犬OSMR單株抗體可中和IL-31誘導狗之搔癢症的能力,2)在基於細胞之分析中藉由阻斷OSMR抑制IL-31介導之信號傳導與活體內功效相關及3)利用IL-31模型進行抗體評估所需的參數已建立,用於評估其他候選抗體。
在IL-31誘導之活體內貓模型中評定抗貓OSMR的功效。自第-7天至第28天評定媒劑安慰劑組及抗體組之攻擊前搔癢行為,第零天為抗體投予日。在第零天,向貓皮下給與抗OSMR抗體,此為第一次貓IL-31攻擊前七天。在IL-31蛋白之靜脈內攻擊後第7天、第21天及第28天,評定搔癢行為1小時。當與媒劑安慰劑對照相比時,在IL-31攻擊後第7天、第21天或第28天觀察到的搔癢減少視為功效。此等資料支持抗OSMR抗體能夠中和由貓IL-31活體內誘導之搔癢,且表明該抗體可充當治療劑治療貓之IL-31介導之疾病,包括但不限於異位性皮膚炎。
實例16. 使用小鼠及小鼠:犬嵌合抗OSMR抗體之額外基於細胞之資料
進行額外基於細胞之實驗,以評定抗OSMR抗體在細胞攻擊分析中對IL-31及OSM介導之pSTAT3信號傳導的效力。此等資料係為了支持實例6及7中所述之先前研究而產生。小鼠及小鼠:狗嵌合抗體之序列分別描述於實例6及7中。此等資料表明,抗體10F07及19F07均對抑制犬及貓細胞中犬及貓IL-31及OSM介導之pSTAT3信號傳導具有優越的效力。亦關注的是抗體14C04對抑制犬科動物介導之信號傳導及02D09對貓科動物之選擇性效力,表明OSMR受體上之結構變異的潛力,其導致此兩種抗體識別之抗原決定基的差異特異性。
表5. 用抗犬及/或抗貓小鼠:犬抗OSMR嵌合抗體抑制犬DH82及貓Fcwf-4細胞中IL-31及OSM介導之pSTAT3信號傳導。
實例17. 犬類化及貓類化抗OSMR抗體之結合資料
選殖、表現及純化犬類化(犬)及貓類化(貓)抗OSMR抗體。表6中各種化抗體之序列描述於實例8中。使用Biacore量測此等種化抗體對犬及貓OSMR之親和力。表5描述經表現且結合犬及/或貓OSMR之種化抗體之此等Biacore實驗的結果。如表中所示,此第一輪種化產生19F07、09E09及10F07譜系之抗體,其經表現且與其蛋白質目標結合。關於與具有與此等種化型式相同之CDR的小鼠及小鼠:犬嵌合體的比較,分別參見表1及表3。此三個系列抗體中之每一者的最高親和力種化為Fel_09E09_1.1與貓OSMR結合之KD為7.73E-9 M,Fel_10F07_2.2與貓OSMR結合之KD為1.21E-9 M,Can_19F07_2.1與犬OSMR結合之KD為8.30E-9 M,及Fel_19F07_2.2與貓OSMR結合之KD為3.32E-12 M。種化過程中之目標為維持種化抗體形式對其各自目標蛋白(在此情況下為犬及/或貓OSMR)之親和力。此處詳述例示此目標之抗體的結合動力學。
表6. 犬類化及貓類化抗OSMR抗體對犬及貓OSMR之Biacore結合資料。實驗對照顯示抗人類OSMR抗體僅與人類OSMR結合。具有此等CDR之小鼠祖先mAb中無一者顯示與人類OSMR結合(參見表1)。未轉染對照與此等種化重組mAb一樣生長及純化,沒有質體表現功能性抗體。cOSM結合顯示此三種OSMR受體形式能夠與犬類形式之OSM蛋白結合。Ctrl-HBS-EP為Biacore儀器之緩衝液對照。
實例18. 使用丙胺酸取代之抗OSMR CDR之突變分析
為了建立抗體CDR上之各胺基酸殘基與該殘基參與抗體與其目標蛋白之結合之間的功能關係,進行丙胺酸置換突變分析。為表1中所述之五種抗OSMR抗體中之四種合成含有重鏈及輕鏈小鼠可變序列之個別哺乳動物表現質體(未進行抗體Mu_14C04之丙胺酸置換)。如本文關於嵌合抗體之產生所述,選殖分別具有重鏈及輕鏈犬類恆定區之可變重鏈及可變輕鏈(實例7)。此等嵌合抗體之表現及純化係根據本文所述之程序(實例1)進行。為了進行比較分析,各嵌合體係在初始小鼠可變重鏈及可變輕鏈序列(野生型)無任何變化的情況下製得。對於各突變體,產生用丙胺酸取代各可變重鏈及輕鏈CDR位置之各非丙胺酸殘基的個別質體。各質體在各CDR之單個位置處含有單個丙胺酸取代,與相應重鏈或輕鏈之野生型質體配對且使用瞬時CHO細胞系統表現。
實例19. 抗OSMR抗體之丙胺酸突變體的ELISA及Biacore結合結果
丙胺酸置換突變分析之目標為進一步瞭解個別CDR胺基酸殘基在與OSMR目標蛋白結合中的參與。CDR胺基酸殘基置換為丙胺酸之單個取代可能會導致功能變化,從而使抗體與其目標之結合受到負面影響(意味著與不含CDR取代之野生型抗體相比,與抗體蛋白質目標之結合減少,或結合親和力降低,或ELISA信號降低)。使用間接ELISA對各丙胺酸突變體之結合進行評定,其中貓OSMR蛋白(SEQ ID NO: 112)被動固定化至聚苯乙烯ELISA盤。ELISA係根據標準阻斷及洗滌程序進行,各步驟之間有一小時的培育時間。為了確定結合,將各野生型或突變型抗體按指示作為純化抗體(純抗體)或細胞培養物上清液(上清液)添加至ELISA盤之個別孔中。由於此等抗體構築為小鼠:犬嵌合體,因此使用山羊抗犬HRP標記之二級抗體偵測在使用HRP受質顯影後與貓OSMR蛋白結合之抗體的量。為了確定抗體是否自瞬時CHO培養物中產生,使用小鼠抗犬抗體作為ELISA盤上之捕捉試劑進行單獨的ELISA。將各上清液或純抗體製備物添加至個別孔中且使其結合。使用HRP標記之山羊抗狗偵測mAb(抗體表現對照)確定抗體之存在。將各ELISA盤產生之比色信號相對於不存在分析物之背景對照標準化。資料表示為與貓OSMR結合之ELISA的光密度(OD)(ELISA信號)與抗體對照盤(抗體表現對照)之OD的比率。導致OD比率(ELISA信號/mAb對照)小於或等於1.3之丙胺酸突變被認為對結合有負面影響。各野生型表現對照之OD比率大於1.6。一般而言,大多數對結合有負面影響的突變導致OD比率小於0.5(表A)。
表A. 總結ELISA及Biacore之結果,其中描述四種抗OSMR嵌合抗體之各CDR位置上之丙胺酸置換突變。描述欄中指出之丙胺酸置換突變係基於整個可變區落在所述CDR(CDR欄)中之位置來編號。
ELISA資料為由丙胺酸置換突變體與貓OSMR之結合產生之信號的比率。此比率為由與貓OSMR結合產生之信號除以來自抗體表現對照之信號(其表明存在重組抗體)。此處亦顯示與犬及貓OSMR之Biacore結合動力學以及來自表現對照之相應信號。此表中所示之資料來自使用相同抗體製劑(上清液或純抗體)之實驗,且僅來自在ELISA分析中結合受到負面影響之彼等丙胺酸置換突變體。
表A中之Biacore資料顯示各丙胺酸置換突變之動力學結合資料,其中結合在貓OSMR ELISA實驗中受到負面影響。來自ELISA之資料代表平衡狀態,其中允許抗體在一小時時段內締合及解離,從而產生穩態結合。使用Biacore,將目標蛋白固定至表面且使抗體在移動液相中通過此表面。蛋白質-蛋白質相互作用係由表面共振之變化來確定,從而可計算出締合(k
a)、解離(k
d)及親和力常數(KD)。儘管不希望束縛於一個假設,但吾等提出使用相同抗體製劑之ELISA及Biacore實驗的資料可能導致兩種方法在結合方面一致,但亦可能由於結合動力學之性質及不同分析動力學而顯示出矛盾的結果。表A中提供之資料(結合實例21中酵母呈現突變分析之實驗結果)允許定義欲在此處所述之抗OSMR抗體與其結合及阻斷IL-31及OSM介導之經由OSMR受體之信號傳導的能力之間定義的結構:功能關係。
實例20. 使用酵母表面呈現(YSD)結合突變掃描確定抗OSMR CDR殘基之結構-功能關係的方法
為了進一步確定抗OSMR抗體19F07中對與OSMR蛋白目標相互作用重要的胺基酸殘基,採用獨立的實驗方法,其使用在酵母釀酒酵母(
Saccharomyces cerevisiae)表面上呈現抗體可變域。使用Klesmith等人(2019)
Biochemistry 58, 4869-4881定義之方法對抗體Mu_19F07進行突變耐受性抗原決定基定位。重鏈及輕鏈可變域作為gBlocks(IDT)購買,且經由(G
4S)
4連接子連接以構築19F07單鏈可變結合片段(scFv)。使用HiFi組裝將基因選殖至含有BbvCI切口限制位點之最小細菌質體(New England Biolabs)中。使用切口突變誘發,使用此載體創建兩個單位點飽和庫,其中兩個不同寡核苷酸池(IDT)分別為VH及VL域內之各密碼子位置編碼NNK密碼子(Wrenbeck等人(2016)
Nature Methods 13, 928-930)。對於所有選殖步驟,存在足夠數目之轉型體對所設計的庫進行過取樣(VH及VL庫之理論庫大小分別為3744及3424個變異體)。親本未突變scFv gBlock(野生型)以及VH及VL突變體庫經PCR擴增,且使用同源重組用線性化酵母表面呈現載體電穿孔至EBY100酵母中。線性化酵母呈現載體為C端呈現載體,其特徵在於基因插入物之5'的(PAS)
40-HA標籤-(G
4S)
3連接子及基因插入物之3'的myc標籤。酵母培養物在30℃下在50 mL具有葡萄糖及酪蛋白胺基酸之合成的成分確定培養基(SDCAA)中生長一天,且在SDCAA中繼代一次用於第二天的生長。隨後將細胞集結粒轉移至50 mL SGCAA(半乳糖)培養物中,在18℃下持續2-3天。
經由在呈現親本序列性酵母上滴定重組犬OSMR-hFc1且使用流式細胞分析儀(BD Accuri)讀取結合的部分來發現可分類的條件。使用可變體積-恆定蛋白質呈現配體方法對呈現親本scFv構築體之酵母細胞進行滴定,持續足夠的標記天數,直至預期標記分數為0.9。對於所有濃度,蛋白質與呈現配體比率為至少10:1且在各條件之間保持恆定。細胞用雞抗myc FITC抗體(ICLlab)及蛋白A-AlexaFlour 647染色,以分別使全長呈現及重組蛋白結合可視化。經由FlowJo計算之全長呈現細胞的中值647螢光用以計算配體相對於濃度之結合概況。將100 nM配體之標記濃度用於兩種庫分類之重組犬及貓OSMR。庫分類係在SH800 (Sony Biotechnology)上以純度模式用100 µm晶片來進行。簡而言之,細胞在散佈、單細胞、全長呈現且隨後結合與呈現上進行閘控。收集在結合與呈現對角線以下的細胞(亦即相對於呈現標準化之大量群體,結合減少之變異體)。所有分類收集之細胞數均大於其各自理論庫大小的67倍覆蓋率。
分類庫及參考庫經製備用於Illumina定序,且定序至非同義變異體之至少75倍過取樣的讀取深度(Kowalsky等人(2015)
PLOS ONE 10, e0118193)。使用PACT計算分類庫與參考庫的突變適應性z評分,使用參考庫讀取計數閾值為12,且自總讀取計數排除非設計的變異體(Klesmith等人(2019)
Bioinformatics 35, 2707-2712)。Z評分定義為個別突變相對於野生型log
2富集之log
2富集比率,藉由野生型同義密碼子富集之方差([ε
i-ε
wt]/σ
wt,synon)進行標準化。利用2.0之z評分閾值以將經由分類收集之減少結合的富集突變與可耐受的突變分開。因此,可耐受的突變定義為z評分小於2.0之突變。
實例21. 藉由YSD確定抗OSMR抗體上對與犬及貓OSMR結合重要的胺基酸殘基的結果
此等酵母呈現實驗之結果描述另一種確定抗體19F07之CDR結合域中之相關胺基酸殘基的方法。如實例19中所述,分析抗體親和力改變之各獨立方法均受結合及解離事件期間發生之實驗動力學的影響。抗體互補位之酵母呈現突變分析在流體相環境中進行,抗體之結合部分(ScFv)呈現於酵母細胞之表面上,允許接近目標抗原蛋白,同時將編碼突變之基因型資訊連接至細胞內。此使得所呈現之結合片段的物理特性與編碼可變重鏈及輕鏈片段之DNA之間存在聯繫。此方法不僅允許CDR之個別位置處之個別突變與目標蛋白之結合聯繫起來,且亦允許分析各CDR之個別位置處之所有胺基酸突變。此等資料允許確定容許(允許結合)、不容許(對結合產生負面影響)或在一些情況下有利於結合(功能獲得型突變)的彼等突變。
表B描述抗體Mu_19F07之CDR中的突變,根據酵母表面呈現實驗之結果,該等突變為允許的。各位置處之所有胺基酸的取代資料均來源於此實驗,然而此表僅顯示在所述位置處之彼等突變,在該等位置處允許較小的胺基酸子集代替野生型胺基酸。此等允許極少(或無)胺基酸取代之胺基酸位置表明(藉由此與目標OSMR蛋白結合之方法)此等位置與抗體CDR結構與功能結果(與OSMR結合)之聯繫更為相關。結合丙胺酸取代ELISA及Biacore實驗之結果,觀察到此等抗OSMR抗體上之必要結構要素的更完整圖像。
表B
表B. 抗體19F07上各CDR之酵母呈現突變分析結果顯示各指定位置處之容許(允許結合)取代。此處所述之結果來自發生有限數目之允許取代之胺基酸位置處的彼等突變,該等取代影響結合,而非來自發生許多允許取代之彼等位置。
實例22. 藉由YSD確定OSMR上參與抗OSMR抗體結合之胺基酸殘基的結果
SEQ ID NO: | 具有允許取代之序列定義 | 描述與(結合目標蛋白) |
25 | D 1Y 2Y 3M 4A 5其中Y 3為Y | CDR-H1 (犬OSMR) |
26 | N 1I 2N 3Y 4D 5G 6S 7S 8T 9Y 10Y 11L 12D 13S 14L 15K 16S 1 7 其中Y 10為Y、C、F、H、T或W | CDR-H2 (犬OSMR) |
27 | G 1L 2T 3W 4D 5F 6D 7V 8W 9其中W 4為W、G或C | CDR-H3 (犬OSMR) |
27 | G 1L 2T 3W 4D 5F 6D 7V 8W 9其中W 4為W、G或F | CDR-H3 (貓OSMR) |
28 | K 1A 2S 3Q 4D 5V 6D 7T 8A 9V 10A 11其中V 6為V、L、M、A、N、S、E、I、H或C;D 7為D、G、Y、N或E;A 9為A、S或G;V 10為V、L、I、A、D、T、M或C;A 11為A、S、T、G或C | CDR-L1 (犬OSMR) |
28 | K 1A 2S 3Q 4D 5V 6D 7T 8A 9V 10A 11其中V 6為V、L、M、A、G、N、T、S、P、I、F或H;D 7為D、G、Y、N、E、S、R、A、L、M、H、T、Q、I或W;A 9為A、S、V、T或G;V 10為V、L、F、I、A、S、G、T、M、Q、N或C;A 11為A、S、T、V、G、C 、N或D | CDR-L1 (貓OSMR) |
29 | L 1A 2S 3T 4R 5H 6T 7其中L 1為L、S、F、M、A、G或Q;A 2為A、S、V、G、D、P、T、L、E或C | CDR-L 2(犬OSMR) |
29 | L 1A 2S 3T 4R 5H 6T 7其中A 2為A、S、V、G、D、T、L、E、R、C、Y | CDR-L2 (貓OSMR) |
30 | Q 1Q 2Y 3S 4R 5F 6P 7L 8T 9F 10其中Q 1為Q、S、H、K、E、G、M、A、N、F或Y;Q 2為Q或H;Y 3為Y或F;S 4為S、I、N、A或T;F 6為F、L、I、V、Y、M、E、W或D;P 7為P、S、C、A、G或D;L 8為L、R、P、M、S、V、I、W、F或E;F 10為F、L、M、I、Y或W | CDR-L3 (犬OSMR) |
30 | Q 1Q 2Y 3S 4R 5F 6P 7L 8T 9F 10其中Q 1為Q、L、S、H、K、V、E、G、M、A、T、N、F、Y或C;Q 2為Q、M、H、S、Y、T、N、F、E、C或A;Y 3為Y、L、R、M、F、W、H、I或N;P 7為P、S、H、T、R、C、A、G或D | CDR-L3 (貓OSMR) |
實例20描述用於確定抗體19F07之結合互補位上對與犬及貓OSMR之相互作用重要的胺基酸殘基的方法。使用類似方法確定貓OSMR上與貓IL-31相互作用之胺基酸殘基。貓OSMR(SEQ ID NO: 112(
貓_OSMR_hIgG1_Fc))以其野生型形式呈現於酵母表面上,且使與貓IL-31(SEQ ID NO: 125)結合之條件最佳化。如所述生成貓OSMR之突變庫,且進行流動式細胞測量術分選及深度定序,以確定貓OSMR上之突變,該等突變定義與貓IL-31之相關胺基酸接觸。此等資料揭示貓IL-31與貓OSMR結合之抗原決定基為貓OSMR上位於SEQ ID NO: 112之白胺酸157(L157)至苯丙胺酸229(F229)之間的區域(資料未示出)。值得注意的是,此等資料支持本申請案之實例10中提出的同源模型。此同源模型描述犬及貓OSM與OSMR相互作用之區域。本文所述之基於細胞之分析的功能資料表明,此等選擇的抗OSMR抗體對IL-31及OSM介導之pSTAT3信號傳導均具有抑制特性,表明IL-31及OSM在OSMR蛋白上之結合位點非常接近。此等定位資料確實支持貓IL-31在貓OSMR上具有類似結合位點,如犬及貓OSM在其各自OSMR蛋白上之同源模型所提出。綜合而言,此等結果支持關於結合抗體以抑制活體內OSMR之信號傳導功能所需之犬及貓OSMR上之相關抗原決定基空間的知識。
實例23. 犬OSM在犬滑膜細胞中之促炎性作用
已證實OSMR信號傳導之拮抗作用有效抑制犬軟骨細胞及犬關節源性滑膜細胞中單核球趨化蛋白-1(MCP-1)之下游活化,且活體外顯著減少關節源性滑膜細胞中抑瘤素M(OSM)誘導之細胞增殖,表明其為減少活體內疼痛及炎症之潛在新穎治療。抗OSMR單株抗體代表新類別的新穎治療劑,其阻斷OSM信號傳導以緩解與犬及貓骨關節炎(OA)相關之疼痛及炎症。為了確定活體外效力,在基於增殖及抑制細胞之分析中評估抗OSMR抗體在關節源性滑膜細胞中之功能活性。採用CellTiter-GLO發光細胞活力分析套組評估抗OSMR mAb對犬OSM誘導之細胞增殖的影響。初級犬關節源性滑膜細胞經分離且確定為藉由活化STAT-3路徑及在較小程度上活化STAT-5及STAT-1來響應於OSM刺激。當接種於經1型膠原蛋白塗佈之盤時,犬關節源性滑膜細胞藉由在24和72小時內快速增殖來響應於OSM刺激(圖9a)。抗OSMR抗體Mu_10F07強效抑制犬關節源性滑膜細胞中OSM誘導之細胞增殖(圖9b)。犬滑膜細胞亦藉由迅速合成MCP-1(將單核球、巨噬細胞、樹突狀細胞及T細胞募集至活躍的炎症部位)對OSM刺激作出反應(圖10a)。抗OSMR抗體10F07劑量依賴性地減少犬OSM誘導之MCP-1合成。總體而言,此等活體外研究之結果證實與使用新穎抗OSMR抗體阻斷OSMR信號傳導之消炎作用有關的功能活性。
實例24. OSM之促纖維變性作用
確定犬初級犬腎纖維母細胞中MCP-1之活化,以研究OSM在與狗及貓慢性腎病有關之腎纖維化中的作用。犬OSM(SEQ ID NO: 109)在72小時時段內顯示MCP-1水準之劑量依賴性增加(圖11)。用抗OSMR抗體阻斷腎纖維母細胞中之此趨化蛋白可有利於改變纖維變性疾病之進展。
實例25. 在IL-31誘導之搔癢症的犬模型中評估抗犬OSMR mAb
IL-31攻擊程序在第-7天(建立基線搔癢評分)及第7天進行。靜脈內溶液係由儲備濃度之犬重組IL-31製備。所有狗之搔癢活動記錄在研究第-7天及第7天向最後一隻狗投予攻擊後開始。投予IL-31攻擊之個體在不知道治療分配的情況下亦可記錄搔癢活動。
使用以下分類評分系統確定每隻狗的搔癢評分(攻擊後時段)。具體而言,在連續的1分鐘間隔內,對每隻狗是否表現出搔癢行為做出「是」/「否」的判斷。在觀察期內之各離散的1分鐘時間間隔內,以下搔癢行為的表現足以引起「是」的反應。此等行為包括舔或咬(例如,爪子、腹部、尾巴、肛門區域),抓(例如,腹部或頸部),搖頭或搖身,以及摩擦身體的任何部分(例如,在籠子的地板/牆壁上)。在針對特定的1分鐘間隔提供的空間中藉由標記「1」指示「是」的反應且藉由標記「0」指示「否」的反應。是的反應的累積數量決定了搔癢評分。位於監控室每個圍欄正上方的實況轉播攝像機允許評分員自單獨的房間觀察狗。各評分員同時觀察4隻狗,每隻狗的即時影像顯示在單個監視器上。在120分鐘的時段內,動物的最大可能攻擊後搔癢評分為120。觀察期結束後,狗返回至其正常圈養位置。
每隻動物的搔癢評分計算為每個時間點(第-7天及第7天)觀察到的一分鐘時間段搔癢行為的總數。使用成對t檢驗來檢驗第-7天及第7天搔癢評分之間的平均值差異。小鼠:犬嵌合抗OSMR抗體19F07(T01)及10F07(T02)以12.0 mg/kg之單次SC注射投予,且給藥7天後觀察搔癢反應。圖12顯示研究第-7天及研究第7天總共2小時觀察期的攻擊後評分。
此等結果表明,與研究第-7天記錄的搔癢評分相比,單次皮下12 mg/kg劑量之嵌合19F07及10F07在IL-31誘導之搔癢的犬模型中在研究第7天顯示出顯著較低的總搔癢評分。
[圖1]為顯示在a)犬DH82細胞及b)貓Fcwf4細胞中處理犬及貓OSM產生之pSTAT3劑量-反應的圖式。
[圖2]為顯示用於選擇本申請案中所述之抗OSMR抗體之步驟的流程圖。
[圖3]為本申請案中所述之抗OSMR抗體之可變重鏈及可變輕鏈序列的比對。
[圖4]為顯示對本申請案中所述之5種抗OSMR抗體生成之同源模型之結構進行成對比較後CDR之RMSD值的矩陣。
[圖5]A)為顯示犬OSM之二聚體與犬OSMR蛋白之二聚體結合的同源模型。黑色圓圈突出顯示OSM及OSMR之結合界面。B)顯示結合界面之放大區域,突出顯示已知在人類OSM:OSMR相互作用中重要的胺基酸。
[圖6]基於OSM與OSMR結合之邏輯位置以及人類、犬及貓OSMR蛋白之間的序列多樣性顯示本文所述之抗體的抗原決定基結合位點。
[圖7]顯示使用RNAscope ISH探針對貓科動物皮膚中OSMR mRNA之定量。對照組織來自正常貓科動物皮膚生物檢體,且患病組織來自患有過敏性皮膚病之貓科動物的皮膚生物檢體。
[圖8]顯示來自對照(非過敏性)與患病(過敏性)皮膚組織之OSMR蛋白之IHC染色的單個代表性影像。
[圖9]A)顯示在24小時時間段內,響應於增加劑量之犬OSM蛋白之犬滑膜細胞的增殖。B)顯示與對照抗體相比,抗OSMR小鼠抗體10F07(本文所述)對OSM誘導之犬滑膜細胞增殖的抑制作用(亦為24小時培育)。
[圖10]A)顯示在24小時時間段內,響應於增加劑量之犬OSM蛋白對犬滑膜細胞中犬MCP-1蛋白的誘導。B)顯示與對照抗體相比,抗OSMR小鼠抗體10F07(本文所述)對OSM誘導之犬滑膜細胞MCP-1產生的抑制作用(亦為24小時培育)。
[圖10]A)顯示在24小時時間段內,響應於增加劑量之犬OSM蛋白對犬滑膜細胞中犬MCP-1蛋白的誘導。B)顯示與對照抗體相比,抗OSMR小鼠抗體10F07(本文所述)對OSM誘導之犬滑膜細胞MCP-1產生的抑制作用(亦為24小時培育)。
[圖11]顯示在72小時時間段內,響應於增加劑量之犬OSM蛋白對初級犬腎纖維母細胞中犬MCP-1蛋白的誘導。
[圖12]A)顯示在IL-31誘導之搔癢症的犬模型中比較抗OSMR小鼠:犬嵌合體19F07(T01)及10F07(T02)之給藥前及給藥後搔癢評分,兩種嵌合體均在第零天以12.0 mg/kg之劑量皮下給藥至每組六隻動物。B)顯示處理組之攻擊後評分及使用平均值及90%信賴界限之配對t檢驗的摘要統計。
【 序列表】 <![CDATA[<110> 美商碩騰服務公司(Zoetis Services LLC)]]> <![CDATA[<120> 犬及貓抑瘤素M受體β之抗體及其用途]]> <![CDATA[<130> ZP000355A]]> <![CDATA[<150> 63/093607]]> <![CDATA[<151> 2020-10-19]]> <![CDATA[<160> 136 ]]> <![CDATA[<170> PatentIn版本3.5]]> <![CDATA[<210> 1]]> <![CDATA[<211> 5]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 1]]> Asp Tyr Gly Met His 1 5 <![CDATA[<210> 2]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 2]]> Tyr Ile Ser Ser Gly Ser Arg Ala Val Phe Phe Ala Asp Thr Val Lys 1 5 10 15 Gly <![CDATA[<210> 3]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 3]]> Asp Arg Tyr Asp Gly Arg Gly Phe Ala Tyr 1 5 10 <![CDATA[<210> 4]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 4]]> Arg Ala Ser Gln Ser Ile Ser Asn Asn Leu His 1 5 10 <![CDATA[<210> 5]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 5]]> Tyr Ala Ser Gln Ser Ile Ser 1 5 <![CDATA[<210> 6]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 6]]> Gln Gln Ser Asn Ser Trp Pro Leu Thr 1 5 <![CDATA[<210> 7]]> <![CDATA[<211> 5]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 7]]> Ser Tyr Ala Met Ser 1 5 <![CDATA[<210> 8]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 8]]> Tyr Ile Ser Ser Gly Gly Asp Tyr Ile Tyr Tyr Ala Asp Thr Val Lys 1 5 10 15 Gly <![CDATA[<210> 9]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 9]]> Asp Pro Ile Thr Gly Thr Phe Ala Tyr 1 5 <![CDATA[<210> 10]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 10]]> Arg Ala Ser Gln Asp Ile Asn Asn Tyr Leu Asn 1 5 10 <![CDATA[<210> 11]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 11]]> Tyr Thr Ser Thr Leu His Ser 1 5 <![CDATA[<210> 12]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 12]]> Gln Gln Gly Asn Thr Leu Pro Trp Thr 1 5 <![CDATA[<210> 13]]> <![CDATA[<211> 5]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 13]]> Ser Tyr Ala Met Ser 1 5 <![CDATA[<210> 14]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 14]]> Tyr Ile Ser Ser Gly Gly Asp Tyr Phe Tyr Tyr Ala Asp Thr Val Lys 1 5 10 15 Gly <![CDATA[<210> 15]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 15]]> Asp Pro Ile Thr Gly Thr Phe Ala Tyr 1 5 <![CDATA[<210> 16]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 16]]> Arg Ala Ser Gln Asp Ile Thr Asn Tyr Leu Asn 1 5 10 <![CDATA[<210> 17]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 17]]> Tyr Thr Ser Thr Leu His Ser 1 5 <![CDATA[<210> 18]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 18]]> Gln Gln Gly His Met Leu Pro Trp Thr 1 5 <![CDATA[<210> 19]]> <![CDATA[<211> 5]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 19]]> Asn Tyr Trp Met Asn 1 5 <![CDATA[<210> 20]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 20]]> Gln Ile Tyr Pro Gly His Val Asn Thr Asn Tyr Asn Gly Asn Phe Lys 1 5 10 15 Asp <![CDATA[<210> 21]]> <![CDATA[<211> 12]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 21]]> Ser Ala Asp Asn Ser Gly Phe Val Leu Phe Ala Tyr 1 5 10 <![CDATA[<210> 22]]> <![CDATA[<211> 15]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 22]]> Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Leu His 1 5 10 15 <![CDATA[<210> 23]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 23]]> Leu Ala Ser Asn Leu Glu Ser 1 5 <![CDATA[<210> 24]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 24]]> Gln His Ser Arg Glu Leu Pro Leu Thr 1 5 <![CDATA[<210> 25]]> <![CDATA[<211> 5]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 25]]> Asp Tyr Tyr Met Ala 1 5 <![CDATA[<210> 26]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 26]]> Asn Ile Asn Tyr Asp Gly Ser Ser Thr Tyr Tyr Leu Asp Ser Leu Lys 1 5 10 15 Ser <![CDATA[<210> 27]]> <![CDATA[<211> 8]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 27]]> Gly Leu Thr Trp Asp Phe Asp Val 1 5 <![CDATA[<210> 28]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 28]]> Lys Ala Ser Gln Asp Val Asp Thr Ala Val Ala 1 5 10 <![CDATA[<210> 29]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 29]]> Leu Ala Ser Thr Arg His Thr 1 5 <![CDATA[<210> 30]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 30]]> Gln Gln Tyr Ser Arg Phe Pro Leu Thr 1 5 <![CDATA[<210> 31]]> <![CDATA[<211> 119]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 31]]> Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Thr Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Gly Met His Trp Leu Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Ser Arg Ala Val Phe Phe Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe 65 70 75 80 Leu Gln Met Thr Ser Leu Arg Ser Asp Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Tyr Asp Gly Arg Gly Phe Ala Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ala 115 <![CDATA[<210> 32]]> <![CDATA[<211> 357]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 32]]> gaggtgcagc tggtggagtc tgggggaggc ttagtgaagc ctggagggtc cctgacactc 60 tcctgtgcag cctctggatt cactttcagt gactatggaa tgcactggct tcgtcaggct 120 ccagagaagg ggctggagtg ggtcgcatac atcagtagtg gcagtcgtgc cgtcttcttt 180 gcagacacgg tgaagggccg attcaccatc tccagagaca atgccaagaa caccctgttc 240 ctgcaaatga ccagtctgag gtctgacgac acggccatgt attactgtgc aagggacagg 300 tacgacggac gaggttttgc ttactggggc caagggactc tggtcactgt ctctgca 357 <![CDATA[<210> 33]]> <![CDATA[<211> 107]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 33]]> Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly 1 5 10 15 Asp Ser Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asn Asn 20 25 30 Leu His Trp Tyr Gln Gln Thr Ser His Glu Ser Pro Arg Leu Leu Ile 35 40 45 Thr Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Thr 65 70 75 80 Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Ser Trp Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 <![CDATA[<210> 34]]> <![CDATA[<211> 321]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 34]]> gatattgtgc taactcagtc tccagccacc ctgtctgtga ctccaggaga tagcgtcagt 60 ctttcctgca gggccagcca aagtattagc aacaacctac actggtatca acaaacatca 120 catgagtctc caaggcttct catcacgtat gcttcccagt ccatctctgg gatcccctcc 180 aggttcagtg gcagtggatc agggacagat ttcactctca gtatcaacag tgtggagact 240 gaagattttg gaatgtattt ctgtcaacag agtaacagct ggcctctcac gttcggtgct 300 gggaccaagc tggagctgaa a 321 <![CDATA[<210> 35]]> <![CDATA[<211> 118]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 35]]> Asp Val Lys Leu Val Glu Ser Gly Glu Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Gly Asp Tyr Ile Tyr Tyr Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Thr Arg Asp Pro Ile Thr Gly Thr Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <![CDATA[<210> 36]]> <![CDATA[<211> 354]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 36]]> gacgtgaagc tggtggagtc tggggaaggc ttagtgaagc ctggagggtc cctgaaactc 60 tcctgtgcag cctctggatt cactttcagt agctatgcca tgtcttgggt tcgccagact 120 ccagagaaga ggctggagtg ggtcgcatac attagtagtg gtggtgatta catctactat 180 gcagacactg tgaagggccg attcaccatc tccagagaca atgccaggaa caccctgtac 240 ctgcaaatga gcagtctgaa gtctgaggac acagccatgt attactgtac aagagatccc 300 ataactggga cgtttgctta ctggggccaa gggactctgg tcactgtctc tgca 354 <![CDATA[<210> 37]]> <![CDATA[<211> 107]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 37]]> Asp Leu Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asn Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <![CDATA[<210> 38]]> <![CDATA[<211> 321]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 38]]> gatctccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60 atcagttgca gggcaagtca ggacattaac aattatttaa actggtatca gcagaaacca 120 gatggaactg ttaaactcct gatctactac acatcaacat tacactcagg agtcccatca 180 aggttcagtg gcagtgggtc tggaacagat tattctctca ccattagcaa cctggagcaa 240 gaagatattg ccacttactt ttgccaacag ggtaatacgc ttccgtggac gttcggtgga 300 ggcaccaagc tggaaatcaa a 321 <![CDATA[<210> 39]]> <![CDATA[<211> 118]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 39]]> Asp Val Lys Leu Val Glu Ser Gly Glu Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 35 40 45 Thr Tyr Ile Ser Ser Gly Gly Asp Tyr Phe Tyr Tyr Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Thr Arg Asp Pro Ile Thr Gly Thr Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ala 115 <![CDATA[<210> 40]]> <![CDATA[<211> 354]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 40]]> gacgtgaagc tggtggagtc tggggaaggc ttagtgaagc ctggagggtc cctgaaactc 60 tcctgtgcag cctctggatt cactttcagt agctatgcca tgtcttgggt tcgccagact 120 ccagagaaga ggctggagtg ggtcacatat attagtagtg gtggtgatta cttctactat 180 gcagacactg tgaagggccg attcaccatc tccagagaca atgccaggaa caccctgtac 240 ctgcaaatga gcagtctgaa gtctgaggac acagccatgt attactgtac aagagatccc 300 ataactggga cgtttgctta ctggggccaa gggactctgg tcactgtctc tgca 354 <![CDATA[<210> 41]]> <![CDATA[<211> 107]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 41]]> Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Thr Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly His Met Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <![CDATA[<210> 42]]> <![CDATA[<211> 321]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 42]]> gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60 atcagttgca gggcaagtca ggacattacc aattatttaa actggtatca gcagaaacca 120 gatggaactg ttaaactcct gatctactac acatcaacat tacactcagg agtcccgtca 180 aggttcagtg gcagtgggtc tggaacagat ttttctctca ccattagcaa cctggagcaa 240 gaagatattg ccacttactt ttgccaacag ggtcatatgc ttccgtggac gttcggtgga 300 ggcaccaagc tggaaatcaa a 321 <![CDATA[<210> 43]]> <![CDATA[<211> 120]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 43]]> Glu Val Gln Leu Gln Glu Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Met Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Gln Ile Tyr Pro Gly His Val Asn Thr Asn Tyr Asn Gly Asn Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Ser Ala Asp Asn Ser Gly Phe Val Leu Phe Ala Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser 115 120 <![CDATA[<210> 44]]> <![CDATA[<211> 364]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 44]]> gaggtgcagc tgcaggagtc tggggctgag ctggtgaagc ctggggcctc agtgaagatt 60 tcctgcaaag cttctggcta cgcattcagt aactactgga tgaactggat gaagcagagg 120 cctggaaagg gtcttgagtg gattggacag atttatcctg gacatgttaa tactaactac 180 aacggaaatt tcaaggacaa ggccacactg actgcagaca aatcctccag cacagcctac 240 atgcagctca gcagcctgac ctctgaggac tctgcggtct atttctgtgc aagatcggca 300 gacaactcag gcttcgtcct ttttgcttac tggggccaag ggactctggt caccgtctct 360 ccag 364 <![CDATA[<210> 45]]> <![CDATA[<211> 111]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 45]]> Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 20 25 30 Gly Tyr Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Phe Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg 85 90 95 Glu Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 110 <![CDATA[<210> 46]]> <![CDATA[<211> 334]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 46]]> gacattgtgc tgacacagtc tcctgcttcc ttagctgtat ctctggggca gagggccacc 60 atctcatgca gggccagcaa aagtgtcagt acatctggct atagttattt gcactggtac 120 caacagaaac caggacagcc acccaaactc ctcatctttc ttgcatccaa cctagaatct 180 ggggtccctg ccaggttcag tggcagtggg tctgggacag acttcaccct caacatccat 240 cctgtggagg aggaggatgc tgcaacctat tactgtcagc acagtaggga gcttcctctc 300 acgttcggtg ctgggaccaa gctggagctg aaac 334 <![CDATA[<210> 47]]> <![CDATA[<211> 117]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 47]]> Glu Val Lys Leu Val Glu Ser Glu Gly Gly Leu Val Gln Pro Gly Ser 1 5 10 15 Ser Met Lys Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Ala Trp Val Arg Gln Val Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn Ile Asn Tyr Asp Gly Ser Ser Thr Tyr Tyr Leu Asp Ser Leu 50 55 60 Lys Ser Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ile Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Arg Gly Leu Thr Trp Asp Phe Asp Val Trp Gly Thr Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <![CDATA[<210> 48]]> <![CDATA[<211> 351]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 48]]> gaagtgaagc tggtggagtc tgagggaggc ttagtgcagc ctggaagttc catgaaactc 60 tcctgcacag cctctggatt cactttcagt gactattaca tggcttgggt ccgccaggtt 120 ccagaaaagg gtctagaatg ggttgcaaac attaattatg atggtagtag cacctactat 180 ctggactcct tgaagagccg tttcatcatc tcgagagaca atgcaaagaa cattctatac 240 ctgcaaatga gcagtctgaa gtctgaggac acagccacgt attactgtgc aagagggctt 300 acgtgggact tcgatgtctg gggcacaggg accacggtca ccgtctcctc a 351 <![CDATA[<210> 49]]> <![CDATA[<211> 107]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 49]]> Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Pro Ser Val Gly 1 5 10 15 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Asp Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Leu Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 65 70 75 80 Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Arg Phe Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 <![CDATA[<210> 50]]> <![CDATA[<211> 321]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 50]]> gacattgtga tgacccagtc tcacaaattc atgtccccat cagtaggaga cagggtcagc 60 atcacctgca aggccagtca ggatgtggat actgctgtag cctggtatca acagaaacca 120 gggcaatctc ctaaactact gatttacttg gcatccaccc ggcacactgg agtccctgat 180 cgcttcacag gcagtggatc tgggacagat ttcactctca ccattagcaa tgtgcagtct 240 gaagacttgg cagattattt ctgtcagcag tatagcaggt ttccgctcac gttcggtgct 300 gggaccaagc tggagctgaa a 321 <![CDATA[<210> 51]]> <![CDATA[<211> 119]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 51]]> Asp Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Thr Cys Val Ala Ser Gly Phe Thr Tyr Ser Asp Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Ser Arg Ala Val Phe Phe Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Val Arg Asp Arg Tyr Asp Gly Arg Gly Phe Ala Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <![CDATA[<210> 52]]> <![CDATA[<211> 357]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 52]]> gacgttcagc ttgtcgaatc tggcggagac ctggtaaagc cgggaggctc actccgcctt 60 acttgcgtag caagtggctt tacctacagc gattatggca tgcactgggt gaggcaggcc 120 cctggaaagg ggctccagtg ggtagcatac atatccagcg ggtcacgagc agttttcttc 180 gcggacacgg tcaaggggcg cttcacgatt agccgggaca atgcaaagaa cacactgtat 240 ttgcaaatga actctctcaa gactgaggac acagctacct attactgtgt tcgagaccgc 300 tacgacggca ggggattcgc ctattggggg caaggaactc tcgtaacggt ctcgagc 357 <![CDATA[<210> 53]]> <![CDATA[<211> 119]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 53]]> Asp Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Thr Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Ser Arg Ala Val Phe Phe Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Gly Leu Arg Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Tyr Asp Gly Arg Gly Phe Ala Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <![CDATA[<210> 54]]> <![CDATA[<211> 357]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 54]]> gatgtacagc ttgtggaaag tggcggtgat ttggtcaaac ctgggggctc cctcaggctt 60 acgtgcgttg catcaggttt tacgttctca gattacggta tgcactgggt tagacaagcg 120 cctgggaaag gcttgcagtg ggttgcttac atttcaagtg gctctcgggc tgtattcttc 180 gcggacactg tcaaggggag gtttacgatc tccagggata atgctaagaa tacactttac 240 cttcagatga acggcctgag gacggaagat acagcgacgt attattgcgc cagggataga 300 tatgacggga gaggtttcgc gtactgggga caaggtacgc ttgtcacggt ctcgagc 357 <![CDATA[<210> 55]]> <![CDATA[<211> 102]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 55]]> Glu Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Pro Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Asn 20 25 30 Leu His Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Ala Ser Gln Ser Ile Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Ser Trp Pro Leu 85 90 95 Thr Phe Gly Gln Gly Thr 100 <![CDATA[<210> 56]]> <![CDATA[<211> 306]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 56]]> gagatccaaa tgacacagtc cccttcttcc ttgagtgctt cacctggtga tagggtaacg 60 attacatgtc gcgcgtcaca gagcatatca aacaatcttc actggtatca gcagaaacca 120 ggaaaagttc ccaaactgtt gatctattac gcgagccagt ccattagcgg ggttccatca 180 cgcttctctg gtagtgggag cggtactgat tttactttga ccatttcctc attggaaccg 240 gaggacgctg caacgtacta ctgccagcaa agcaactcat ggcccctgac atttggacag 300 ggtacc 306 <![CDATA[<210> 57]]> <![CDATA[<211> 102]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 57]]> Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 1 5 10 15 Glu Ser Ala Ser Ile Ser Cys Arg Ala Ser Gln Ser Ile Ser Asn Asn 20 25 30 Leu His Trp Tyr Leu Gln Lys Ser Gly Gln Ser Pro Arg Arg Leu Ile 35 40 45 Tyr Tyr Ala Ser Gln Ser Ile Ser Gly Val Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile Ser Arg Val Glu Ala 65 70 75 80 Asp Asp Val Gly Val Tyr Tyr Cys Gln Gln Ser Asn Ser Trp Pro Leu 85 90 95 Thr Phe Gly Gln Gly Thr 100 <![CDATA[<210> 58]]> <![CDATA[<211> 306]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 58]]> gatattgtga tgactcagac tccactttcc cttagtgtta ctcctggtga aagtgctagt 60 atctcatgtc gggcaagcca atcaatatca aacaatctgc actggtactt gcaaaagtct 120 gggcagtctc ccagaagact catctattac gcctcacaaa gtattagtgg cgttcctgat 180 cggttctcag gcagtggctc aggaaccgat ttcaccttgc gcatcagtag agtcgaggct 240 gatgacgttg gggtttatta ctgccaacaa tctaactctt ggccgttgac gttcggccaa 300 ggtacc 306 <![CDATA[<210> 59]]> <![CDATA[<211> 118]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 59]]> Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Gly Asp Tyr Ile Tyr Tyr Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Val Arg Asp Pro Ile Thr Gly Thr Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <![CDATA[<210> 60]]> <![CDATA[<211> 354]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 60]]> gaagtccagt tggtagaatc cgggggtgac cttgtcaaac cgggagggtc acttcggctc 60 agttgtgttg cttctgggtt tacattctcc tcctacgcta tgagttgggt tcgccaggca 120 ccaggcaaag gactccaatg ggttgcgtat attagcagtg gcggagatta tatctactac 180 gccgatactg tcaaagggcg atttacgata agccgagaca atgcaaaaaa caccctgtat 240 cttcagatga actcactgag ggctgaagac acggctatgt actactgtgt cagagatcca 300 ataaccggga cctttgcata ttggggacag gggacactgg tcactgtctc gagc 354 <![CDATA[<210> 61]]> <![CDATA[<211> 118]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 61]]> Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Ala Gly 1 5 10 15 Ser Leu Thr Leu Ser Cys Leu Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Gly Leu Gln Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Gly Asp Tyr Ile Tyr Tyr Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Ile Thr Gly Thr Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <![CDATA[<210> 62]]> <![CDATA[<211> 354]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 62]]> gaagtacaac ttgtggagag cgggggcgac ttggttaagc ctgcgggatc tttgaccttg 60 tcctgtctgg cttcaggctt tacctttagt agttacgcca tgagttgggt ccggcaaacc 120 ccggaaaagg ggctgcagtg ggtagcttat ataagttccg ggggggatta tatctactat 180 gctgacaccg tcaagggacg cttcacaata agccgagata atgcaaaaaa tacactgtac 240 ctccagatga atagcctgcg agacgaggac actgccgtct attattgtgc tcgagaccca 300 ataacgggaa cttttgcgta ttggggtcaa ggcacactgg ttactgtctc gagc 354 <![CDATA[<210> 63]]> <![CDATA[<211> 102]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 63]]> Glu Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ser Leu Ser Gln Glu 1 5 10 15 Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Asn Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Ser Phe Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr 100 <![CDATA[<210> 64]]> <![CDATA[<211> 306]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 64]]> gagattgtta tgactcagag cccggctagc ctgtcactct cacaggagga aaaagttacc 60 atcacctgcc gggcatctca ggacataaat aactatttga actggtatca gcaaaagccc 120 ggacaagctc cgaagctgct catttactat accagcacac tgcacagcgg agtgccaagc 180 agatttagcg ggagcggaag tggaaccgac ttcagcttca ctatatcctc actcgagcct 240 gaggatgtgg ccgtttatta ctgtcaacaa gggaatacgc ttccctggac ttttgggcaa 300 ggtacc 306 <![CDATA[<210> 65]]> <![CDATA[<211> 101]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 65]]> Asp Ile Val Leu Thr Gln Pro Thr Ser Val Ser Gly Ser Leu Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Asn Asn Tyr Leu 20 25 30 Asn Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Leu Val Tyr 35 40 45 Tyr Thr Ser Thr Leu His Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Ser Ser Ala Thr Leu Thr Ile Thr Gly Leu Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Gln Gly Asn Thr Leu Pro Trp Thr 85 90 95 Phe Gly Gln Gly Thr 100 <![CDATA[<210> 66]]> <![CDATA[<211> 303]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 66]]> gacattgtat tgactcagcc cacgtccgtc tctggctctt tggggcagcg ggtgaccatc 60 tcatgccgag cgtcacaaga cataaacaat tatttgaatt ggtatcagca acttccaggc 120 aaagcgccaa aacttctcgt ctattacacg tctacacttc atagcggggt ccccgataga 180 ttctccgggt caaatagtgg gagttcagct actttgacaa taacaggtct tcaggccgag 240 gacgaggcag actattactg tcagcaagga aatactctgc cttggacttt cggtcaaggt 300 acc 303 <![CDATA[<210> 67]]> <![CDATA[<211> 118]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 67]]> Asp Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Thr Cys Val Ala Ser Gly Phe Thr Tyr Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Gly Asp Tyr Ile Tyr Tyr Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Val Arg Asp Pro Ile Thr Gly Thr Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <![CDATA[<210> 68]]> <![CDATA[<211> 354]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 68]]> gatgttcaac ttgtcgaaag tggcggagac ctggtcaagc cagggggttc actccgactg 60 acctgcgtag cctcaggatt tacttattcc agctacgcta tgtcctgggt gaggcaagca 120 ccggggaaag ggttgcagtg ggttgcatac atttcttctg gtggagacta tatttactac 180 gcagacactg tgaaggggcg attcacaatt tcacgggata acgccaaaaa taccttgtac 240 cttcagatga actcattgaa gactgaagac acagctacct attactgtgt acgagatccg 300 attacgggaa catttgccta ttggggtcaa gggactctgg taaccgtctc gagc 354 <![CDATA[<210> 69]]> <![CDATA[<211> 118]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 69]]> Asp Val Gln Leu Val Glu Ser Gly Gly Asn Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Thr Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Gly Asp Tyr Ile Tyr Tyr Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Ile Thr Gly Thr Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <![CDATA[<210> 70]]> <![CDATA[<211> 354]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 70]]> gacgttcagc ttgtggaaag tggagggaac ctcgtgaagc ccggtgggtc attgaggttg 60 acgtgcgtcg cgtcaggttt cacttttagc tcctatgcta tgtcatgggt tcggcaggca 120 ccagggaaag gacttcagtg ggttgcgtat ataagcagcg ggggcgacta catctactac 180 gcagacactg tcaaggggcg ctttacaatc agcaaggata atgcgaagaa caccctttat 240 cttcaaatga acagcctgaa aactgaggac actgctacat attattgcgc cagggacccc 300 atcacgggca cttttgcgta ttgggggcaa ggtacgctgg ttactgtctc gagc 354 <![CDATA[<210> 71]]> <![CDATA[<211> 102]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 71]]> Glu Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Pro Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Asn Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr 100 <![CDATA[<210> 72]]> <![CDATA[<211> 306]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 72]]> gaaattcaga tgacgcaatc accatcctcc ttgagtgcgt cccctggaga tagagtgact 60 attacgtgtc gcgcctccca agacattaat aattacctca attggtatca gcagaagccc 120 ggaaaagtac cgaagctcct gatttattat acgagtaccc tgcactcagg ggtcccatct 180 cgattcagcg ggtcaggctc tggcactgat ttcacattga ccatcagtag tcttgaacca 240 gaggacgcag caacttatta ctgccaacaa ggcaatactc ttccctggac attcggccaa 300 ggtacc 306 <![CDATA[<210> 73]]> <![CDATA[<211> 102]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 73]]> Asp Ile Thr Met Thr Gln Ser Pro Gly Ser Leu Ala Gly Ser Pro Gly 1 5 10 15 Gln Gln Val Thr Met Asn Cys Arg Ala Ser Gln Asp Ile Asn Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln His Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Ala 65 70 75 80 Glu Asp Val Ala Ser Tyr Tyr Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr 100 <![CDATA[<210> 74]]> <![CDATA[<211> 306]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 74]]> gatataacaa tgactcaatc acccggctcc ttggctgggt cccctggcca gcaagtaact 60 atgaattgcc gcgctagcca ggacattaac aactacttga actggtatca gcaaaaacca 120 ggccagcatc ccaagctgct gatttattac acatctaccc ttcacagtgg ggttcccgat 180 aggttctctg gtagcggatc aggcacggat tttacactta ccatttccaa tctccaggct 240 gaagatgtcg ccagttatta ctgtcagcag ggcaatacgc tgccctggac gtttggtcag 300 ggtacc 306 <![CDATA[<210> 75]]> <![CDATA[<211> 118]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 75]]> Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Gly Asp Tyr Phe Tyr Tyr Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Val Arg Asp Pro Ile Thr Gly Thr Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <![CDATA[<210> 76]]> <![CDATA[<211> 354]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 76]]> gaagtacaac tcgtagagtc tggcggtgac ctggtcaagc caggcggtag tctgagactc 60 tcatgtgtag cttctggttt caccttttct agctatgcaa tgtcttgggt ccgccaagca 120 cccggaaagg gtcttcaatg ggtcgcttac atttcatctg gcggggatta cttttattat 180 gctgacacag tcaagggacg cttcacgatc tcaagagaca acgctaagaa tacgctctat 240 ctccaaatga acagcctcag agctgaagat acggcaatgt attactgtgt gcgcgatcca 300 ataaccggaa cctttgctta ctgggggcaa ggcaccctcg tgactgtctc gagc 354 <![CDATA[<210> 77]]> <![CDATA[<211> 102]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 77]]> Glu Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ser Leu Ser Gln Glu 1 5 10 15 Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Thr Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Ser Phe Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Gly His Met Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr 100 <![CDATA[<210> 78]]> <![CDATA[<211> 306]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 78]]> gagattgtaa tgacgcagtc acccgcatcc ttgtctttga gccaagagga aaaagttact 60 atcacatgca gagcgagcca agacatcacg aattatctga actggtatca gcagaagcct 120 ggtcaggcac cgaaattgct tatttattat accagcaccc ttcactcagg agtaccttca 180 agattcagcg gttccggctc tggaacagac ttttcattta ccattagttc actcgagccc 240 gaggacgtag ccgtatatta ctgccagcag ggacatatgt tgccctggac atttgggcaa 300 ggtacc 306 <![CDATA[<210> 79]]> <![CDATA[<211> 118]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 79]]> Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Ala Gly 1 5 10 15 Ser Leu Thr Leu Ser Cys Leu Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Gly Leu Gln Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Gly Asp Tyr Phe Tyr Tyr Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Pro Ile Thr Gly Thr Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <![CDATA[<210> 80]]> <![CDATA[<211> 354]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 80]]> gaagtgcaac ttgtggaatc tgggggtgat ctcgtcaagc cagcagggtc attgaccttg 60 tcttgcctgg caagcggatt cactttctct tcctatgcaa tgtcctgggt gcggcagaca 120 ccggagaagg ggcttcagtg ggttgcttat attagtagtg gtggcgacta cttctattat 180 gccgatactg tgaaggggcg cttcacaatt tccagagaca atgcgaagaa cacattgtat 240 ctgcaaatga acagcttgcg cgatgaagat accgcggttt attactgtgc gcgcgaccct 300 ataacgggca cctttgccta ttggggccaa ggaacgcttg tgactgtctc gagc 354 <![CDATA[<210> 81]]> <![CDATA[<211> 101]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 81]]> Asp Ile Val Leu Thr Gln Pro Thr Ser Val Ser Gly Ser Leu Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Thr Asn Tyr Leu 20 25 30 Asn Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Leu Val Tyr 35 40 45 Tyr Thr Ser Thr Leu His Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Ser Ser Ala Thr Leu Thr Ile Thr Gly Leu Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Gln Gly His Met Leu Pro Trp Thr 85 90 95 Phe Gly Gln Gly Thr 100 <![CDATA[<210> 82]]> <![CDATA[<211> 303]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 82]]> gacatcgtcc tcactcaacc cacctcagtg tctgggtctc ttggtcaacg agttaccatt 60 tcatgcaggg catctcagga cattacgaat tatcttaact ggtatcaaca actcccaggt 120 aaagcgccaa aattgctcgt atactacacg tcaacattgc attctggtgt accagatagg 180 ttctctggaa gcaactcagg aagctccgcc accctcacga tcacgggtct ccaggcggag 240 gacgaggcag attactactg ccagcagggg catatgttgc cttggacctt tgggcaaggt 300 acc 303 <![CDATA[<210> 83]]> <![CDATA[<211> 118]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 83]]> Asp Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Thr Cys Val Ala Ser Gly Phe Thr Tyr Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Gly Asp Tyr Phe Tyr Tyr Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Val Arg Asp Pro Ile Thr Gly Thr Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <![CDATA[<210> 84]]> <![CDATA[<211> 354]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 84]]> gacgtgcagc ttgtagagtc cggtggcgac ctcgttaaac ctggcgggag tctgaggctt 60 acctgcgtag ccagcggatt cacatatagt tcatacgcga tgtcttgggt caggcaagct 120 ccaggaaaag gactccaatg ggtcgcttac atttcttctg gtggggacta cttttattac 180 gcagatacag tcaagggacg ctttacgatc tcccgcgata acgccaaaaa tactctttac 240 ctccaaatga actctctgaa aaccgaagac actgctacat actattgtgt gagggacccg 300 atcacaggga cctttgcata ttgggggcaa ggaactctgg ttacggtctc gagc 354 <![CDATA[<210> 85]]> <![CDATA[<211> 102]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 85]]> Glu Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Pro Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Thr Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Gly His Met Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr 100 <![CDATA[<210> 86]]> <![CDATA[<211> 306]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 86]]> gaaatacaaa tgacacagtc accatctagt ttgtcagcct ccccaggcga ccgggtaaca 60 atcacctgca gagccagcca ggacataacc aactacctga attggtatca gcaaaaaccc 120 ggcaaagtgc caaaactcct catctactac acttccacac tgcattctgg tgttccgtcc 180 cgattttctg gatcaggatc aggaaccgac tttacactta cgatttcaag tttggagccg 240 gaagacgcag caacttatta ctgtcaacaa gggcacatgc tcccctggac ctttggtcaa 300 ggtacc 306 <![CDATA[<210> 87]]> <![CDATA[<211> 118]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 87]]> Asp Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Thr Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Gly Asp Tyr Phe Tyr Tyr Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Thr Gly Asp Pro Ile Thr Gly Thr Phe Ala Tyr Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <![CDATA[<210> 88]]> <![CDATA[<211> 354]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 88]]> gacgtacagc ttgtagagag cgggggggat cttgttaagc cgggtggttc tctccgactt 60 acttgtgtag catctggctt cactttcagc tcttatgcga tgtcatgggt ccggcaagct 120 ccgggtaagg gtctccagtg ggtggcctac ataagctcag gaggtgacta tttctactat 180 gctgacaccg ttaagggacg cttcacaatc tctagagatg atgcgaaaaa tacgctctac 240 ctgcaaatga gcagcctcaa aacagaagac acggccacct attattgtac tggagatccc 300 ataacaggta cgtttgcgta ctgggggcag gggaccctgg tcactgtctc gagc 354 <![CDATA[<210> 89]]> <![CDATA[<211> 102]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 89]]> Asp Ile Thr Met Thr Gln Ser Pro Gly Ser Leu Ala Gly Ser Pro Gly 1 5 10 15 Gln Gln Val Thr Met Asn Cys Arg Ala Ser Gln Asp Ile Thr Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gln His Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Ala 65 70 75 80 Glu Asp Val Ala Ser Tyr Tyr Cys Gln Gln Gly His Met Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr 100 <![CDATA[<210> 90]]> <![CDATA[<211> 306]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 90]]> gacataacta tgactcagtc ccctggttcc ttggccgggt ctccggggca gcaggtgaca 60 atgaattgca gagcgtccca ggacattact aattatctca actggtatca gcagaagcct 120 ggtcagcacc caaagctgct gatttattac acgtcaacgc ttcactcagg ggttccagac 180 aggttctcag gctctggctc aggaactgat tttaccctga cgatatctaa tctccaagcg 240 gaggatgtgg ctagttacta ttgccaacaa gggcacatgc ttccctggac atttggccag 300 ggtacc 306 <![CDATA[<210> 91]]> <![CDATA[<211> 117]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 91]]> Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45 Ala Asn Ile Asn Tyr Asp Gly Ser Ser Thr Tyr Tyr Leu Asp Ser Leu 50 55 60 Lys Ser Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Val Arg Gly Leu Thr Trp Asp Phe Asp Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <![CDATA[<210> 92]]> <![CDATA[<211> 351]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 92]]> gaggtacagc ttgtggaatc tgggggggat ttggtaaagc ctggcggttc cctgcgcctc 60 tcctgtgtgg cctcaggttt caccttttca gactactaca tggcgtgggt gcgccaggca 120 cccggaaaag gtctccaatg ggttgcaaat atcaattatg acggttcttc aacatactac 180 ttggactcac ttaagtctcg gtttactatt agtcgggaca atgctaaaaa taccttgtat 240 ttgcagatga actcactccg ggcggaggac acggcgatgt attactgtgt tcgcggtctt 300 acatgggact tcgatgtttg ggggcagggt acactcgtta cagtctcgag c 351 <![CDATA[<210> 93]]> <![CDATA[<211> 102]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 93]]> Glu Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ser Leu Ser Gln Glu 1 5 10 15 Glu Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Asp Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Leu Ala Ser Thr Arg His Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Ser Phe Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Arg Phe Pro Leu 85 90 95 Thr Phe Gly Gln Gly Thr 100 <![CDATA[<210> 94]]> <![CDATA[<211> 306]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 94]]> gagatagtga tgacccagtc tccagctagc ctgtctttgt cccaggaaga gaaggtgacc 60 atcacatgca aagcgagtca agatgtagat acagcggttg cgtggtatca acaaaaaccc 120 ggacaggcac ctaaattgct gatttatctc gccagtacga ggcacactgg ggtcccatcc 180 cgctttagtg ggtcaggatc agggacggat ttttctttta ccataagtag tcttgaacct 240 gaagacgtgg ctgtttatta ttgccaacaa tactcaaggt tccctttgac tttcgggcaa 300 ggtacc 306 <![CDATA[<210> 95]]> <![CDATA[<211> 117]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 95]]> Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Ala Gly 1 5 10 15 Ser Leu Thr Leu Ser Cys Leu Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Ala Trp Val Arg Gln Thr Pro Glu Lys Gly Leu Gln Trp Val 35 40 45 Ala Asn Ile Asn Tyr Asp Gly Ser Ser Thr Tyr Tyr Leu Asp Ser Leu 50 55 60 Lys Ser Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Leu Thr Trp Asp Phe Asp Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <![CDATA[<210> 96]]> <![CDATA[<211> 351]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 96]]> gaagtacaac tcgtggagag tgggggtgat ctcgtaaaac cagcggggtc tttgactctc 60 tcttgtttgg ccagtggctt tacgttctca gattattata tggcttgggt tcgacaaaca 120 cccgaaaagg gtttgcagtg ggtagcaaac attaactacg acgggagtag cacgtattac 180 ctcgactctc tgaagagtag atttacaatt agtcgcgata acgctaaaaa cacgctctac 240 cttcaaatga atagcctcag ggatgaggac acagcagtct attattgtgc cagaggtttg 300 acatgggatt tcgacgtatg gggtcaaggg actctcgtca ccgtctcgag c 351 <![CDATA[<210> 97]]> <![CDATA[<211> 102]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 97]]> Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Thr Ala Ser Ile Ser Cys Lys Ala Ser Gln Asp Val Asp Thr Ala 20 25 30 Val Ala Trp Phe Arg Gln Lys Pro Gly Gln Ser Pro Gln Arg Leu Ile 35 40 45 Tyr Leu Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile Ser Arg Val Glu Ala 65 70 75 80 Asp Asp Thr Gly Val Tyr Tyr Cys Gln Gln Tyr Ser Arg Phe Pro Leu 85 90 95 Thr Phe Gly Gln Gly Thr 100 <![CDATA[<210> 98]]> <![CDATA[<211> 306]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 98]]> gatatagtga tgacccagac tccacttagc ctttccgtca gtccgggcga gacggcgagt 60 atctcttgta aagcctcaca ggacgtagac accgctgtgg cgtggtttcg acaaaagccg 120 ggtcagtctc cgcaacgcct gatttacttg gcctcaacgc gccacaccgg cgttcctgac 180 aggtttagtg gaagcgggag cggaactgac ttcacacttc gaatctccag agtagaagct 240 gatgatactg gcgtgtatta ttgccagcag tattcccggt ttccactgac ctttgggcag 300 ggtacc 306 <![CDATA[<210> 99]]> <![CDATA[<211> 117]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 99]]> Asp Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Thr Cys Val Ala Ser Gly Phe Thr Tyr Ser Asp Tyr 20 25 30 Tyr Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45 Ala Asn Ile Asn Tyr Asp Gly Ser Ser Thr Tyr Tyr Leu Asp Ser Leu 50 55 60 Lys Ser Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Val Arg Gly Leu Thr Trp Asp Phe Asp Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <![CDATA[<210> 100]]> <![CDATA[<211> 351]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 100]]> gacgtgcaac ttgtcgagtc tggtggggat ttggttaagc cgggaggatc tcttaggctg 60 acatgtgtgg catcaggttt tacatatagt gattactaca tggcatgggt ccgacaagcg 120 cccggtaaag gactccagtg ggttgcgaat ataaattatg atggtagttc aacctactat 180 ttggatagct tgaaatctag gttcaccatt tcacgcgata acgcgaagaa tacgctgtac 240 ctgcaaatga acagccttaa gacagaagat accgctactt actactgcgt aaggggactg 300 acgtgggact ttgatgtgtg ggggcaaggg acacttgtaa cggtctcgag c 351 <![CDATA[<210> 101]]> <![CDATA[<211> 102]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 101]]> Glu Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Pro Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Asp Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile 35 40 45 Tyr Leu Ala Ser Thr Arg His Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Arg Phe Pro Leu 85 90 95 Thr Phe Gly Gln Gly Thr 100 <![CDATA[<210> 102]]> <![CDATA[<211> 306]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 102]]> gaaattcaaa tgactcaatc accgtcatcc ttgtccgcca gccccggcga cagggtaaca 60 ataacttgta aggccagcca agatgtagat acggcggtag cgtggtatca acagaagccg 120 ggtaaggttc caaagctgct gatctatctc gcatccacca gacatacagg tgttccatcc 180 cgctttagcg ggtccggttc cggcactgat ttcaccctta ccatttccag tctggagccg 240 gaggacgctg ctacctatta ttgtcaacag tattcccgct tcccccttac ctttggacag 300 ggtacc 306 <![CDATA[<210> 103]]> <![CDATA[<211> 117]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 103]]> Asp Val Gln Leu Val Glu Ser Gly Gly Asn Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Thr Cys Val Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45 Ala Asn Ile Asn Tyr Asp Gly Ser Ser Thr Tyr Tyr Leu Asp Ser Leu 50 55 60 Lys Ser Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Ala Arg Gly Leu Thr Trp Asp Phe Asp Val Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <![CDATA[<210> 104]]> <![CDATA[<211> 351]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 104]]> gatgtgcaac tggttgagtc tggtgggaat ctggttaagc caggcggttc cctgagactt 60 acctgcgttg cgagtggctt tacctttagt gattattaca tggcatgggt acggcaagcg 120 ccaggaaaag gtctccaatg ggtagcaaac ataaattatg atggcagctc tacctactac 180 cttgacagcc ttaaatccag attcacgatt agtcgagata acgctaaaaa tactctctac 240 ttgcaaatga atagtctcaa aacggaagac accgcgacat actactgcgc tcgcggcctg 300 acttgggact tcgacgtgtg ggggcagggg acccttgtta ccgtctcgag c 351 <![CDATA[<210> 105]]> <![CDATA[<211> 102]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 105]]> Asp Ile Thr Met Thr Gln Ser Pro Gly Ser Leu Ala Gly Ser Pro Gly 1 5 10 15 Gln Gln Val Thr Met Asn Cys Lys Ala Ser Gln Asp Val Asp Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln His Pro Lys Leu Leu Ile 35 40 45 Tyr Leu Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Ala 65 70 75 80 Glu Asp Val Ala Ser Tyr Tyr Cys Gln Gln Tyr Ser Arg Phe Pro Leu 85 90 95 Thr Phe Gly Gln Gly Thr 100 <![CDATA[<210> 106]]> <![CDATA[<211> 306]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 106]]> gacataacga tgactcagtc ccccggatct cttgcaggct ctcccggcca gcaagtgacg 60 atgaactgca aggcgagcca agatgtagat accgccgtcg catggtatca gcagaaacca 120 ggccaacatc cgaaactcct catctatctg gcaagtacac gccacaccgg ggtccctgat 180 aggttttccg ggtctgggtc cggaacggac ttcacactga ctatatccaa cctgcaagca 240 gaagatgtag caagttacta ttgtcagcag tactcacgct tccccctcac tttcggacag 300 ggtacc 306 <![CDATA[<210> 107]]> <![CDATA[<211> 652]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 107]]> Met Ala Val Phe Ser Val Phe Gln Thr Thr Phe Phe Leu Ala Leu Leu 1 5 10 15 Ser Leu Arg Thr Leu Gln Ser Glu Val Leu Ser Glu Pro Leu Pro Trp 20 25 30 Ala Pro Glu Ser Leu Lys Val Ser Ile Asn Ser Thr His Gln Cys Leu 35 40 45 His Leu Gln Trp Ser Val His Asn Leu Ala Tyr His Gln Glu Leu Lys 50 55 60 Met Val Phe Gln Ile Glu Ile Ser Arg Ile Lys Thr Ser Asn Val Ile 65 70 75 80 Trp Val Glu Asn Tyr Ser Thr Thr Val Lys Gly Asn Gln Leu Leu His 85 90 95 Trp Ser Trp Glu Ser Gln Leu Pro Leu Glu Cys Ala Lys His Phe Ile 100 105 110 Arg Met Arg Ser Ala Val Asp Asp Ala Thr Thr Pro Glu Gln Arg Phe 115 120 125 Trp Ser Asn Trp Ser Ser Trp Glu Glu Val Asp Val Gln Asn Ser Leu 130 135 140 Gly His Glu Pro Leu Phe Val Phe Pro Lys Asp Lys Leu Val Glu Glu 145 150 155 160 Gly Ser Asn Val Thr Ile Cys Tyr Val Ser Arg Ser Gln Gln Asn Asn 165 170 175 Ile Ser Cys Tyr Leu Glu Gly Val Arg Met Gln Gly Gln Gln Leu Asp 180 185 190 Pro Asn Val Ser Met Phe Asn Leu His Asn Val Ala Phe Ile Arg Glu 195 200 205 Thr Gly Thr Asn Ile Tyr Cys Lys Val Asp Arg Gly Asp Asp Ile Lys 210 215 220 Gly Ile Val Leu Phe Val Ser Lys Ile Leu Glu Glu Pro Lys Asp Phe 225 230 235 240 Ser Cys Glu Thr Arg Asp Phe Gln Thr Leu Ser Cys Thr Trp Asp Pro 245 250 255 Gly Arg Asp Thr Gly Leu Leu Lys Gln Leu Pro Gln Ser Tyr Thr Leu 260 265 270 Phe Glu Ser Phe Ser Gly Lys Lys Thr Leu Cys Lys His Lys Ser Trp 275 280 285 Cys Asn Trp Gln Val Ala Ser Glu Ser Gln Glu Met Tyr Asn Phe Thr 290 295 300 Leu Thr Ala Glu Asn Tyr Leu Arg Lys Arg Ser Val His Ile Leu Phe 305 310 315 320 Asn Leu Thr His Arg Val His Pro Met Ala Pro Phe Asn Val Leu Phe 325 330 335 Lys Asp Val Ser Val Thr Asn Ala Thr Met Thr Trp Lys Val His Ser 340 345 350 Thr Gly Asn Tyr Tyr Thr Leu Leu Cys Gln Val Glu Leu Tyr Gly Glu 355 360 365 Gly Lys Val Ile Gln Lys His Asn Val Ser Val Lys Val Asn Gly Glu 370 375 380 Leu Val Leu Ser Gly Leu Glu Pro Asp Thr Glu Tyr Ser Ala Gln Val 385 390 395 400 Arg Cys Ala Asn Ala Asn His Phe Trp Lys Trp Ser Glu Trp Thr Arg 405 410 415 Gln Asn Phe Thr Thr Val Glu Ala Ala Asp Lys Thr His Thr Cys Pro 420 425 430 Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 435 440 445 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 450 455 460 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 465 470 475 480 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 485 490 495 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 500 505 510 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 515 520 525 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 530 535 540 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 545 550 555 560 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 565 570 575 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 580 585 590 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 595 600 605 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 610 615 620 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 625 630 635 640 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 645 650 <![CDATA[<210> 108]]> <![CDATA[<211> 1956]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 108]]> atggccgtgt tctccgtgtt tcagaccaca ttctttctgg ctctgctgag cctgaggacc 60 ctgcagagcg aggtgctgtc tgagccactg ccatgggctc ctgagtccct gaaggtgagc 120 atcaactcta cacaccagtg cctgcatctg cagtggagcg tgcacaatct ggcttaccat 180 caggagctga agatggtgtt ccagatcgag atctcccgga tcaagaccag caacgtgatc 240 tgggtggaga attatagcac cacagtgaag ggcaaccagc tgctgcactg gtcctgggag 300 agccagctgc ctctggagtg tgccaagcat ttcatcagga tgcggtctgc cgtggacgat 360 gctaccacac cagagcagag attttggagc aactggtcca gctgggagga ggtggacgtg 420 cagaattctc tgggccacga gcccctgttc gtgtttccta aggataagct ggtcgaggag 480 ggcagcaacg tgaccatctg ctacgtgtct aggtcccagc agaacaatat ctcttgttat 540 ctggagggcg tgcggatgca gggacagcag ctggacccca acgtgtccat gttcaacctg 600 cataatgtgg cttttatcag ggagaccggc acaaatatct actgcaaggt ggatcggggc 660 gacgacatca agggcatcgt gctgtttgtg agcaagatcc tggaggagcc taaggacttc 720 tcttgcgaga ccagagattt tcagaccctg tcctgtacat gggaccctgg ccgcgataca 780 ggcctgctga agcagctgcc acagtcttat accctgttcg agagcttttc tggcaagaag 840 acactgtgca agcacaagtc ctggtgtaac tggcaggtgg cctccgagag ccaggagatg 900 tacaacttca ccctgacagc tgagaattat ctgagaaaga ggtccgtgca tatcctgttt 960 aatctgaccc accgcgtgca tccaatggcc cccttcaacg tgctgtttaa ggacgtgtct 1020 gtgacaaatg ctaccatgac atggaaggtg cactccaccg gcaactacta tacactgctg 1080 tgccaggtgg agctgtacgg cgagggcaaa gtgatccaga agcataacgt gtccgtgaaa 1140 gtgaatggcg agctggtgct gtctggcctg gagccagata ccgagtattc cgcccaggtg 1200 agatgtgcca acgctaatca cttctggaag tggtccgagt ggacacgcca gaacttcacc 1260 acagtggagg ccgctgacaa gacccataca tgcccccctt gtcctgctcc agagctgctg 1320 ggaggaccaa gcgtgttcct gtttccaccc aagcccaagg ataccctgat gatctccagg 1380 accccagagg tgacatgcgt ggtggtggac gtgagccacg aggatcccga ggtgaagttc 1440 aactggtacg tggacggcgt ggaggtgcat aatgccaaga ccaagcccag ggaggagcag 1500 tacaactcta cctatcgggt ggtgtccgtg ctgacagtgc tgcaccagga ttggctgaac 1560 ggcaaggagt ataagtgcaa ggtgtctaat aaggccctgc ccgctcctat cgagaagacc 1620 atctccaagg ccaagggcca gcctagagag ccacaggtgt acacactgcc tccaagccgc 1680 gaggagatga ccaagaacca ggtgtctctg acatgtctgg tgaagggctt ctatccctcc 1740 gacatcgctg tggagtggga gagcaatggc cagcctgaga acaattacaa gaccacaccc 1800 cctgtgctgg actctgatgg ctccttcttt ctgtatagca agctgaccgt ggataagtct 1860 aggtggcagc agggcaacgt gttttcttgt tccgtgatgc acgaggctct gcacaatcat 1920 tacacacaga agagcctgtc tctgtcccca ggcaag 1956 <![CDATA[<210> 109]]> <![CDATA[<211> 181]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 109]]> Ser Cys Ser Asp Lys Tyr Pro Glu Leu Leu Gly Gln Leu Gln Lys Gln 1 5 10 15 Ala Asp Phe Met Gln His Thr Asn Thr Leu Leu Asp Leu Tyr Ile Arg 20 25 30 Ser Gln Gly Leu Asp Lys Asn Gly Leu Lys Glu His Cys Arg Glu Arg 35 40 45 Pro Gly Ala Phe Pro Ser Lys Asp Ala Leu Gln Arg Leu Ser Arg Arg 50 55 60 Val Phe Leu Arg Thr Leu Asp Thr Thr Leu Gly Gln Val Leu Leu Arg 65 70 75 80 Leu Ala Ala Leu Glu Gln Asp Ile Pro Lys Ala Gln Asp Leu Glu Met 85 90 95 Leu Ser Gly Val Lys Leu Asn Ile Arg Gly Phe Lys Asn Asn Ile His 100 105 110 Cys Met Ala Gln Leu Leu Pro Gly Ser Ser Glu Thr Thr Glu Pro Thr 115 120 125 Pro Thr Ser Pro Gly Ala Ser Pro Ser Pro Thr Pro Thr Leu Asp Thr 130 135 140 Phe Gln Arg Arg Leu Glu Gly Cys Arg Phe Leu His Gly Tyr His Arg 145 150 155 160 Phe Met Arg Ser Val Gly Gln Val Phe Arg Glu Trp Gly Lys Ser Leu 165 170 175 Ser Arg Ser Arg Arg 180 <![CDATA[<210> 110]]> <![CDATA[<211> 461]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 110]]> Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 1 5 10 15 Val His Ser Ala Met Gly Ser Cys Leu Asp Asn Tyr Gln Glu Leu Leu 20 25 30 Gly Gln Leu Gln Lys Gln Ala Asp Phe Met Gln His Thr Ser Met Leu 35 40 45 Leu Asp Pro Tyr Ile Ser Ile Gln Gly Leu Asp Lys Asp Gly Leu Lys 50 55 60 Glu His Cys Arg Glu Arg Pro Gly Val Phe Pro Ser Lys Asp Ala Leu 65 70 75 80 Gln Arg Leu Ser Arg Gln Glu Phe Leu Gln Ile Leu Asn Thr Thr Leu 85 90 95 Gly His Val Leu His Arg Leu Arg Thr Leu Gln Lys Asp Ile Pro Lys 100 105 110 Ala Gln Asp Leu Glu Lys Leu Asn Ile Ala Lys Leu Asn Ile Arg Gly 115 120 125 Phe Lys Asn Asn Ile His Cys Met Ala Gln Leu Leu Pro Gly Ser Leu 130 135 140 Glu Lys Thr Glu Pro Thr Pro Thr Gly Pro Gly Ala Ser Pro Ser Pro 145 150 155 160 Thr Pro Ile Ser Asp Ala Phe Gln Arg Arg Leu Glu Gly Cys Arg Phe 165 170 175 Leu His Gly Tyr His Arg Phe Met His Ser Val Gly Gln Val Phe Arg 180 185 190 Glu Trp Gly Gln Ser Pro Ser Arg Ser Arg Arg His Ser Pro Arg Arg 195 200 205 Gly Leu Arg Lys Gly Thr His Arg Thr His Leu Ser Ser Arg Asn Lys 210 215 220 Arg Leu Met Pro Arg Gly Trp Leu Pro Arg Asp Lys Thr His Thr Cys 225 230 235 240 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu 245 250 255 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 260 265 270 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 275 280 285 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 290 295 300 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 305 310 315 320 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 325 330 335 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 340 345 350 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 355 360 365 Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 370 375 380 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 385 390 395 400 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 405 410 415 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 420 425 430 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 435 440 445 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 450 455 460 <![CDATA[<210> 111]]> <![CDATA[<211> 1383]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 111]]> atgggctggt cctgcatcat cctgttcctg gtggccaccg ctacaggcgt gcactctgcc 60 atgggctcct gtctggacaa ctaccaggag ctgctgggcc agctgcagaa gcaggctgac 120 tttatgcagc acacctctat gctgctggat ccctatatct ccatccaggg cctggacaag 180 gatggcctga aggagcattg cagagagcgc cctggcgtgt tcccaagcaa ggatgccctg 240 cagagactgt ctcgccagga gtttctgcag atcctgaata ccacactggg ccacgtgctg 300 cataggctgc ggaccctgca gaaggacatc cctaaggccc aggatctgga gaagctgaac 360 atcgctaagc tgaatatcag aggcttcaag aacaatatcc attgcatggc tcagctgctg 420 ccaggaagcc tggagaagac cgagccaacc ccaacaggcc ctggagcttc tccttcccca 480 acacccatct ctgacgcttt ccagaggcgg ctggagggct gtagattcct gcacggctac 540 catcgcttta tgcactctgt gggccaggtg tttagggagt ggggacagag cccatctcgg 600 tccagacgcc attccccaag gaggggactg agaaagggaa cccaccgcac acatctgtcc 660 agcaggaaca agcggctgat gccaagggga tggctgccta gggacaagac ccacacatgc 720 cccccttgtc ctgctccaga gctgctggga ggacctagcg tgttcctgtt tccacccaag 780 ccaaaggata ccctgatgat cagccgcacc cctgaggtga catgcgtggt ggtggacgtg 840 tctcacgagg atccagaggt gaagtttaac tggtacgtgg acggcgtgga ggtgcataat 900 gctaagacaa agccaagaga ggagcagtac aatagcacct atcgcgtggt gtctgtgctg 960 acagtgctgc atcaggattg gctgaacggc aaggagtata agtgcaaggt gtccaataag 1020 gccctgcccg ctcctatcga gaagaccatc agcaaggcta agggacagcc aagggagcca 1080 caggtgtaca cactgcctcc atctcgggag gagatgacca agaaccaggt gtccctgaca 1140 tgtctggtga agggcttcta tccatccgac atcgctgtgg agtgggagag caatggccag 1200 cccgagaaca attacaagac cacaccccct gtgctggact ccgatggcag cttctttctg 1260 tattccaagc tgaccgtgga taagagccgg tggcagcagg gcaacgtgtt tagctgttct 1320 gtgatgcacg aggccctgca caatcattat acacagaagt ccctgagcct gtctcccggc 1380 aag 1383 <![CDATA[<210> 112]]> <![CDATA[<211> 652]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 112]]> Met Ala Leu Phe Ser Ala Phe Gln Thr Thr Phe Leu Leu Ala Leu Leu 1 5 10 15 Ser Leu Lys Thr Tyr Gln Ser Glu Val Leu Ser Glu Pro Leu Ser Leu 20 25 30 Ala Pro Glu Ser Leu Glu Val Ser Ile Asp Ser Ala Arg Gln Cys Leu 35 40 45 His Leu Lys Trp Ser Val His Asn Leu Ala Tyr His Gln Glu Leu Lys 50 55 60 Met Val Phe Gln Ile Glu Ile Ser Arg Ile Lys Thr Ser Asn Val Ile 65 70 75 80 Trp Val Glu Asn Tyr Ser Thr Thr Val Lys Arg Asn Gln Val Leu Arg 85 90 95 Trp Ser Trp Glu Ser Lys Leu Pro Leu Glu Cys Ala Lys His Ser Val 100 105 110 Arg Met Arg Gly Ala Val Asp Asp Ala Gln Val Pro Glu Leu Arg Phe 115 120 125 Trp Ser Asn Trp Thr Ser Trp Glu Glu Val Asp Val Gln Ser Ser Leu 130 135 140 Gly His Asp Pro Leu Phe Val Phe Pro Lys Asp Lys Leu Val Glu Glu 145 150 155 160 Gly Ser Asn Val Thr Ile Cys Tyr Val Ser Arg Ser His Gln Asn Asn 165 170 175 Ile Ser Cys Tyr Leu Glu Gly Val Arg Met His Gly Glu Gln Leu Asp 180 185 190 Pro Asn Val Cys Val Phe His Leu Lys Asn Val Pro Phe Ile Arg Glu 195 200 205 Thr Gly Thr Asn Ile Tyr Cys Lys Ala Asp Gln Gly Asp Val Ile Lys 210 215 220 Gly Ile Val Leu Phe Val Ser Lys Val Phe Glu Glu Pro Lys Asp Phe 225 230 235 240 Ser Cys Glu Thr Arg Asp Leu Lys Thr Leu Asn Cys Thr Trp Ala Pro 245 250 255 Gly Ser Asp Ala Gly Leu Leu Thr Gln Leu Ser Gln Ser Tyr Thr Leu 260 265 270 Phe Glu Ser Phe Ser Gly Lys Lys Thr Leu Cys Lys His Lys Ser Trp 275 280 285 Cys Asn Trp Gln Val Ser Pro Asp Ser Gln Glu Met Tyr Asn Phe Thr 290 295 300 Leu Thr Ala Glu Asn Tyr Leu Arg Lys Arg Ser Val His Leu Leu Phe 305 310 315 320 Asn Leu Thr His Arg Val His Pro Met Ala Pro Phe Asn Val Phe Val 325 330 335 Lys Asn Val Ser Ala Thr Asn Ala Thr Met Thr Trp Lys Val His Ser 340 345 350 Ile Gly Asn Tyr Ser Thr Leu Leu Cys Gln Ile Glu Leu Asp Gly Glu 355 360 365 Gly Lys Val Ile Gln Lys Gln Asn Val Ser Val Lys Val Asn Gly Lys 370 375 380 His Leu Met Lys Lys Leu Glu Pro Ser Thr Glu Tyr Ala Ala Gln Val 385 390 395 400 Arg Cys Ala Asn Ala Asn His Phe Trp Lys Trp Ser Glu Trp Thr Arg 405 410 415 Arg Asn Phe Thr Thr Ala Glu Ala Ala Asp Lys Thr His Thr Cys Pro 420 425 430 Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe 435 440 445 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 450 455 460 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 465 470 475 480 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 485 490 495 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 500 505 510 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 515 520 525 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 530 535 540 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 545 550 555 560 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 565 570 575 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 580 585 590 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 595 600 605 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 610 615 620 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 625 630 635 640 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 645 650 <![CDATA[<210> 113]]> <![CDATA[<211> 2076]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 113]]> atggccctgt tcagcgcctt ccagaccacc ttcctgctgg ccctgctgag cctgaaaacc 60 taccagagcg aggtgctgag cgagcccctg tctctggccc ctgagagcct ggaagtgtcc 120 atcgacagcg ccagacagtg cctgcacctg aagtggagcg tgcacaacct ggcctaccac 180 caggaactga agatggtgtt ccagatcgag atcagccgga tcaagaccag caacgtgatc 240 tgggtggaaa actacagcac caccgtgaag cggaaccagg tgctgcggtg gtcctgggag 300 tctaagctgc ctctggaatg cgccaagcac agcgtgcgga tgagaggcgc cgtggatgat 360 gcccaggtgc ccgagctgag attctggtcc aactggacct cctgggaaga ggtggacgtg 420 cagtctagcc tgggccacga ccccctgttc gtgttcccca aggacaagct ggtggaagag 480 ggctccaacg tgaccatctg ctacgtgtcc agaagccacc agaacaacat cagctgctac 540 ctggaaggcg tgcgcatgca cggcgagcag ctggacccta acgtgtgcgt gttccacctg 600 aagaacgtgc ccttcatcag agagacaggc accaacatct actgcaaggc cgaccagggc 660 gacgtgatca agggcatcgt gctgtttgtg tccaaggtgt tcgaggaacc caaggacttc 720 agctgcgaga cacgggatct gaaaaccctg aactgtacct gggcccctgg ctccgatgcc 780 ggactgctga ctcagctgtc ccagagctac accctgttcg agagcttcag cggcaaaaag 840 accctgtgca agcacaagag ctggtgcaac tggcaagtgt cccccgatag ccaggaaatg 900 tacaacttca ccctgaccgc cgagaactac ctgcggaaga gatccgtgca tctgctgttc 960 aacctgaccc acagagtgca ccccatggcc cccttcaacg tgttcgtgaa gaatgtgtcc 1020 gccaccaacg ccaccatgac atggaaggtg cacagcatcg gcaactactc caccctgctg 1080 tgtcagatcg agctggacgg cgagggcaaa gtgatccaga aacagaacgt gtcagtgaaa 1140 gtgaacggca agcacctgat gaagaagctg gaacccagca ccgagtacgc cgcccaggtg 1200 cgctgtgcca acgccaacca cttctggaag tggagtgaat ggacccggcg gaacttcacc 1260 acagccgaag ccgccgctga gaacgaggtg tccacaccta tgcaggccct gaccaccaac 1320 aaggacgacg acaacatcct gttccgggac tccgccaatg ccaccagcct gcctgtgcag 1380 gatagcagct ctgtgctgcc cgccaagccc gagaacatct cctgcgtgtt ctactacgag 1440 gaaaacttca cttgcacctg gtcccccgag aaagaggcca gctacacctg gtacaaagtg 1500 aagagaacct acagctacgg ctacaagagc gacatctgcc ccagcgacaa cagcaccaga 1560 ggcaaccaca ccttctgcag ctttctgccc cccaccatca ccaaccccga caactacacc 1620 atccaggtgg aagcccagaa cgccgacggc atcatcaagt ccgacatcac ccactggtcc 1680 ctggacgcca tcacaaagat cgagcccccc gagatcttct ccgtgaagcc tgtgctgggc 1740 gtgaagagga tggtgcagat caagtggatc cggcccgtgc tggccccagt gtctagcacc 1800 ctgaagtaca ccctgcggtt caagaccgtg aacagcgcct actggatgga agtgaatttc 1860 accaaagagg acatcgaccg ggacgagaca tacaatctga ccggactgca ggccttcaca 1920 gagtacgtgc tggctctgag atgcgccacc aaagaatcca tgttttggag cggctggtcc 1980 caggaaaaga tgggcaccac cgaagagggt aagcctatcc ctaaccctct cctcggtctc 2040 gattctacgc gtaccggtca tcatcaccat caccat 2076 <![CDATA[<210> 114]]> <![CDATA[<211> 335]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 114]]> Ala Ser Thr Thr Ala Pro Ser Val Phe Pro Leu Ala Pro Ser Cys Gly 1 5 10 15 Ser Thr Ser Gly Ser Thr Val Ala Leu Ala Cys Leu Val Ser Gly Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ser Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ser Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Met Val Thr Val Pro Ser Ser Arg Trp Pro Ser Glu Thr 65 70 75 80 Phe Thr Cys Asn Val Ala His Pro Ala Ser Lys Thr Lys Val Asp Lys 85 90 95 Pro Val Pro Lys Arg Glu Asn Gly Arg Val Pro Arg Pro Pro Asp Cys 100 105 110 Pro Lys Cys Pro Ala Pro Glu Met Leu Gly Gly Pro Ser Val Phe Ile 115 120 125 Phe Pro Pro Lys Pro Lys Asp Thr Leu Leu Ile Ala Arg Thr Pro Glu 130 135 140 Val Thr Cys Val Val Val Asp Leu Asp Pro Glu Asp Pro Glu Val Gln 145 150 155 160 Ile Ser Trp Phe Val Asp Gly Lys Gln Met Gln Thr Ala Lys Thr Gln 165 170 175 Pro Arg Glu Glu Gln Phe Asn Gly Thr Tyr Arg Val Val Ser Val Leu 180 185 190 Pro Ile Gly His Gln Asp Trp Leu Lys Gly Lys Gln Phe Thr Cys Lys 195 200 205 Val Asn Asn Lys Ala Leu Pro Ser Pro Ile Glu Arg Thr Ile Ser Lys 210 215 220 Ala Arg Gly Gln Ala His Gln Pro Ser Val Tyr Val Leu Pro Pro Ser 225 230 235 240 Arg Glu Glu Leu Ser Lys Asn Thr Val Ser Leu Thr Cys Leu Ile Lys 245 250 255 Asp Phe Phe Pro Pro Asp Ile Asp Val Glu Trp Gln Ser Asn Gly Gln 260 265 270 Gln Glu Pro Glu Ser Lys Tyr Arg Thr Thr Pro Pro Gln Leu Asp Glu 275 280 285 Asp Gly Ser Tyr Phe Leu Tyr Ser Lys Leu Ser Val Asp Lys Ser Arg 290 295 300 Trp Gln Arg Gly Asp Thr Phe Ile Cys Ala Val Met His Glu Ala Leu 305 310 315 320 His Asn His Tyr Thr Gln Glu Ser Leu Ser His Ser Pro Gly Lys 325 330 335 <![CDATA[<210> 115]]> <![CDATA[<211> 1005]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 115]]> gcctcaacaa ctgctcctag cgtgtttccc ctggccccta gctgcggaag tacctcaggc 60 agcacagtgg ccctggcttg tctggtgtct ggatatttcc ctgagccagt gaccgtgagt 120 tggaacagcg gctctctgac ctccggggtg cacacatttc catctgtgct gcagtctagt 180 ggcctgtact ccctgtcaag catggtgact gtgccttcct ctaggtggcc atcagaaact 240 ttcacctgca acgtggccca tcccgccagc aagaccaaag tggacaagcc cgtgcctaaa 300 agggagaatg gaagggtgcc aagaccacct gattgcccta agtgtccagc tccagaagcg 360 gcgggagcac caagcgtgtt catctttcca cccaagccca aagacacact gctgattgct 420 agaactcccg aggtgacctg cgtggtggtg gacctggatc cagaggaccc cgaagtgcag 480 atctcctggt tcgtggatgg gaagcagatg cagacagcca aaactcagcc tcgggaggaa 540 cagtttaacg gaacctatag agtggtgtct gtgctgccaa ttggacacca ggactggctg 600 aagggcaaac agtttacatg caaggtgaac aacaaggccc tgcctagtcc aatcgagagg 660 actatttcaa aagctagggg acaggctcat cagccttccg tgtatgtgct gcctccatcc 720 cgggaggaac tgtctaagaa cacagtgagt ctgacttgtc tgatcaaaga tttctttccc 780 cctgacattg atgtggagtg gcagagcaat gggcagcagg agccagaatc caagtacaga 840 accacaccac cccagctgga cgaagatggc tcctatttcc tgtacagtaa gctgtcagtg 900 gacaaatcta ggtggcagcg cggggatacc tttatctgcg ccgtgatgca cgaggctctg 960 cacaatcatt acacacaaga aagtctgtca catagccccg gcaag 1005 <![CDATA[<210> 116]]> <![CDATA[<211> 106]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 116]]> Arg Asn Asp Ala Gln Pro Ala Val Tyr Leu Phe Gln Pro Ser Pro Asp 1 5 10 15 Gln Leu His Thr Gly Ser Ala Ser Val Val Cys Leu Leu Asn Ser Phe 20 25 30 Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Val Asp Gly Val Ile Gln 35 40 45 Asp Thr Gly Ile Gln Glu Ser Val Thr Glu Gln Asp Lys Asp Ser Thr 50 55 60 Tyr Ser Leu Ser Ser Thr Leu Thr Met Ser Ser Thr Glu Tyr Leu Ser 65 70 75 80 His Glu Leu Tyr Ser Cys Glu Ile Thr His Lys Ser Leu Pro Ser Thr 85 90 95 Leu Ile Lys Ser Phe Gln Arg Ser Glu Cys 100 105 <![CDATA[<210> 117]]> <![CDATA[<211> 318]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 117]]> aggaacgacg cccagcctgc tgtgtatctg tttcagccct cccctgatca gctgcacact 60 ggctctgcta gtgtggtgtg tctgctgaac agcttctacc caaaggatat caatgtgaag 120 tggaaagtgg acggcgtgat ccaggatact gggattcagg agtccgtgac cgaacaggac 180 aaagattcaa catatagcct gagctccact ctgaccatgt ctagtaccga gtacctgagc 240 cacgaactgt attcctgcga gatcactcat aagtccctgc cctctaccct gatcaagagc 300 ttccagagat cagagtgt 318 <![CDATA[<210> 118]]> <![CDATA[<211> 335]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 118]]> Ala Ser Thr Thr Ala Pro Ser Val Phe Pro Leu Ala Pro Ser Cys Gly 1 5 10 15 Thr Thr Ser Gly Ala Thr Val Ala Leu Ala Cys Leu Val Leu Gly Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ala Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Met Val Thr Val Pro Ser Ser Arg Trp Leu Ser Asp Thr 65 70 75 80 Phe Thr Cys Asn Val Ala His Pro Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Thr Val Arg Lys Thr Asp His Pro Pro Gly Pro Lys Pro Cys Asp Cys 100 105 110 Pro Lys Cys Pro Pro Pro Glu Ala Ala Gly Ala Pro Ser Ile Phe Ile 115 120 125 Phe Pro Pro Lys Pro Lys Asp Thr Leu Ser Ile Ser Arg Thr Pro Glu 130 135 140 Val Thr Cys Leu Val Val Asp Leu Gly Pro Asp Asp Ser Asp Val Gln 145 150 155 160 Ile Thr Trp Phe Val Asp Asn Thr Gln Val Tyr Thr Ala Lys Thr Ser 165 170 175 Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu 180 185 190 Pro Ile Leu His Gln Asp Trp Leu Lys Gly Lys Glu Phe Lys Cys Lys 195 200 205 Val Asn Ser Lys Ser Leu Pro Ser Pro Ile Glu Arg Thr Ile Ser Lys 210 215 220 Ala Lys Gly Gln Pro His Glu Pro Gln Val Tyr Val Leu Pro Pro Ala 225 230 235 240 Gln Glu Glu Leu Ser Arg Asn Lys Val Ser Val Thr Cys Leu Ile Lys 245 250 255 Ser Phe His Pro Pro Asp Ile Ala Val Glu Trp Glu Ile Thr Gly Gln 260 265 270 Pro Glu Pro Glu Asn Asn Tyr Arg Thr Thr Pro Pro Gln Leu Asp Ser 275 280 285 Asp Gly Thr Tyr Phe Val Tyr Ser Lys Leu Ser Val Asp Arg Ser His 290 295 300 Trp Gln Arg Gly Asn Thr Tyr Thr Cys Ser Val Ser His Glu Ala Leu 305 310 315 320 His Ser His His Thr Gln Lys Ser Leu Thr Gln Ser Pro Gly Lys 325 330 335 <![CDATA[<210> 119]]> <![CDATA[<211> 1005]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 119]]> gcctccacca cggccccatc ggtgttccca ctggccccca gctgcgggac cacatctggc 60 gccaccgtgg ccctggcctg cctggtgtta ggctacttcc ctgagccggt gaccgtgtcc 120 tggaactccg gcgccctgac cagcggtgtg cacaccttcc cggccgtcct gcaggcctcg 180 gggctgtact ctctcagcag catggtgaca gtgccctcca gcaggtggct cagtgacacc 240 ttcacctgca acgtggccca cccgcccagc aacaccaagg tggacaagac cgtgcgcaaa 300 acagaccacc caccgggacc caaaccctgc gactgtccca aatgcccacc ccctgaggcg 360 gctggagcac cgtccatctt catcttcccc ccaaaaccca aggacaccct ctcgatttcc 420 cggacgcccg aggtcacatg cttggtggtg gacttgggcc cagatgactc cgatgtccag 480 atcacatggt ttgtggataa cacccaggtg tacacagcca agacgagtcc gcgtgaggag 540 cagttcaaca gcacctaccg tgtggtcagt gtcctcccca tcctacacca ggactggctc 600 aaggggaagg agttcaagtg caaggtcaac agcaaatccc tcccctcccc catcgagagg 660 accatctcca aggccaaagg acagccccac gagccccagg tgtacgtcct gcctccagcc 720 caggaggagc tcagcaggaa caaagtcagt gtgacctgcc tgatcaaatc cttccacccg 780 cctgacattg ccgtcgagtg ggagatcacc ggacagccgg agccagagaa caactaccgg 840 acgaccccgc cccagctgga cagcgacggg acctacttcg tgtacagcaa gctctcggtg 900 gacaggtccc actggcagag gggaaacacc tacacctgct cggtgtcaca cgaagctctg 960 cacagccacc acacacagaa atccctcacc cagtctccgg gtaaa 1005 <![CDATA[<210> 120]]> <![CDATA[<211> 110]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 120]]> Arg Ser Asp Ala Gln Pro Ser Val Phe Leu Phe Gln Pro Ser Leu Asp 1 5 10 15 Glu Leu His Thr Gly Ser Ala Ser Ile Val Cys Ile Leu Asn Asp Phe 20 25 30 Tyr Pro Lys Glu Val Asn Val Lys Trp Lys Val Asp Gly Val Val Gln 35 40 45 Asn Lys Gly Ile Gln Glu Ser Thr Thr Glu Gln Asn Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Met Ser Ser Thr Glu Tyr Gln 65 70 75 80 Ser His Glu Lys Phe Ser Cys Glu Val Thr His Lys Ser Leu Ala Ser 85 90 95 Thr Leu Val Lys Ser Phe Gln Arg Ser Glu Cys Gln Arg Glu 100 105 110 <![CDATA[<210> 121]]> <![CDATA[<211> 330]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 121]]> cggagtgatg ctcagccatc tgtctttctc ttccaaccat ctctggacga gttacataca 60 ggaagtgcct ctatcgtgtg catattgaat gacttctacc ccaaagaggt caatgtcaag 120 tggaaagtgg atggcgtagt ccaaaacaaa ggcatccagg agagcaccac agagcagaac 180 agcaaggaca gcacctacag cctcagcagc accctgacga tgtccagtac ggagtaccaa 240 agtcatgaaa agttctcctg cgaggtcact cacaagagcc tggcctccac cctcgtcaag 300 agcttccaga ggagcgagtg tcagagagag 330 <![CDATA[<210> 122]]> <![CDATA[<211> 739]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 122]]> Met Ala Leu Phe Ala Val Phe Gln Thr Thr Phe Phe Leu Thr Leu Leu 1 5 10 15 Ser Leu Arg Thr Tyr Gln Ser Glu Val Leu Ala Glu Arg Leu Pro Leu 20 25 30 Thr Pro Val Ser Leu Lys Val Ser Thr Asn Ser Thr Arg Gln Ser Leu 35 40 45 His Leu Gln Trp Thr Val His Asn Leu Pro Tyr His Gln Glu Leu Lys 50 55 60 Met Val Phe Gln Ile Gln Ile Ser Arg Ile Glu Thr Ser Asn Val Ile 65 70 75 80 Trp Val Gly Asn Tyr Ser Thr Thr Val Lys Trp Asn Gln Val Leu His 85 90 95 Trp Ser Trp Glu Ser Glu Leu Pro Leu Glu Cys Ala Thr His Phe Val 100 105 110 Arg Ile Lys Ser Leu Val Asp Asp Ala Lys Phe Pro Glu Pro Asn Phe 115 120 125 Trp Ser Asn Trp Ser Ser Trp Glu Glu Val Ser Val Gln Asp Ser Thr 130 135 140 Gly Gln Asp Ile Leu Phe Val Phe Pro Lys Asp Lys Leu Val Glu Glu 145 150 155 160 Gly Thr Asn Val Thr Ile Cys Tyr Val Ser Arg Asn Ile Gln Asn Asn 165 170 175 Val Ser Cys Tyr Leu Glu Gly Lys Gln Ile His Gly Glu Gln Leu Asp 180 185 190 Pro His Val Thr Ala Phe Asn Leu Asn Ser Val Pro Phe Ile Arg Asn 195 200 205 Lys Gly Thr Asn Ile Tyr Cys Glu Ala Ser Gln Gly Asn Val Ser Glu 210 215 220 Gly Met Lys Gly Ile Val Leu Phe Val Ser Lys Val Leu Glu Glu Pro 225 230 235 240 Lys Asp Phe Ser Cys Glu Thr Glu Asp Phe Lys Thr Leu His Cys Thr 245 250 255 Trp Asp Pro Gly Thr Asp Thr Ala Leu Gly Trp Ser Lys Gln Pro Ser 260 265 270 Gln Ser Tyr Thr Leu Phe Glu Ser Phe Ser Gly Glu Lys Lys Leu Cys 275 280 285 Thr His Lys Asn Trp Cys Asn Trp Gln Ile Thr Gln Asp Ser Gln Glu 290 295 300 Thr Tyr Asn Phe Thr Leu Ile Ala Glu Asn Tyr Leu Arg Lys Arg Ser 305 310 315 320 Val Asn Ile Leu Phe Asn Leu Thr His Arg Val Tyr Leu Met Asn Pro 325 330 335 Phe Ser Val Asn Phe Glu Asn Val Asn Ala Thr Asn Ala Ile Met Thr 340 345 350 Trp Lys Val His Ser Ile Arg Asn Asn Phe Thr Tyr Leu Cys Gln Ile 355 360 365 Glu Leu His Gly Glu Gly Lys Met Met Gln Tyr Asn Val Ser Ile Lys 370 375 380 Val Asn Gly Glu Tyr Phe Leu Ser Glu Leu Glu Pro Ala Thr Glu Tyr 385 390 395 400 Met Ala Arg Val Arg Cys Ala Asp Ala Ser His Phe Trp Lys Trp Ser 405 410 415 Glu Trp Ser Gly Gln Asn Phe Thr Thr Leu Glu Ala Ala Pro Ser Glu 420 425 430 Ala Pro Asp Val Trp Arg Ile Val Ser Leu Glu Pro Gly Asn His Thr 435 440 445 Val Thr Leu Phe Trp Lys Pro Leu Ser Lys Leu His Ala Asn Gly Lys 450 455 460 Ile Leu Phe Tyr Asn Val Val Val Glu Asn Leu Asp Lys Pro Ser Ser 465 470 475 480 Ser Glu Leu His Ser Ile Pro Ala Pro Ala Asn Ser Thr Lys Leu Ile 485 490 495 Leu Asp Arg Cys Ser Tyr Gln Ile Cys Val Ile Ala Asn Asn Ser Val 500 505 510 Gly Ala Ser Pro Ala Ser Val Ile Val Ile Ser Ala Asp Pro Glu Asn 515 520 525 Lys Glu Val Glu Glu Glu Arg Ile Ala Gly Thr Glu Gly Gly Phe Ser 530 535 540 Leu Ser Trp Lys Pro Gln Pro Gly Asp Val Ile Gly Tyr Val Val Asp 545 550 555 560 Trp Cys Asp His Thr Gln Asp Val Leu Gly Asp Phe Gln Trp Lys Asn 565 570 575 Val Gly Pro Asn Thr Thr Ser Thr Val Ile Ser Thr Asp Ala Phe Arg 580 585 590 Pro Gly Val Arg Tyr Asp Phe Arg Ile Tyr Gly Leu Ser Thr Lys Arg 595 600 605 Ile Ala Cys Leu Leu Glu Lys Lys Thr Gly Tyr Ser Gln Glu Leu Ala 610 615 620 Pro Ser Asp Asn Pro His Val Leu Val Asp Thr Leu Thr Ser His Ser 625 630 635 640 Phe Thr Leu Ser Trp Lys Asp Tyr Ser Thr Glu Ser Gln Pro Gly Phe 645 650 655 Ile Gln Gly Tyr His Val Tyr Leu Lys Ser Lys Ala Arg Gln Cys His 660 665 670 Pro Arg Phe Glu Lys Ala Val Leu Ser Asp Gly Ser Glu Cys Cys Lys 675 680 685 Tyr Lys Ile Asp Asn Pro Glu Glu Lys Ala Leu Ile Val Asp Asn Leu 690 695 700 Lys Pro Glu Ser Phe Tyr Glu Phe Phe Ile Thr Pro Phe Thr Ser Ala 705 710 715 720 Gly Glu Gly Pro Ser Ala Thr Phe Thr Lys Val Thr Thr Pro Asp Glu 725 730 735 His Ser Ser <![CDATA[<210> 123]]> <![CDATA[<211> 159]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 123]]> Met Leu Ser His Thr Gly Pro Ser Arg Phe Ala Leu Phe Leu Leu Cys 1 5 10 15 Ser Met Glu Thr Leu Leu Ser Ser His Met Ala Pro Thr His Gln Leu 20 25 30 Pro Pro Ser Asp Val Arg Lys Ile Ile Leu Glu Leu Gln Pro Leu Ser 35 40 45 Arg Gly Leu Leu Glu Asp Tyr Gln Lys Lys Glu Thr Gly Val Pro Glu 50 55 60 Ser Asn Arg Thr Leu Leu Leu Cys Leu Thr Ser Asp Ser Gln Pro Pro 65 70 75 80 Arg Leu Asn Ser Ser Ala Ile Leu Pro Tyr Phe Arg Ala Ile Arg Pro 85 90 95 Leu Ser Asp Lys Asn Ile Ile Asp Lys Ile Ile Glu Gln Leu Asp Lys 100 105 110 Leu Lys Phe Gln His Glu Pro Glu Thr Glu Ile Ser Val Pro Ala Asp 115 120 125 Thr Phe Glu Cys Lys Ser Phe Ile Leu Thr Ile Leu Gln Gln Phe Ser 130 135 140 Ala Cys Leu Glu Ser Val Phe Lys Ser Leu Asn Ser Gly Pro Gln 145 150 155 <![CDATA[<210> 124]]> <![CDATA[<211> 477]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 124]]> atgctctccc acacaggacc atccaggttt gccctgttcc tgctctgctc tatggaaacc 60 ttgctgtcct cccatatggc acccacccat cagctaccac caagtgatgt acgaaaaatc 120 atcttggaat tacagccctt gtcgagggga cttttggaag actatcagaa gaaagagaca 180 ggggtgccag aatccaaccg taccttgctg ctgtgtctca cctctgattc ccaaccacca 240 cgcctcaaca gctcagccat cttgccttat ttcagggcaa tcagaccatt atcagataag 300 aacattattg ataaaatcat agaacagctt gacaaactca aatttcaaca tgaaccagaa 360 acagaaattt ctgtgcctgc agatactttt gaatgtaaaa gcttcatctt gacgatttta 420 cagcagttct cggcgtgcct ggaaagtgtg tttaagtcac taaactctgg acctcag 477 <![CDATA[<210> 125]]> <![CDATA[<211> 165]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 125]]> Met Leu Ser His Ala Gly Pro Ala Arg Phe Ala Leu Phe Leu Leu Cys 1 5 10 15 Cys Met Glu Thr Leu Leu Pro Ser His Met Ala Pro Ala His Arg Leu 20 25 30 Gln Pro Ser Asp Ile Arg Lys Ile Ile Leu Glu Leu Arg Pro Met Ser 35 40 45 Lys Gly Leu Leu Gln Asp Tyr Leu Lys Lys Glu Ile Gly Leu Pro Glu 50 55 60 Ser Asn His Ser Ser Leu Pro Cys Leu Ser Ser Asp Ser Gln Leu Pro 65 70 75 80 His Ile Asn Gly Ser Ala Ile Leu Pro Tyr Phe Arg Ala Ile Arg Pro 85 90 95 Leu Ser Asp Lys Asn Thr Ile Asp Lys Ile Ile Glu Gln Leu Asp Lys 100 105 110 Leu Lys Phe Gln Arg Glu Pro Glu Ala Lys Val Ser Met Pro Ala Asp 115 120 125 Asn Phe Glu Arg Lys Asn Phe Ile Leu Ala Val Leu Gln Gln Phe Ser 130 135 140 Ala Cys Leu Glu His Val Leu Gln Ser Leu Asn Ser Gly Pro Gln His 145 150 155 160 His His His His His 165 <![CDATA[<210> 126]]> <![CDATA[<211> 495]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家貓]]> <![CDATA[<400> 126]]> atgctttcac acgctggacc agcccgattc gccctcttcc tcctctgctg tatggagact 60 ctgttgccgt cccacatggc cccggcacat aggctgcagc cgtctgacat ccggaagatc 120 attctcgaac ttcgccccat gtcgaagggg ttgctgcaag actacctgaa gaaggagatc 180 ggcctgcccg aaagcaacca ctcctcgctg ccttgcctgt caagcgattc ccagctgccc 240 cacattaacg gttccgccat cctcccgtac ttccgggcca tcagaccact gtcggacaag 300 aacaccatcg acaagatcat tgaacagctg gacaagctga agtttcagcg cgagcctgaa 360 gccaaagtgt ccatgcccgc cgataacttc gagcggaaga atttcattct cgcggtgctg 420 cagcagttct ccgcgtgcct ggagcacgtc ctgcaatccc tgaacagcgg acctcagcac 480 caccatcacc accat 495 <![CDATA[<210> 127]]> <![CDATA[<211> 121]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 127]]> Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45 Ala Gln Ile Tyr Pro Gly His Val Asn Thr Asn Tyr Asn Gly Asn Phe 50 55 60 Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Ala Asp Asn Ser Gly Phe Val Leu Phe Ala Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <![CDATA[<210> 128]]> <![CDATA[<211> 363]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 128]]> gaggtgcagc ttgtagagag tgggggcgac ttggttaagc caggcgggag tttgcgcttg 60 agctgcgtag cgagcggctt cacctttagt aattattgga tgaactgggt gaggcaggcc 120 ccaggaaaag gtctgcagtg ggtcgcccaa atatacccag gccatgtgaa cacaaattat 180 aacggtaatt tcaaagatag gtttacaata tctcgggaca atgcccgcaa cacggtttat 240 ctgcaaatga atagcctgag ggccgaagac acggcggttt attattgtgc taggagcgct 300 gacaacagcg gcttcgtgct gtttgcctac tggggacaag gcactctcgt gaccgtctcg 360 agc 363 <![CDATA[<210> 129]]> <![CDATA[<211> 121]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 129]]> Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Gln Trp Val 35 40 45 Ala Gln Ile Tyr Pro Gly His Val Asn Thr Asn Tyr Asn Gly Asn Phe 50 55 60 Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys 85 90 95 Ala Arg Ser Ala Asp Asn Ser Gly Phe Val Leu Phe Ala Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <![CDATA[<210> 130]]> <![CDATA[<211> 363]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 130]]> gaagtccagt tggtcgaatc aggcggggac cttgtcaaac caggtggtag cttgcgcctc 60 tcatgcgtgg cgtccggttt tactttttcc aattactgga tgaactgggt ccgacagtcc 120 cccggcaaag ggttgcaatg ggtagcacaa atatatccag ggcacgtaaa caccaactat 180 aatggcaact tcaaggatag gtttactatt agcagggaca acgccaaaaa cacactgtat 240 ctgcaaatga actctcttcg cgctgaagac accgccgttt atttttgtgc gcggagcgcc 300 gacaattccg gctttgtcct tttcgcttat tggggtcagg gtacattggt gacagtctcg 360 agc 363 <![CDATA[<210> 131]]> <![CDATA[<211> 106]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 131]]> Glu Ile Val Met Thr Gln Ser Pro Ala Ser Leu Ser Leu Ser Gln Glu 1 5 10 15 Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 20 25 30 Gly Tyr Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Phe Thr Ile Ser 65 70 75 80 Ser Leu Glu Pro Glu Asp Val Ala Val Tyr Tyr Cys Gln His Ser Arg 85 90 95 Glu Leu Pro Leu Thr Phe Gly Gln Gly Thr 100 105 <![CDATA[<210> 132]]> <![CDATA[<211> 318]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 132]]> gaaatagtga tgactcagag ccctgctagt ctctctttgt cacaagagga aaaggtaact 60 attacgtgtc gggcaagtaa gagtgtttcc acaagcggtt actcttattt gcattggtat 120 caacaaaaac ctggacaggc acctaagctg cttatctatc tggccagcaa cttggagtca 180 ggcgtcccgt cccgcttctc aggaagcggc agtggcactg acttttcctt caccatctct 240 tcccttgaac ctgaggacgt ggcggtgtac tactgtcagc attcacggga gctgccactg 300 acattcggcc aaggtacc 318 <![CDATA[<210> 133]]> <![CDATA[<211> 106]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 133]]> Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Thr Ala Ser Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser 20 25 30 Gly Tyr Ser Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro 35 40 45 Gln Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Ser Lys 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile Ser 65 70 75 80 Arg Val Glu Ala Asp Asp Thr Gly Ile Tyr Tyr Cys Gln His Ser Arg 85 90 95 Glu Leu Pro Leu Thr Phe Gly Gln Gly Thr 100 105 <![CDATA[<210> 134]]> <![CDATA[<211> 318]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 家犬]]> <![CDATA[<400> 134]]> gatatagtta tgacacagac tccgctctcc ctcagtgtga gccctgggga aaccgccagt 60 atatcatgcc gggcatccaa aagtgtcagc acttcaggct acagttattt gcattggtat 120 cttcagaaac cgggacagag cccgcagctc ttgatctatt tggcttccaa cctggaaagc 180 ggagtttcta agcgcttttc aggttccggg agcgggacgg atttcacact tcggatctct 240 agagtggaag ccgatgatac tggaatctat tactgtcagc acagtagaga actccctctc 300 acattcgggc agggtacc 318 <![CDATA[<210> 135]]> <![CDATA[<211> 789]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 135]]> Gln Lys Lys Gly Ala Pro His Asp Leu Lys Cys Val Thr Asn Asn Leu 1 5 10 15 Gln Val Trp Asn Cys Ser Trp Lys Ala Pro Ser Gly Thr Gly Arg Gly 20 25 30 Thr Asp Tyr Glu Val Cys Ile Glu Asn Arg Ser Arg Ser Cys Tyr Gln 35 40 45 Leu Glu Lys Thr Ser Ile Lys Ile Pro Ala Leu Ser His Gly Asp Tyr 50 55 60 Glu Ile Thr Ile Asn Ser Leu His Asp Phe Gly Ser Ser Thr Ser Lys 65 70 75 80 Phe Thr Leu Asn Glu Gln Asn Val Ser Leu Ile Pro Asp Thr Pro Glu 85 90 95 Ile Leu Asn Leu Ser Ala Asp Phe Ser Thr Ser Thr Leu Tyr Leu Lys 100 105 110 Trp Asn Asp Arg Gly Ser Val Phe Pro His Arg Ser Asn Val Ile Trp 115 120 125 Glu Ile Lys Val Leu Arg Lys Glu Ser Met Glu Leu Val Lys Leu Val 130 135 140 Thr His Asn Thr Thr Leu Asn Gly Lys Asp Thr Leu His His Trp Ser 145 150 155 160 Trp Ala Ser Asp Met Pro Leu Glu Cys Ala Ile His Phe Val Glu Ile 165 170 175 Arg Cys Tyr Ile Asp Asn Leu His Phe Ser Gly Leu Glu Glu Trp Ser 180 185 190 Asp Trp Ser Pro Val Lys Asn Ile Ser Trp Ile Pro Asp Ser Gln Thr 195 200 205 Lys Val Phe Pro Gln Asp Lys Val Ile Leu Val Gly Ser Asp Ile Thr 210 215 220 Phe Cys Cys Val Ser Gln Glu Lys Val Leu Ser Ala Leu Ile Gly His 225 230 235 240 Thr Asn Cys Pro Leu Ile His Leu Asp Gly Glu Asn Val Ala Ile Lys 245 250 255 Ile Arg Asn Ile Ser Val Ser Ala Ser Ser Gly Thr Asn Val Val Phe 260 265 270 Thr Thr Glu Asp Asn Ile Phe Gly Thr Val Ile Phe Ala Gly Tyr Pro 275 280 285 Pro Asp Thr Pro Gln Gln Leu Asn Cys Glu Thr His Asp Leu Lys Glu 290 295 300 Ile Ile Cys Ser Trp Asn Pro Gly Arg Val Thr Ala Leu Val Gly Pro 305 310 315 320 Arg Ala Thr Ser Tyr Thr Leu Val Glu Ser Phe Ser Gly Lys Tyr Val 325 330 335 Arg Leu Lys Arg Ala Glu Ala Pro Thr Asn Glu Ser Tyr Gln Leu Leu 340 345 350 Phe Gln Met Leu Pro Asn Gln Glu Ile Tyr Asn Phe Thr Leu Asn Ala 355 360 365 His Asn Pro Leu Gly Arg Ser Gln Ser Thr Ile Leu Val Asn Ile Thr 370 375 380 Glu Lys Val Tyr Pro His Thr Pro Thr Ser Phe Lys Val Lys Asp Ile 385 390 395 400 Asn Ser Thr Ala Val Lys Leu Ser Trp His Leu Pro Gly Asn Phe Ala 405 410 415 Lys Ile Asn Phe Leu Cys Glu Ile Glu Ile Lys Lys Ser Asn Ser Val 420 425 430 Gln Glu Gln Arg Asn Val Thr Ile Lys Gly Val Glu Asn Ser Ser Tyr 435 440 445 Leu Val Ala Leu Asp Lys Leu Asn Pro Tyr Thr Leu Tyr Thr Phe Arg 450 455 460 Ile Arg Cys Ser Thr Glu Thr Phe Trp Lys Trp Ser Lys Trp Ser Asn 465 470 475 480 Lys Lys Gln His Leu Thr Thr Glu Ala Ser Pro Ser Lys Gly Pro Asp 485 490 495 Thr Trp Arg Glu Trp Ser Ser Asp Gly Lys Asn Leu Ile Ile Tyr Trp 500 505 510 Lys Pro Leu Pro Ile Asn Glu Ala Asn Gly Lys Ile Leu Ser Tyr Asn 515 520 525 Val Ser Cys Ser Ser Asp Glu Glu Thr Gln Ser Leu Ser Glu Ile Pro 530 535 540 Asp Pro Gln His Lys Ala Glu Ile Arg Leu Asp Lys Asn Asp Tyr Ile 545 550 555 560 Ile Ser Val Val Ala Lys Asn Ser Val Gly Ser Ser Pro Pro Ser Lys 565 570 575 Ile Ala Ser Met Glu Ile Pro Asn Asp Asp Leu Lys Ile Glu Gln Val 580 585 590 Val Gly Met Gly Lys Gly Ile Leu Leu Thr Trp His Tyr Asp Pro Asn 595 600 605 Met Thr Cys Asp Tyr Val Ile Lys Trp Cys Asn Ser Ser Arg Ser Glu 610 615 620 Pro Cys Leu Met Asp Trp Arg Lys Val Pro Ser Asn Ser Thr Glu Thr 625 630 635 640 Val Ile Glu Ser Asp Glu Phe Arg Pro Gly Ile Arg Tyr Asn Phe Phe 645 650 655 Leu Tyr Gly Cys Arg Asn Gln Gly Tyr Gln Leu Leu Arg Ser Met Ile 660 665 670 Gly Tyr Ile Glu Glu Leu Ala Pro Ile Val Ala Pro Asn Phe Thr Val 675 680 685 Glu Asp Thr Ser Ala Asp Ser Ile Leu Val Lys Trp Glu Asp Ile Pro 690 695 700 Val Glu Glu Leu Arg Gly Phe Leu Arg Gly Tyr Leu Phe Tyr Phe Gly 705 710 715 720 Lys Gly Glu Arg Asp Thr Ser Lys Met Arg Val Leu Glu Ser Gly Arg 725 730 735 Ser Asp Ile Lys Val Lys Asn Ile Thr Asp Ile Ser Gln Lys Thr Leu 740 745 750 Arg Ile Ala Asp Leu Gln Gly Lys Thr Ser Tyr His Leu Val Leu Arg 755 760 765 Ala Tyr Thr Asp Gly Gly Val Gly Pro Glu Lys Ser Met Tyr Val Val 770 775 780 Thr Lys Glu Asn Ser 785 <![CDATA[<210> 136]]> <![CDATA[<211> 180]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 136]]> Ser Pro Leu Pro Ile Thr Pro Val Asn Ala Thr Cys Ala Ile Arg His 1 5 10 15 Pro Cys His Asn Asn Leu Met Asn Gln Ile Arg Ser Gln Leu Ala Gln 20 25 30 Leu Asn Gly Ser Ala Asn Ala Leu Phe Ile Leu Tyr Tyr Thr Ala Gln 35 40 45 Gly Glu Pro Phe Pro Asn Asn Leu Asp Lys Leu Cys Gly Pro Asn Val 50 55 60 Thr Asp Phe Pro Pro Phe His Ala Asn Gly Thr Glu Lys Ala Lys Leu 65 70 75 80 Val Glu Leu Tyr Arg Ile Val Val Tyr Leu Gly Thr Ser Leu Gly Asn 85 90 95 Ile Thr Arg Asp Gln Lys Ile Leu Asn Pro Ser Ala Leu Ser Leu His 100 105 110 Ser Lys Leu Asn Ala Thr Ala Asp Ile Leu Arg Gly Leu Leu Ser Asn 115 120 125 Val Leu Cys Arg Leu Cys Ser Lys Tyr His Val Gly His Val Asp Val 130 135 140 Thr Tyr Gly Pro Asp Thr Ser Gly Lys Asp Val Phe Gln Lys Lys Lys 145 150 155 160 Leu Gly Cys Gln Leu Leu Gly Lys Tyr Lys Gln Ile Ile Ala Val Leu 165 170 175 Ala Gln Ala Phe 180
Claims (33)
- 一種與犬或貓抑瘤素M受體β(OSMR-β)或兩者特異性結合之經分離抗體或其抗原結合部分,其中該抗體在犬及/或貓細胞中拮抗IL-31介導之信號傳導或OSM介導之信號傳導或兩者。
- 如請求項1之抗體或其抗原結合部分,其中該抗體在犬及/或貓細胞中拮抗IL-31介導之信號傳導及OSM介導之信號傳導。
- 如請求項1或請求項2之抗體或其抗原結合部分,其包含選自由以下組成之群的互補決定區(CDR)序列之組合: 7) 02D09:SEQ ID NO: 1(DYGMH)之可變重鏈(VH)-CDR1、SEQ ID NO: 2(YISSGSRAVFFADTVKG)之VH-CDR2、SEQ ID NO: 3(DRYDGRGFAY)之VH-CDR3、SEQ ID NO: 4(RASQSISNNLH)之可變輕鏈(VL)-CDR1、SEQ NO: 5(YASQSIS)之VL-CDR2及SEQ ID NO: 6(QQSNSWPLT)之VL-CDR3; 8) 09E09:SEQ ID NO: 7(SYAMS)之VH-CDR1、SEQ ID NO: 8(YISSGGDYIYYADTVKG)之VH-CDR2、SEQ ID NO: 9(DPITGTFAY)之VH-CDR3、SEQ ID NO: 10 (RASQDINNYLN)之VL-CDR1、SEQ ID NO: 11(YTSTLHS)之VL-CDR2及SEQ ID NO: 12(QQGNTLPWT)之VL-CDR3; 9) 10F07:SEQ ID NO: 13(SYAMS)之VH-CDR1、SEQ ID NO: 14(YISSGGDYFYYADTVKG)之VH-CDR2、SEQ ID NO: 15(DPITGTFAY)之VH-CDR3、SEQ ID NO: 16 (RASQDITNYLN)之VL-CDR1、SEQ ID NO: 17(YTSTLHS)之VL-CDR2及SEQ ID NO: 18(QQGHMLPWT)之VL-CDR3; 10) 14C04:SEQ ID NO: 19(NYWMN)之VH-CDR1、SEQ ID NO: 20(QIYPGHVNTNYNGNFKD)之VH-CDR2、SEQ ID NO: 21(SADNSGFVLFAY)之VH-CDR3、SEQ ID NO: 22(RASKSVSTSGYSYLH)之VL-CDR1、SEQ ID NO: 23 (LASNLES)之VL-CDR2及SEQ ID NO: 24(QHSRELPLT)之VL-CDR3; 11) 19F07:SEQ ID NO: 25(DYYMA)之VH-CDR1、SEQ ID NO: 26(NINYDGSSTYYLDSLKS)之VH-CDR2、SEQ ID NO: 27(GLTWDFDV)之VH-CDR3、SEQ ID NO: 28 (KASQDVDTAVA)之VL-CDR1、SEQ ID NO: 29 (LASTRHT)之VL-CDR2及SEQ ID NO: 30(QQYSRFPLT)之VL-CDR3;或 12) 1、2、3、4或5之CDR變異體。
- 如請求項1至4中任一項之抗體,其中該抗體為嵌合的。
- 如請求項1至4中任一項之抗體,其中該抗體經犬類化或貓類化。
- 如請求項1至4中任一項之抗體,其中該抗體抑制或中和狗或貓之IL-31介導或OSM介導之搔癢性或過敏性病況。
- 如請求項7之抗體,其中該IL-31介導或OSM介導之搔癢性病況係選自由異位性皮膚炎、濕疹、牛皮癬、硬皮病及搔癢症組成之群。
- 如請求項8之抗體,其中該IL-31介導或OSM介導之過敏性病況係選自由以下組成之群:過敏性皮膚炎、夏季濕疹、蕁麻疹、氣喘病、發炎性氣道疾病、復發性氣道阻塞、氣道高反應性、慢性阻塞性肺病及由自體免疫導致之發炎性過程。
- 如請求項1至4中任一項之抗體,其中該抗體抑制IL-31介導或OSM介導之纖維變性或發炎性病症。
- 如請求項10之抗體,其中該IL-31介導或OSM介導之纖維變性病症係選自由腎纖維化、肺纖維化及皮膚纖維化組成之群。
- 如請求項10之抗體,其中該IL-31介導或OSM介導之發炎性病症係選自由以下組成之群:由自體免疫導致之發炎性過程、受骨關節炎影響之動物的皮膚或關節之炎症、免疫介導之多發性關節炎、慢性支氣管炎、過敏性哮喘、異位性皮膚炎、過敏性皮膚炎、膿性創傷性皮膚炎、動脈粥樣硬化及心血管疾病。
- 如請求項1至4中任一項之抗體,其中該抗體減少IL-31介導或OSM介導之發炎性疼痛。
- 如請求項13之抗體,其中該IL-31介導或OSM介導之發炎性疼痛為骨關節炎疼痛。
- 一種獸用組合物,其包含治療有效量之如請求項1至4中任一項之抗體。
- 一種治療個體之IL-31介導或OSM介導之病症之方法,其包含向該個體投予如請求項1至4中任一項之抗體。
- 如請求項16之方法,其中該IL-31介導或OSM介導之病症係選自由以下組成之群:搔癢性病況、過敏性病況、纖維變性病症、發炎性病症及發炎性疼痛。
- 如請求項17之方法,其中該IL-31介導或OSM介導之搔癢性病況係選自由異位性皮膚炎、濕疹、牛皮癬、硬皮病及搔癢症組成之群。
- 如請求項17之方法,其中該IL-31介導或OSM介導之過敏性病況係選自由以下組成之群:過敏性皮膚炎、夏季濕疹、蕁麻疹、氣喘病、發炎性氣道疾病、復發性氣道阻塞、氣道高反應性、慢性阻塞性肺病及由自體免疫導致之發炎性過程。
- 如請求項17之方法,其中該IL-31介導或OSM介導之纖維變性病症係選自由腎纖維化、肺纖維化及皮膚纖維化組成之群。
- 如請求項17之方法,其中該IL-31介導或OSM介導之發炎性病症係選自由以下組成之群:由自體免疫導致之發炎性過程、受骨關節炎影響之動物的皮膚或關節之炎症、免疫介導之多發性關節炎、慢性支氣管炎、過敏性哮喘、異位性皮膚炎、過敏性皮膚炎、膿性創傷性皮膚炎、動脈粥樣硬化及心血管疾病。
- 如請求項17之方法,其中該IL-31介導或OSM介導之發炎性疼痛為骨關節炎疼痛。
- 如請求項16至22中任一項之方法,其中該個體為狗或貓。
- 一種抑制狗或貓之IL-31及/或OSM活性之方法,其包含向該狗或貓投予如請求項1至4中任一項之抗體。
- 一種偵測樣品中之OSMR β之方法,其包含: a) 在如請求項1至4中任一項之抗體存在下培育包含OSMR β之樣品;及 b) 偵測與該樣品中之OSMR β結合的該抗體。
- 如請求項25之方法,其中該抗體包含標記。
- 如請求項25或請求項26之方法,其進一步包含定量該樣品中之該OSMR β。
- 一種產生經分離抗體或其抗原結合部分之宿主細胞,該抗體或其抗原結合部分包含以下互補決定區(CDR)序列之組合中之至少一者: 7) 02D09:SEQ ID NO: 1(DYGMH)之可變重鏈(VH)-CDR1、SEQ ID NO: 2(YISSGSRAVFFADTVKG)之VH-CDR2、SEQ ID NO: 3(DRYDGRGFAY)之VH-CDR3、SEQ ID NO: 4(RASQSISNNLH)之可變輕鏈(VL)-CDR1、SEQ NO: 5(YASQSIS)之VL-CDR2及SEQ ID NO: 6 (QQSNSWPLT)之VL-CDR3; 8) 09E09:SEQ ID NO: 7(SYAMS)之VH-CDR1、SEQ ID NO: 8(YISSGGDYIYYADTVKG)之VH-CDR2、SEQ ID NO: 9(DPITGTFAY)之VH-CDR3、SEQ ID NO: 10 (RASQDINNYLN)之VL-CDR1、SEQ ID NO: 11(YTSTLHS)之VL-CDR2及SEQ ID NO: 12(QQGNTLPWT)之VL-CDR3; 9) 10F07:SEQ ID NO: 13(SYAMS)之VH-CDR1、SEQ ID NO: 14(YISSGGDYFYYADTVKG)之VH-CDR2、SEQ ID NO: 15(DPITGTFAY)之VH-CDR3、SEQ ID NO: 16 (RASQDITNYLN)之VL-CDR1、SEQ ID NO: 17(YTSTLHS)之VL-CDR2及SEQ ID NO: 18(QQGHMLPWT)之VL-CDR3; 10) 14C04:SEQ ID NO: 19(NYWMN)之VH-CDR1、SEQ ID NO: 20(QIYPGHVNTNYNGNFKD)之VH-CDR2、SEQ ID NO: 21(SADNSGFVLFAY)之VH-CDR3、SEQ ID NO: 22(RASKSVSTSGYSYLH)之VL-CDR1、SEQ ID NO: 23 (LASNLES)之VL-CDR2及SEQ ID NO: 24(QHSRELPLT)之VL-CDR3; 11) 19F07:SEQ ID NO: 25(DYYMA)之VH-CDR1、SEQ ID NO: 26(NINYDGSSTYYLDSLKS)之VH-CDR2、SEQ ID NO: 27(GLTWDFDV)之VH-CDR3、SEQ ID NO: 28 (KASQDVDTAVA)之VL-CDR1、SEQ ID NO: 29 (LASTRHT)之VL-CDR2及SEQ ID NO: 30(QQYSRFPLT)之VL-CDR3;或 12) 1、2、3、4或5之CDR變異體。
- 一種經分離之核酸,其包含編碼以下互補決定區(CDR)序列之組合中之至少一者的核酸序列: 7) 02D09:SEQ ID NO: 1(DYGMH)之可變重鏈(VH)-CDR1、SEQ ID NO: 2(YISSGSRAVFFADTVKG)之VH-CDR2及SEQ ID NO: 3(DRYDGRGFAY)之VH-CDR3; 8) 09E09:SEQ ID NO: 7(SYAMS)之VH-CDR1、SEQ ID NO: 8(YISSGGDYIYYADTVKG)之VH-CDR2及SEQ ID NO: 9(DPITGTFAY)之VH-CDR3; 9) 10F07:SEQ ID NO: 13(SYAMS)之VH-CDR1、SEQ ID NO: 14(YISSGGDYFYYADTVKG)之VH-CDR2及SEQ ID NO: 15(DPITGTFAY)之VH-CDR3; 10) 14C04:SEQ ID NO: 19(NYWMN)之VH-CDR1、SEQ ID NO: 20(QIYPGHVNTNYNGNFKD)之VH-CDR2及SEQ ID NO: 21(SADNSGFVLFAY)之VH-CDR3; 11) 19F07:SEQ ID NO: 25(DYYMA)之VH-CDR1、SEQ ID NO: 26(NINYDGSSTYYLDSLKS)之VH-CDR2及SEQ ID NO: 27(GLTWDFDV)之VH-CDR3;或 12) 1、2、3、4或5之CDR變異體。
- 如請求項29之核酸,其進一步包含編碼以下CDR序列之組合中之至少一者的核酸序列: 1)02D09:SEQ ID NO: 4(RASQSISNNLH)之可變輕鏈(VL)-CDR1、SEQ NO: 5(YASQSIS)之VL-CDR2及SEQ ID NO: 6(QQSNSWPLT)之VL-CDR3; 2)09E09:SEQ ID NO: 10(RASQDINNYLN)之VL-CDR1、SEQ ID NO: 11(YTSTLHS)之VL-CDR2及SEQ ID NO: 12(QQGNTLPWT)之VL-CDR3; 3)10F07:SEQ ID NO: 16(RASQDITNYLN)之VL-CDR1、SEQ ID NO: 17(YTSTLHS)之VL-CDR2及SEQ ID NO: 18(QQGHMLPWT)之VL-CDR3; 4)14C04:SEQ ID NO: 22(RASKSVSTSGYSYLH)之VL-CDR1、SEQ ID NO: 23(LASNLES)之VL-CDR2及SEQ ID NO: 24(QHSRELPLT)之VL-CDR3; 5)19F07:SEQ ID NO: 28(KASQDVDTAVA)之VL-CDR1、SEQ ID NO: 29(LASTRHT)之VL-CDR2及SEQ ID NO: 30(QQYSRFPLT)之VL-CDR3;或 6)1、2、3、4或5之CDR變異體。
- 一種核酸序列,其編碼以下CDR序列之組合中之至少一者: 1)02D09:SEQ ID NO: 4(RASQSISNNLH)之可變輕鏈(VL)-CDR1、SEQ NO: 5(YASQSIS)之VL-CDR2及SEQ ID NO: 6(QQSNSWPLT)之VL-CDR3; 2)09E09:SEQ ID NO: 10(RASQDINNYLN)之VL-CDR1、SEQ ID NO: 11(YTSTLHS)之VL-CDR2及SEQ ID NO: 12(QQGNTLPWT)之VL-CDR3; 3)10F07:SEQ ID NO: 16(RASQDITNYLN)之VL-CDR1、SEQ ID NO: 17(YTSTLHS)之VL-CDR2及SEQ ID NO: 18(QQGHMLPWT)之VL-CDR3; 4)14C04:SEQ ID NO: 22(RASKSVSTSGYSYLH)之VL-CDR1、SEQ ID NO: 23(LASNLES)之VL-CDR2及SEQ ID NO: 24(QHSRELPLT)之VL-CDR3; 5)19F07:SEQ ID NO: 28(KASQDVDTAVA)之VL-CDR1、SEQ ID NO: 29(LASTRHT)之VL-CDR2及SEQ ID NO: 30(QQYSRFPLT)之VL-CDR3;或 6)1、2、3、4或5之CDR變異體。
- 一種載體,其包含如請求項29、30或31中任一項之核酸。
- 一種產生抗體之方法,其包含在引起該抗體產生之條件下培養如請求項28之宿主細胞,及自該宿主細胞或該宿主細胞之培養基分離該抗體。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063093607P | 2020-10-19 | 2020-10-19 | |
US63/093,607 | 2020-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202221039A true TW202221039A (zh) | 2022-06-01 |
Family
ID=78622023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW110138302A TW202221039A (zh) | 2020-10-19 | 2021-10-15 | 犬及貓抑瘤素M受體β之抗體及其用途 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220177594A1 (zh) |
EP (1) | EP4229087A1 (zh) |
JP (1) | JP2023546161A (zh) |
KR (1) | KR20230092978A (zh) |
CN (1) | CN116406378A (zh) |
AR (1) | AR123839A1 (zh) |
AU (1) | AU2021364308A1 (zh) |
CA (1) | CA3196925A1 (zh) |
CL (1) | CL2023001108A1 (zh) |
CO (1) | CO2023004837A2 (zh) |
EC (1) | ECSP23028951A (zh) |
IL (1) | IL302147A (zh) |
MX (1) | MX2023004500A (zh) |
PE (1) | PE20231210A1 (zh) |
TW (1) | TW202221039A (zh) |
UY (1) | UY39474A (zh) |
WO (1) | WO2022086837A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024145280A2 (en) | 2022-12-27 | 2024-07-04 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
US20240209096A1 (en) | 2022-12-27 | 2024-06-27 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
WO2024155982A2 (en) | 2023-01-20 | 2024-07-25 | Invetx, Inc. | Bispecific binding agents for use in companion animals |
WO2024186963A1 (en) * | 2023-03-07 | 2024-09-12 | Genentech, Inc. | Methods for treating pulmonary fibrotic diseases or disorders with an anti oncostatin m receptor beta antibody |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736378A (en) * | 1991-09-12 | 1998-04-07 | The Scripps Research Institute | Molecular cloning and characterization of the feline immunodeficiency virus isolate PPR |
US5350576A (en) | 1991-09-13 | 1994-09-27 | Mycogen Corporation | Bacillus thuringiensis isolates for controlling acarides |
US6194167B1 (en) | 1997-02-18 | 2001-02-27 | Washington State University Research Foundation | ω-3 fatty acid desaturase |
EP1161530B1 (en) | 1999-03-18 | 2005-05-18 | MERCK PATENT GmbH | Protein for blocking platelet adhesion |
EP1130098A3 (en) | 2000-02-29 | 2003-09-10 | Pfizer Products Inc. | Mammalian osteoregulins |
KR100419555B1 (ko) | 2000-05-29 | 2004-02-19 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
EP2258723A1 (en) * | 2009-06-02 | 2010-12-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Treatment of oncostatin M receptor ß mediated heart failure |
US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
ES2895824T3 (es) * | 2013-05-30 | 2022-02-22 | Kiniksa Pharmaceuticals Ltd | Proteínas de enlace al antígeno del receptor de oncastatina M |
MX2020009642A (es) | 2018-03-16 | 2021-01-08 | Zoetis Services Llc | Anticuerpos monoclonales de interleucina-31 para uso veterinario. |
-
2021
- 2021-10-15 TW TW110138302A patent/TW202221039A/zh unknown
- 2021-10-18 AU AU2021364308A patent/AU2021364308A1/en active Pending
- 2021-10-18 AR ARP210102871A patent/AR123839A1/es unknown
- 2021-10-18 EP EP21807370.8A patent/EP4229087A1/en active Pending
- 2021-10-18 WO PCT/US2021/055366 patent/WO2022086837A1/en active Application Filing
- 2021-10-18 JP JP2023523540A patent/JP2023546161A/ja active Pending
- 2021-10-18 CN CN202180071431.5A patent/CN116406378A/zh active Pending
- 2021-10-18 CA CA3196925A patent/CA3196925A1/en active Pending
- 2021-10-18 UY UY0001039474A patent/UY39474A/es unknown
- 2021-10-18 PE PE2023001443A patent/PE20231210A1/es unknown
- 2021-10-18 US US17/503,592 patent/US20220177594A1/en active Pending
- 2021-10-18 IL IL302147A patent/IL302147A/en unknown
- 2021-10-18 MX MX2023004500A patent/MX2023004500A/es unknown
- 2021-10-18 KR KR1020237016835A patent/KR20230092978A/ko active Search and Examination
-
2023
- 2023-04-17 CL CL2023001108A patent/CL2023001108A1/es unknown
- 2023-04-18 CO CONC2023/0004837A patent/CO2023004837A2/es unknown
- 2023-04-19 EC ECSENADI202328951A patent/ECSP23028951A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021364308A9 (en) | 2023-07-13 |
WO2022086837A1 (en) | 2022-04-28 |
ECSP23028951A (es) | 2023-07-31 |
UY39474A (es) | 2022-06-30 |
AR123839A1 (es) | 2023-01-18 |
CA3196925A1 (en) | 2022-04-28 |
CL2023001108A1 (es) | 2023-11-24 |
CN116406378A (zh) | 2023-07-07 |
CO2023004837A2 (es) | 2023-05-19 |
EP4229087A1 (en) | 2023-08-23 |
KR20230092978A (ko) | 2023-06-26 |
PE20231210A1 (es) | 2023-08-17 |
AU2021364308A1 (en) | 2023-05-18 |
MX2023004500A (es) | 2023-05-10 |
US20220177594A1 (en) | 2022-06-09 |
IL302147A (en) | 2023-06-01 |
JP2023546161A (ja) | 2023-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102587633B1 (ko) | 수의학적 용도를 위한 인터류킨-31 단클론성 항체 | |
DK2734549T3 (en) | MONOCLONAL ANTIBODY AGAINST DOG INTERLEUKIN-31 | |
JP2022176324A (ja) | ヒトil-15に特異的に結合する抗体及びその使用 | |
TW202221039A (zh) | 犬及貓抑瘤素M受體β之抗體及其用途 | |
CN111819197A (zh) | 抗ngf抗体及其方法 | |
KR102672548B1 (ko) | 인터루킨-31에 대한 펩티드 백신 | |
CN115803342A (zh) | 抗TGFβ抗体及其治疗用途 | |
CA3124356A1 (en) | Fn14 antibodies and uses thereof | |
RU2795411C2 (ru) | Моноклональные антитела к интерлейкину-31 для ветеринарного применения | |
RU2786441C2 (ru) | Пептидные вакцины против интерлейкина-31 | |
BR122024020794A2 (pt) | Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo |